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Survival of multicellular organisms requires resilience and regeneration of injured tissues 
due to damaging environmental or genetic factors. Virtually, all organisms from bacteria 
to primates have regeneration abilities at different extend (bacteria wall and flagellum 
regeneration1, limb regrowth in reptiles, blood, nerve and liver regeneration in mammals). 
Regeneration is the process of cell repair, cell replacement and renewal leading to 
morphogenic changes and (re) growth of damaged tissue and organs. The ultimate aim is 
to preserve the physiological organ functionality (homeostasis) since repetitive exposure 
to damaging factors eventually leads to exhaustion of the regenerative properties of cells 
and development of pathological conditions such as malignancies or organ fibrosis. 
Regenerating cells undergo cell duplication (proliferation) and phenotypic changes by gene 
expression modulation thus; they have increased need for DNA and protein 
synthesis. In order to precisely orchestrate these complex molecular processes, cells depend 
on mechanisms that allow communication between different parts of a single cell and among 
different cells. Cell communication during tissue injury occurs via signaling molecules that 
are being produced by injured cells (proteins, miRNAs, ions, chemical 
molecules). These signaling molecules cause a cascade of activation or inhibition of other 
molecules (signaling pathways) leading to a particular biological response in the same 
cell or in adjacent or further located healthy cells in different places in the body via blood 
circulation. 
A major cell signaling pathway orchestrating homeostasis in many organ systems is the 
superfamily of proteins Transforming growth factor β (TGFβ). Its prototype TGFβ1 was 
identified over 3 decades ago. The TGFβ superfamily consists of 33 proteins encoded by 
the human genome, seven in Drosophila and four in C.elegans2.
 Its mechanisms of signal transduction are often deregulated in human diseases; thus, it is 
subject of vigorous investigation in various types of cancer and fibrosis. 
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1.2. Outline of the thesis 
Dysregulation of gene function of TGFβ pathway components is a common cause of human 
diseases such as cancer and fibrosis. The scope of the research described in this thesis is 
to characterize the therapeutic potential of different inhibitory strategies of TGFβ protein 
signaling cascade. The objective is to target and potentially “correct” the expression and 
function of proteins encoding TGFβ signaling components using 
clinically applicable compounds such as antisense oligonucleotides, small molecule 
inhibitors or neutralizing antibodies. We focus on inhibition of TGFβ signaling pathway in 




Small molecule kinase inhibitor 
LY364947 targeting TGFβ receptor
Ex vivo model Dupuytren’s fibrosis
AON application targeting TGFβ receptor
In vivo application of ALK1Fc ligand 
trap in primary cancer 
In Chapter 1, a general introduction on the TGFβ signaling pathway is presented and its 
role in normal conditions (homeostasis and tissue regeneration) as well as in pathological 
conditions (fibrosis, cancer) is described. An overview of different inhibitory strategies for 
molecular manipulation and ongoing clinical trials targeting TGFβ is provided. 
In Chapter 2, a comprehensive review is presented about the pleiotropic role of TGFβ during 
liver development and regeneration with particular emphasis on regulation of epithelial 
cell (hepatocyte) and hepatic progenitor cell- induced regeneration. An overview of the 
current aspects of liver research with regards to cell replacement therapies is presented.
 
In Chapter 3, we show the in vivo use of a small molecule inhibitor (LY364947) targeting 
kinase activity of TGFβ type I receptor in a mouse model of injury-induced liver regeneration. 
In Chapter 4, a novel ex vivo methodology is described for the study of human Dupuytren’s 
fibrosis, a primarily TGFβ-driven disease. A step-by-step protocol of the tissue ex vivo 
culture system and its applications are described. This technique is used in combination 
with biochemical and imaging techniques that could be applicable for the study of various 
types of human fibrosis. 
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In Chapter 5, the ex vivo culture system of human fibrotic tissue is used as a platform for 
TGFβ pathway deactivation using small molecule inhibitor and antisense oligonucleotides. 
Both strategies aim to target the activin receptor-like kinase-5 (ALK5) activity (TGFβ type I 
receptor) either at the protein or messenger RNA level. Specifically, the data suggest that 
inhibition of ALK5 activity is applicable ex vivo and exhibits anti-fibrotic effects evident by 
reduction of extracellular matrix protein deposition. 
Chapter 6 describes the use of anti-human ALK1 neutralizing antibody ACE-041 (ALK1Fc) 
as a tumor angiogenesis inhibitor in primary prostate cancer. This compound is currently 
being tested in clinical trials for solid tumor treatment. In this study, we show the in vivo 
effects of ALK1Fc in tumor burden and angiogenesis in a primary prostate cancer mouse 
model using orthotopic transplantation of human prostate cancer cells.  
In Chapter 7 (Discussion) the results presented in this thesis, implications deriving from 
this work and applicability of TGFβ targeting drugs are discussed. 
In Appendix I we introduce preliminary data supporting a role for CRIPTO, a TGFβ superfamily 
type III receptor, in liver regeneration and human hepatocellular carcinoma. CRIPTO is 
normally expressed only during embryonic development. Our data indicate reactivation 
of CRIPTO in the mouse liver after toxin-induced acute injury and in human liver cancer 
specimens suggesting its use as a potential diagnostic biomarker for human hepatocellular 
carcinoma.  
Summary (Appendix II) includes an overview of the key findings of this thesis.
1.3. TGFβ superfamily
The Transforming growth factors (TGFs) were firstly identified as secreted proteins from 
murine sarcoma virus-transformed fibroblasts; these proteins induced in vitro transformation 
to neoplastic-like phenotype as evidenced by cell division, morphological changes and 
anchorage-independent growth3,4. Two distinct classes of proteins were isolated, the 
type α and type β with different properties and synergistic effects. In fact, the original 
observations suggested that TGFβ per se does not stimulate cell growth unless combined 
with other growth factors such as TGFα and epidermal growth factor (EGF)5. Although 
initially TGFβ was found present in neoplastic cells 6,7 further studies showed its expression in 
various normal human cells and tissues such as platelets8, placenta9 and during embryonic 
development10,11. A physiological role in cell differentiation, wound healing, angiogenesis 
and as an inhibitor of cell growth was attributed to TGFβ in various tissues12. Despite the 
functional complexity of TGFβ the core signaling components and their interactions appear 
at first instance rather simple. 
The TGFβ superfamily of ligands can be divided into subfamilies; TGFβ proteins, bone 
morphogenetic proteins (BMPs), the growth and differentiation factors (GDFs), ACTIVINs, 
MYOSTATINS, NODAL and Anti-Mullerian hormone (AMH). 
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The molecular skeleton of TGFβ pathway is comprised by the extracellular TGFβ-family 
ligands, which elicit their signals into the cell by binding to type II receptor (TβRII), forming 
heterodimer complexes with type I receptor TβRI/ACTIVIN receptor-like kinase (ALK5)13. 
This interaction activates the receptor’s serine/threonine kinase activity to phosphorylate 
and activate SMAD transcription factors. Phosphorylation of receptor-activated SMADs 
(R-SMADs) by the activated type I receptor allows the R-SMADs to form heterodimers with 
partner SMAD (co-SMAD/ SMAD4) and translocate to the nucleus where, in collaboration 
with transcription factor complexes, they activate or inhibit the transcription of target 
genes14 (Fig.1).
1.3.1. BMP subfamily
BMP factors were firstly identified as chondrogenic and osteogenic inducers. Further 
investigations revealed various roles for BMPs during embryogenesis; kidney, skin, hair, 
muscle, haematopoietic and neuronal development, as well as a role in iron metabolism 
and vascular maintenance15-17. Although BMPs typically activate BMP type I receptors 
and R-SMAD1, 5 and 8, they can be further classified into several subgroups, including 
BMP1/2/3/4 group, BMP5/6/7/8 group, growth and differentiation factor (GDF)5/6/7 group 
and BMP9/10 group15,18. BMP2, BMP6 and the most recently identified BMP9 are the most 
potent inducers of osteogenesis19. Although structurally different, other members of the 
BMP pathway are GDF8/MYOSTATIN and GDF9, having a role in muscle tissue and ovarian 
development, respectively20,21. 
Signal transduction of BMP subfamily is conducted in a similar manner as the TGFβ cascade. 
BMP ligands use BMPRII, ACVR2A or ACVR2B type II receptors and have affinity for ALK1, 
ALK2, ALK3 and ALK622. SMAD1, 5 and 8 are the BMP-specific R-SMADs that translocate 
to the nucleus upon activation by the type I receptor and regulate BMP target gene 
transcription15 (Fig.1).
1.3.2. TGFβ canonical pathway
Level 1. Ligand synthesis and secretion 
There are three types of TGFβ ligand isoforms: TGFβ1, TGFβ2, and TGFβ3, all of which are 
highly conserved among species. Mature TGFβ1, TGFβ2 and TGFβ3, which are produced after 
proteolytic activation from cleavage precursor proteins, share high aminoacid sequence 
homology and functional similarity. However, it has been reported that TGFβ2 and TGFβ3 are 
biologically more active than TGFβ123 and their tissue expression follows a distinct pattern24. 
Following the identification of the three isoforms25-28 novel information from transgenic 
mouse models added to our understanding of the crucial and specific role during embryonic 
development for all three isoforms. Genetic deletion of TGFβ1 in mice leads to general 
inflammation29 and early death30 due to vascular and hematopoietic abnormalities during 
development31. Mice lacking TGFβ3 exhibit lung and cleft palate defects due to abnormal 
epithelial-to mesenchymal transition (EMT) and die immediately after birth32. Homozygous 
deletion of TGFβ2 confirmed the previously suggested role of TGFβ2 in cardiogenesis33 but 
also causes multiple defects (cardiac, lung, eye and skeletal tissues among others) that are 










































































Fig.1. Overview of TGFβ signaling pathway
The core of the pathway is comprised by the SMAD effectors that mediate downstream signaling from extracellular 
ligands; TGFβ, ACTIVINS, NODAL, BMPs, GDFs. (left) TGFβ ligands bind to type II receptor TGFβRII, which recruits 
and phosphorylates the type I receptor ALK5 or ALK1 (endothelial cell-specific receptor). ALK5 phosphorylates 
R-SMADs (SMAD2 and SMAD3) that form complexes with phosphorylated SMAD4 and translocate into the nucleus. 
R-SMAD/SMAD4, together with co-factor proteins, bind to gene promoter regions and induce or repress target 
gene transcription. (middle) NODAL, GDF1, GDF3 and ACTIVIN-A, -B bind to ACVR2A, ACVR2B and activate ALK4 or 
ALK7. ALK4/7 transduce their signal via SMAD2 and SMAD3 effectors, similarly to the TGFβ cascade. (right) GDFs/ 
BMPs bind simultaneously to a combination of type II (BMPRII, ACVR2A or ACVR2B) and type I receptors (ALK1, 
ALK2, ALK3 or ALK6). This leads to phosphorylation of R-SMADs, SMAD1, SMAD5 and SMAD8 which couple to 
SMAD4 and as a complex enter the nucleus and regulate GDF/ BMP target gene expression.
TGFβ proteins are expressed as inactive pre-pro-peptides; latency is controlled by binding to 
the latency-associated peptide (LAP) and latent TGFβ binding protein (LTBP) and is reversed 
by proteolytic cleavage35. Briefly, after protein synthesis and signal peptide removal by 
endoplasmic reticulum proteases, the pro-TGFβ peptides assemble in inactive homodimers 
and are secreted in the extracellular space. The pro-TGFβ peptide is further cleaved in the 
secretory vesicles or in the extracellular matrix (ECM) by enzymes (convertases) into two 
fragments; a C-terminal immature TGFβ peptide and an N-terminal peptide (LAP). The 
LAP-TGFβ complex remains non-covalently attached (small latency complex, SLC) or binds 
further to LTBP forming the large latency complex (LLC)36. LTBP stabilizes the complex by 
binding to ECM components such as fibronectin, fibrillin1 and integrins37. 
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Mechanical stress, cell contraction, extreme pH or temperatures are some of the factors 
inducing disintegration of LLC by degradation of fibrous matrix (proteases e.g. plasmin, 
elastase, thrombin). Cleavage of LTBP by BMP1 protease and matrix metalloprotease 
enzymes (MMP-2) leads to release of TGFβ from the LAP complex38. Additional mechanisms 
of activation of latent TGFβ include integrins 39, fibronectin40 and the matricellular protein 
thrombospondin-141. After dissociation from the LAP, the active TGFβ homodimer is then 
recognized by the TGFβ type I and type II receptors on recipient cells in a cell autonomous, 
paracrine and endocrine manner. 
Level 2. Receptor binding 
Receptors of TGFβ signaling are serine/threonine kinase receptors and are distinguished 
in two types (type I and type II)12. The co-receptor class (type III; β-GLYCAN, ENDOGLIN and 
CRIPTO) has auxiliary function. Active TGFβ ligands bind to the constitutively active TGFβ 
type II receptor13. The type II receptor transphosphorylates the type I ACTIVIN receptor-
like kinase (ALK) thus leading to an interacting formation between a ligand homodimer 
and a heterotetramer of type I/ type II receptors14. Five type II receptors (TGFβRII, BMPRII, 
ACVR1A, ACVR1B, and seven type I receptors (ALK1-ALK7) have been identified42. Different 
combinations of receptor-ligand assemblies provide differential signaling specificity 
(Table 1). The predominant type I receptor of TGFβ ligands is the ALK543, with the exception 
of signaling via ALK1 in endothelial cells44. The ALKs contain an extracellular domain for 
ligand interaction, a glycine-serine residue rich (GS) domain; site of phosphorylation by 
the type II receptor occurs and the serine/threonine kinase domain45-47. Levels of activated 
receptors determine the levels and duration of activation of downstream signal mediators 48. 
Table 1. Combinations of receptor- ligand interactions of TGFβ subfamilies 
Abbreviations: ACVR2A; ACTIVIN A receptor type IIA, ACVR2B; ACTIVIN A receptor type IIB, 
ACVRL (ALK); ACTIVIN A receptor type II-like, AMH; anti-mullerian hormone, 
AMHR2; anti-mullerian hormone receptor type II, BMPR; bone morphogenetic protein receptor,
GDF; Growth and differentiation factor. TGFβR; transforming growth factor receptor. Adapted from49.
Ligand Type I receptor Type II receptor






























Level 3. SMAD protein recruitment
The intracellular canonical TGFβ pathway effectors, which mediate signal transduction from 
the receptors towards the nucleus, are the SMAD proteins. Nomenclature of SMAD is based 
on the homology with the C. elegans and Drosophila mutants SMA and MAD, respectively, in 
whom they were firstly identified50. Three classes of proteins are distinguished; the receptor-
associated SMADs (R-SMADs; SMAD1, 2, 3, 5, 8), the inhibitory SMADs (SMAD6, 7) and the 
common SMADs (co-SMAD4)14. Structurally, SMAD proteins have two globular domains 
(MH1 and MH2) associated by a regulatory linker region2. MH1 is required for DNA binding. 
The MH2 domain is required for interaction with membrane receptors, nucleoporins, other 
SMADs and transcription factors51. The linker region is a site for protein-protein interactions 
(positive and negative regulators of SMADs) and is regulated by phosphorylation e.g. by 
cyclin-dependent kinases (CDKs)52, MAPK kinases53. Ligand binding of TGFβ1, β2, and β3 
to the receptors leads to recruitment and activation of the SMAD2 and SMAD3 mediators. 
Instead, BMP ligands lead to recruitment of SMAD1, SMAD5 and SMAD8 to BMP receptors. In 
either case, R-SMADs are phosphorylated by the type I receptor at the Ser-X-Ser motif of the 
MH2 domain (X; any aminoacid) and form a complex with other R-SMADs and subsequently 
with the co-activating SMAD4 mediator42. The R-SMAD/SMAD4 protein complex relocates 
to the nucleus, where it interacts with DNA sequences by assembling with co-activators, 
transcription factors (TFs) and chromatin modifiers to regulate activation and repression 
of certain target genes.
Level 4. Transcriptional activity
Activated R-SMAD2 and -3 form heterodimeric or heterotrimeric complexes with SMAD4 
complexes and bind to DNA in CAGA motifs namely SRE sites (SMAD-response element). 
BMP-related TFs (R-SMAD1, 5, and 8) bind to SRE sites but have higher affinity for GC-rich 
regions containing BMP-response-elements (BRE sites). An additional BMP binding site has 
been identified (GC-BRE) that confers cell type- specific gene transcription in endothelial 
versus smooth muscle cells54. However, R-SMADs DNA binding affinity is weak, thus they 
form complexes with other DNA binding TFs, which explains the multifunctionality of 
SMAD pathway42. Cell type- specific responses are determined by differential interaction 
with specific TFs that direct R-SMAD2 and -3 in certain binding sites; e.g. RUNX factors in 
hematopoietic cells, OCT4 and SOX2 in pluripotent cells, MYO-D to initiate the muscle 
program55. Interactions of R-SMADs with co-activators and co-repressors determine activation 
or inhibition of downstream target gene transcription. Identified co-activators of SMADs 
include adenovirus early gene1 (E1A)- binding protein (p300), CREB binding protein (CBP) 
and Specificity protein-1 (SP1). Co-repressor factors associating with R-SMADs are the SWItch/
Sucrose Non-Fermentable (SWI/SNF) nucleosome positioning proteins, DNA demethylating 
complex (DNDM), Forkhead Box (FOX) and elongation factor-2 (E2F) factors2. The TGFβ target 
genes SKI and SNON are co-repressor factors associating with phosphorylated SMADs in 
the nucleus in order to repress SMAD transcriptional activity56. Multiple target genes are 
controlled by SMAD canonical pathway and can be classified based on the activating ligand 
(TGFβ/ACTIVIN/NODAL or BMPs) or depending on its function on a particular cellular process 
(angiogenesis, ECM, immunosuppression, apoptosis). Table 2 indicates the most common 
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Table 2. Common target genes of TGFβ/ BMP pathways classified in various cellular responses
Abbreviations. ACTA2; aorta smooth muscle actin α 2, BAD (BCL-XL); BCL-2 associated agonist of cell death, BIM; 
BCL-2-like 11, CDKN1A (p21, CIP1); cyclin-dependent kinase inhibitor 1A, CDKN1B (p27KIP1); cyclin-dependent 
kinase inhibitor 1B, CDKN2B (p15INK2B); cyclin-dependent kinase inhibitor 2B, CMYC; v-myc avian myelocytomatosis 
viral oncogene homolog, COL1A1; collagen type 1 α 1, COL1A2; collagen type 1 α 2, CTGF; connective tissue growth 
factor, DCN; decorin, ECM; extracellular matrix, EMT; epithelial-to-mesenchymal transition, GADD45B; growth arrest 
and DNA-damage-inducible 45 beta, FN; fibronectin, GATA3; GATA binding protein 3, HMGA2; high motility group 
AT-hook 2 protein, ID; inhibitor of differentiation, IKBα; nuclear factor of kappa light polypeptide gene enhancer 
in B-cells inhibitor, alpha, JUNB; jun B proto-oncogene, MET; mesenchymal-to-epithelial transition, MMP2; matrix 
metalloprotease 2, NKX2.5; NK 2 homeobox 5, OSX; osterix (Sp7 transcription factor), PAI-1; plasminogen activator 
inhibitor 1, PDGFβ; platelet derived growth factor β polypeptide, RUNX2; runt related transcription factor 2, SMAD; 
Sma-Mad family member, SNAIL; snail zinc finger protein, TIMP1; tissue inhibitor of metalloproteinase 1, TSP-1; 
thrombospondin-1, ZEB; zinc finger E-box binding homeobox, ZO-1; tight junction protein 1.
1.3.3. Regulation of the TGFβ pathway 
Multiple inhibitory mechanisms are integrated within the network of TGFβ pathway to 
control the timing, duration and cell context- dependent activation of the signaling cascade. 
Induction of TGFβ pathway simultaneously elicits negative feedback mechanisms that 
span throughout the cell from the extracellular space to the nucleus (reviewed in51,56-58). 
Understanding these mechanisms is clinically relevant for treatment of human diseases, as 
the intrinsic inhibition of the pathway has been mimicked with drug compounds used in 
clinical trials. An overview of these mechanisms is discussed in this section, starting from 
the cell membrane level and progressing gradually towards the cytoplasmic and nuclear 
level (Fig.2). 
1.3.3.a. Antagonists of ligands 
Extracellular inhibitory mechanisms of the TGFβ signaling include the association with LAP 
and LTBP that keep ligands in inactive state, as discussed in section 1.3.2 (level 1), as well 
as additional molecules with similar function. 
For example, DECORIN is a small leucine-rich proteoglycan produced by smooth muscle 
cells, fibroblasts and vascular endothelial cells with inhibitory role for TGFβ59. It forms a large 
network with matrix proteins, receptor tyrosine kinases and growth factors, in particular 
with components of the TGFβ pathway60. DECORIN inhibits TGFβ signaling by sequestering 
the ligands and preventing their binding to the type II receptor61. 
Alternatively, DECORIN employs the calmodulin-dependent kinase II to phosphorylate 
SMAD2 at the inhibitory Ser-240 site62. This phosphorylation does not prevent nuclear 
translocation of SMAD2 (due to activating Ser 465/467 phosphorylation by type I receptor) 








































































2. Type III receptors















FKBP12 blocks type I receptor phosphorylation 
Phosphatases PP1, PP2A deactivate ALK5 or R-SMADs
SMAD7/SMURF2 mark receptors/R-SMADs for degradation
SMAD6 blocks R-SMAD1/5/8 binding to SMAD4
MAPK
CDK
MAPK, CDK linker phosphorylation of R-SMADs
inhibits nuclear retention
Corepressor TGIF competes with 
coactivators p300/CBP to inhibit transcription
Corepressors SNO and SKI  and FOXO DNA binding factors
inhibit R-SMAD/SMAD4 binding to gene promoters
FOXO3
P300 CBP
I-SMADs occupy SRE binding sites








Fig.2. Regulation of TGFβ pathway from extracellular space to nucleus 
Overview of the intrinsic TGFβ pathway mechanisms that control the duration of TGFβ signal activation at different 
subcellular localizations; (1) ligand antagonism in the extracellular space, (2) modulation of receptors and ligands 
at the membrane level by ENDOGLIN, CRIPTO, β-GLYCAN, pseudoreceptor bone morphogenetic protein and 
activin membrane-bound inhibitor BAMBI, FKBP12, (3) intracellular inhibitors I-SMADs (SMAD6 and SMAD7), 
E3 ligases SMURF1/2, phosphatases PP1/PP2A, MAPK and CDK kinases inhibit R-SMAD nuclear translocation via 
phosphorylation in the linker site of R-SMADs, (4) at the nucleus level, SMURF1/2 mark activated R-SMADs for 
degradation, SMAD7 and FOX0 factors directly inhibit gene transcription, co-repressors TGFβ-induced factor 1 
TGIF, SNO and SKI antagonize for gene promoter binding either with the co-activators p300/ CBP or R-SMAD/
SMAD4 complexes and E3 ubiquitin ligase ARKADIA marks I-SMADs for degradation to elongate signal activation.
Other antagonists of different branches of TGFβ signaling with similar function as DECORIN 
are NOGGIN, GREMLIN, SCLEROSTIN, CHORDIN, FOLLISTATIN, VENTROPTIN, Follistatin-related 
gene protein (FLRG), CERBERUS and LEFTY18,22,63 that negatively regulate signal activation 
at the ligand level. 
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1.3.3.b. Type III receptors 
A third group of TGFβ receptors (type III co-receptors) modulate the interactions between 
the type I/ II receptors and the ligands. To date, three such co-receptors have been identified; 
β-GLYCAN, ENDOGLIN (CD105) and CRIPTO (TDGF1). β-GLYCAN directs TGFβ2 to the type II 
receptor to facilitate signal activation64 and enhances ALK3 and ALK6 signaling65. ENDOGLIN 
plays an important role in angiogenesis along with ALK1, TGFβ, BMP9 and BMP1066,67. 
ENDOGLIN is present in two isoforms (S and L form) as a membranous and secreted protein68 
and facilitates the binding of TGF ligands to the ALK1 in endothelial cells (activation of 
R-SMAD1, 5, 8), therefore preventing association of TGFβ with ALK5 and activation of 
R-SMAD2/369. The TGFβ ligands NODAL and GDF1/3 require association with CRIPTO co-
receptor in order to bind to the ALK4, ALK5 and ALK7 and induce activation of SMAD2 and 
SMAD3. Paradoxically, CRIPTO can inhibit SMAD2/3 phosphorylation mediated by TGFβ by 
binding to TGFβ ligands and preventing their binding to receptors70,71. Multiple functions 
are attributed to CRIPTO that are NODAL and TGFβ-independent, such as modulation of 
a network of signaling pathways (e.g. NOTCH, WNT, AKT) pathways in various tissues72-74 
and regulation of EMT in development and cancer75. The role of CRIPTO will be extensively 
discussed later in this chapter. 
A distinct type of co-receptors are the glycoproteins of the repulsive guidance molecules 
(RGM) family, which inhibit specifically the ligands of the BMP branch76-78, as opposed 
to other co-receptors that recognize various ligands. RGMa, RGMb (Dragon) and RGMc 
(hemojuvelin) particularly enhance signaling mediated by BMP2 and BMP4 or guide them 
to use alternative type II receptors e.g. ACVR2A instead of BMPRII79. 
1.3.3.c. Inhibition at the cell membrane level 
Assembly of type I and II heterodimers is tightly regulated by a certain type of pseudoreceptor 
(BMP and ACTIVIN membrane-bound inhibitors; BAMBI) that consists of an extracellular 
domain of high structural similarity to serine/threonine receptors80. BAMBI binds BMPs and 
type I/ type II receptors but lacks cytoplasmic domain, thus preventing activation of type 
I receptor and downstream signaling22. 
TGFβ and BMPs directly induce BAMBI transcription81,82 as a negative feedback mechanism 
to regulate the duration of signaling. To regulate the step of type II receptor-induced 
type I receptor transphosphorylation, the Ser/Thr residues of the type I receptor, that are 
phosphorylated by the type II kinase, are blocked by the inhibitor FK506-binding protein 
(FKBP12). In the inactive state (absence of ligand), type I receptor interacts via the GS domain 
with the inhibitor FKBP12 at the intracellular cell membrane site83. FKBP12 prevents type I 
phosphorylation rather than interaction with type II receptor and is a regulatory mechanism 
to prevent ligand-independent receptor activation for ALK584 as well as for BMP type I 
receptors85. Phosphorylation in the GS domain (adjacent to FKBP12 binding site) by the 
type II receptor releases FKBP12 and induces conformational change that facilitates binding 
of downstream effectors R-SMADs84,86.
In homeostatic conditions, R-SMADs are actively retained in the cytoplasm while SMAD4 
shuffles continuously from the cytoplasm to the nucleus48. 
The presence of the docking complex SMAD anchor for receptor activation (SARA) in the 
intracellular part of cell membrane keeps SMADs in the cytoplasm to facilitate receptor 
interaction and phosphorylation87. SARA binds SMAD2 and blocks the nuclear import signal 
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1.3.3.d. Post-translational modifications (PTMs) of receptors and R-SMADs
Post-translational modifications (phosphorylation, ubiquitination, sumoylation, glycosylation, 
fucosylation) affect protein folding and activity and as a result may increase or limit the 
bioavailability of the receptors and the activated R-SMADs during TGFβ response. In this 
paragraph an overview of the most common PTMs and their dynamic role in TGFβ pathway 
is discussed. 
Phosphorylation promotes or inhibits kinase activity of both type I and type II receptors; the 
Ser/Thr kinase of TGFβRII is constantly active due to autophosphorylation89, while Ser416 
phosphorylation inhibits kinase activity90. Type I receptor exerts multiple functionalities by 
dual kinase activity; Ser/Thr phosphorylation as well as autophosphorylation of tyrosine (Tyr) 
residues. Lee et al., have demonstrated the way Tyr autophosphorylation of ALK5 activates 
ERK kinase which comprises a cell growth stimulus, counteracting the SMAD2/3 cytostatic 
pathway91. Deactivation of kinase domain and activated SMADs by dephosphorylation 
controls the duration and location of signal. Phosphatases are enzymes that remove the 
phosphate group from proteins and reverse phosphorylation, thus, switching the protein 
activity. There are three types of phosphatases, Ser/Thr, Tyr or of dual activity that contain 
catalytic and regulatory domains. Phosphatases PP1 and PP2A are established regulators 
of TGFβ member dephosphorylation. For instance, PP1 is recruited to dephosphorylate 
the type I receptor by a complex of SMAD7 and growth arrest and DNA damage protein 
GADD34, a regulatory subunit of PP192. Phosphatase PP2A dephosphorylates SMAD3 but not 
type I receptor or SMAD2, indicating the specificity and regulatory role of these enzymes93. 
In addition to Ser/Thr and Tyr phosphorylation multiple other PTMs have been identified to 
positively or negatively regulate the function of the type I/ II receptors, such as sumoylation, 
ubiquitination94 and possibly others. Such modifications also alter protein folding, protein 
localization, assembly with other proteins or target a protein for degradation95. For instance, 
sumoylation marks on unique sumoylation site Lys389 of the ALK5 modulates the kinase 
activity, recruits SMAD3 and potentiates signal activation56,96,97. 
Activated TGFβ/type I and type II complexes follow two intracellular routes; the clathrin-
mediated endocytosis, that propagates the signal downstream, and the caveolae-associated 
cascade that interrupts the signal by degradation of the ligand/receptor complexes57. 
The degradation takes place either in lysosomes or in proteasomes; the latter requires 
ubiquitination by E3 ligases (ARKADIA, SMURF family)98,99. 
SMURF1 and SMURF2 often bind I-SMADs, such as SMAD7100, and migrate from the nucleus 
to the cytoplasm to form complexes with activated receptors in the caveoli. This leads to 
polyubiquitination of the receptors, SMAD7 and SMURFs all of which are proteolytically 
degraded57,80. 
ARKADIA is a RINF-finger E3 ubiquitin ligase that marks SMAD7 for ubiquitin-mediated 
degradation thus aborting SMAD7 inhibitory function and enhancing SMAD signaling101. 
Inflammation-induced nuclear receptor NR4A1 is responsible for ARKADIA activation and 
SMAD7 degradation, a mechanism linking TGFβ hyperactivation with inflammation and 
tumor promoter activity102,103. 
Function of ARKADIA is highly determined by sumoylation104,105. Deletion of ARKADIA 
in mice leads to upregulation of SMAD6, SMAD7 and SKI and it has been shown that it 
located in the MH2 domain; this process is reversible upon phosphorylation of R-SMADs 
by the type I receptor88. 
Page | 12
Chapter 1
ubiquitinates SMAD6 and potentiates BMP signaling106. ARKADIA has dual functions at 
the transcriptional level where it interacts with chromatin remodelers such as Polycomb 
repressive proteins but has also proven to abort methylation-induced gene silencing 
of TGFβ target genes107. In addition, ARKADIA ubiquitinates SKI/ SNON associated with 
pSMAD2/3 complexes108. Degradation of this repressory network allows the formation of 
new pSMAD/ DNA complexes109,110 
In addition, other PTMs of R-SMADs include phosphorylation in the linker region by GSK3, 
MAPK kinases, or cell cycle protein CDK4 which causes ubiquitination by E3 ligases (Lys11, 
Lys48) and proteasomal degradation42. Sumoulation of SMAD4 (Lys 159, 113) has been 
reported to regulate its function in renal and breast cancer cell lines111,112. Nuclear pSMAD4 
is monoubiquitinated by USP9x to disrupt activated R-SMAD/SMAD4 complexes and release 
SMAD4 back to the cytoplasm113. 
1.3.3.e. Inhibitory SMADs (I-SMADs) and transcriptional repression 
An intracellular negative feedback loop mechanism, directly induced by TGFβ114, as well as 
BMPs115, is the activation of I-SMADs, SMAD6 and SMAD7116,117. I-SMADs effectively limit or 
block completely the pathway by functioning in multiple subcellular localizations57,80. The 
intracellular circulation of I-SMADs is coupled to their function; (i) type I receptor blockers at 
the cell membrane117,118, (ii) antagonists of SMAD4 in the cytoplasm119,120 or (iii) occupying 
SRE binding sites to prevent SMAD- DNA functional complexes in the nucleus121.  SMAD7 is 
primarily found in the nucleus during absence of ligand stimulation, while presence of TGFβ1 
directly mediates the nuclear export of SMAD7 to induce inhibition of the type I receptor122. 
In addition, I-SMADs recruit E3 ubiquitin ligases SMURF1 and SMURF2 to direct them 
towards the phosphorylated type I receptors or R-SMADs for degradation2,100. SMAD7 
inhibits both TGFβ and BMP signaling123,124 while SMAD6 has BMP-specific action15. I-SMADs 
are subjected to functional restriction by other interacting proteins; e.g. BMPs activate an 
inhibitor of SMAD6 (associated molecule with the SH3 domain of signal transducing adaptor 
molecule, AMSH), which blocks SMAD6/SMAD1 complex formation and thereby SMAD1 
phosphorylation is maintained125.  
Ultimately, the presence of activating and repressing TFs and complexes at a given gene 
promoter site determines whether SMADs exert a positive or negative transcriptional activity. 
Co-repressors play an important role in regulating the duration of signaling and proper 
target gene expression. Such co-repressors SKI, SNON, TGFβ-induced factor homeobox (TGIF) 
that interfere with SMAD signaling by repressing transcription of TGF/BMP target genes126. 
In turn, expression of these co-repressor proteins is induced by SMAD signaling. Another 
mechanism is the recruitment of HDAC co-repressor complexes to inhibit transcription 
which is mediated by I-SMADs; SKI co-repressor recruits HDACs and methylase complexes 
to repress the expression of SMAD7127. 
1.3.4. NODAL pathway 
NODAL pathway has important functions during gastrulation, mesendoderm formation, 
induction of extraembryonic endoderm and left/ right asymmetry during embryonic 
development63,128-131. During adulthood NODAL pathway is quiescent and its reactivation 
is often associated with pathological situations132. 
Signaling is activated upon NODAL, GDF1 or GDF3 ligand binding to ALK4 or ALK7 and 
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ACTIVIN type II receptors. The accessory type III receptors CRIPTO (obligatory co-receptor for 
NODAL, GDF1/3) and CRYPTIC bind to the activated receptor heterotetramer and mediate 
SMAD2 activation133. CRIPTO and CRYPTIC belong to the epidermal growth factor-like, 
cysteine-rich CRIPTO-FRL1-CRYPTIC (EGF-CFC) protein domain family and have a dual role 
both as membranous and secreted proteins after cleavage of the glucophosphatidylinositol 
(GPI) link134-136. CRIPTO also functions as a chaperone of immature NODAL protein, directs it to 
the extracellular part of cell membrane where it is being subjected to proteolytic activation 
by convertases (FURIN and PACE-4)137. CRIPTO interacts with NODAL and TGFβ ligands via 
the EGF domain and with ALK4 via the CFC domain. CRIPTO interaction with NODAL is 
functionally dependent on PTM O-fucosylation on Thr88 residue which is characteristic 
of EGF domains138. 
Downstream signal transduction is primarily mediated by SMAD2/SMAD4 heterodimers, which 
associate with nuclear co-factors such as p53, FoxH1 to direct target gene transcription139. 
A role for SMAD3 during NODAL signaling remains to be further characterized140. NODAL 
target genes involve NODAL itself63, CRIPTO141 and the negative regulators LEFTY and 
CERBERUS139,142. LEFTY is an extracellular direct antagonist of NODAL ligand and the 
ACTIVIN receptors, while CERBERUS and CERBERUS-like (DAN protein family) bind to NODAL 
preventing its association with the receptors. Other negative regulators of NODAL signaling 
include; DAPPER2 (binds type I/II receptors for lysosomal degradation)143, ECTODERMIN144, 
TGIF1/2 proteins (co-repressors)145, BMP3 and BMP7 (sequesters NODAL ligand)133,146. In turn, 
NODAL can also inhibit BMP signaling in a CRIPTO-independent manner133. 
In addition, CRIPTO has autonomous signaling functions that are NODAL and SMAD-
independent74. In fact, CRIPTO individually regulates a large network of signaling pathways 
e.g. activating p38, ERK and c-SRC/MAPK/AKT pathways130. For this alternative function 
CRIPTO synergizes with glucose-related protein-78 (GRP-78)70,72, GLYPICAN-1 signaling147, 
caveolin148, apelin149, leucine-rich protein 5 (LRP5)150 or NOTCH to modulate WNT and 
NOTCH signal transduction75,151, 
Aberrant CRIPTO pathway activity, particularly mediated via GRP78 by inhibiting TGFβ 
and activating and c-SRC/MAPK/AKT, is associated with human malignancies; breast, lung, 
prostate, ovarian, bladder, colon, liver, melanoma and glioblastoma73,152-160. Prognostic 
methods and strategies for in vivo inhibition of tumor-promoter role of CRIPTO/ GRP78 
(peptides, monoclonal antibodies, tumor vaccines) are being studied preclinically161-163 
and in phase I clinical trials164. 
1.3.5. Non canonical SMAD pathways 
In addition to the classical SMAD pathways TGFβ receptors exert their multifunctionality by 
activating non-SMAD pathways such as PI3K/Akt, Ras/ MAPK kinases ERK, p38 and JNK165 
(Fig.3). Both canonical and non-canonical branches have as starting point the TGFβ receptors, 
however, differential activities of the receptor complex due to PTMs, ligand-independent 
oligomerization or binding to different interaction partners determine which subpathway 
will be activated56. 
Cells circumvent the growth inhibition of TGFβ/SMAD signaling by using TGFβ to activate 
the growth stimulatory RAS/ RAF/ MEK/ ERK MAPK kinase pathway42. The MAPK kinase 
pathway is activated in response to mitogens such as EGF bound to receptor tyrosine 
kinases (RTKs)51. However, TGFβ elicits MAPK response due to the dual kinase activity of 
TGFβRI and TGFβRII to transautophosphorylate not only serine/ threonine but also tyrosine 
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residues (RTK function)56. Activation of RTK leads to activation of monomeric GTPase RAS, 
which acts as a scaffold between the RTK and RAF kinase (MAPKKK). Phosphorylation and 
activation cascade of downstream kinases MEK (MAPKK) and finally ERK (MAPK) propagates 
the signal to alter gene expression in favor of cell growth and proliferation166. ERK MAPK 
kinase propagates the signal via phosphorylation of target proteins in the cytoplasm (e.g. 
inhibition of SMADs by linker phosphorylation) and also translocates to the nucleus to 
activate gene regulatory proteins166,167. 
Another TGFβ/ non-SMAD mediated mechanism is the RTK function of TGFβ receptors, 
which activates the phosphoinositole-3 kinase (PI3K) pathway168. PI3K activation leads to 
recruitment of kinases PDK1 and Akt receptors in phosphorylated lipid docking sites where 
the two kinases phosphorylate each other leading to activation of Akt169. Akt phosphorylates 
other proteins such as cell survival complex mTOR 170 or inactivates the proapoptotic 
protein BAD via recruiting adaptor protein 14-3-3171,172. The net outcome is cell survival, 
growth and proliferation. 
In addition, TGFβ regulates actin cytoskeleton formation and cell adhesion by interfering 
with the monomeric GTPase proteins of the RHO family (RHO, RAC and CDC42)168; TGFβRII 
phosphorylates polarity protein PAR6 that together with SMURF1 marks RHO for ubiquitin-
mediated degradation173. The function of RHO signaling is to maintain the epithelial tight 
junctions, thus, TGFβ induces a mesenchymal transformation of epithelial cells173. 
Another example of non-SMAD activation by TGFβ receptor is the network of ubiquitin 
ligase TNFα-associated factor 6 (TRAF6) and TGFβ-associated kinase 1 (TAK1), key inducers 
of p38 and JNK MAPK pathway56. TGFβ activates TAK1 via TRAF6; TRAF6 is constitutively 
bound to ALK5 and upon oligodimerization due to TGFβ binding, TRAF6 molecules reach 
physical proximity, which facilitates their transautoubiquitination. Subsequently, TRAF6 
ubiquitinates TAK1 and activates its kinase catalytic domain. TAK1 activates p38 and JNK 
MAPK by phosphorylation resulting in activation of transcription factors AP-1, c-JUN and 
c-FOS174-176. Furthermore, as TGFβ activates other non-SMAD pathways similarly members 
of other signaling pathways are modifying SMAD effectors2. Thus, it should be kept under 
consideration that crosstalk between pathways is usually bi- or multidirectional, increasing 




























































Fig.3. TGFβ/non-SMAD pathways and their biological effects
TGFβ receptors alter gene expression via the MAPK/ERK, TRAF6/TAK1/p38/JNK, NF-κB, PI3K/AKT/mTOR and 
PAR6/RHO signaling pathways that lead to multiple cellular responses. 
1.4. TGFβ signaling pathway in homeostasis and disease- studies in 
liver, prostate and connective tissue
A plethora of biological processes are regulated by TGFβ cytokine in embryonic and adult 
tissues by means of growth arrest, cell differentiation, EMT, immune system regulation and 
angiogenesis. In fact, the description attributed to TGFβ as cytokine (growth factor) is a 
paradox since it promotes growth inhibition and halts cell proliferation (cytostasis) under 
nearly all physiological conditions. Transcriptomic analyses have revealed that TGFβ signaling 
controls the activation and repression of hundreds of genes in a single cell and leads to 
differential gene responses177,178. Thus, tight regulation of this pathway is crucial to guard 
signal specificity; the importance of growth inhibition is evident in human cancers where 
TGFβ-induced cytostasis is often disrupted.
The homeostatic role of TGFβ is cell type and microenvironment-dependent.  In brief, 
anti-proliferative effects are exerted in epithelial tissues (for instance; skin, liver, breast, 
prostate, and lung)58. Mechanistically, TGFβ inhibits cell cycle progression via regulation 
of cyclin-dependent kinase inhibitors p15INK4B, p21CIP1, and p27KIP1179,180, inhibits cell 
cycle promoters such as the proto-oncogene C-MYC and ID proteins. Apoptosis is induced 
through activation of caspase protein cascade181. Non-epithelial tissues are also under growth 
control e.g. endothelium182,183, fibroblasts184, neuronal tissues185, cells of the immune and 
hematopoietic system186. In addition, TGFβ signaling orchestrates wound-healing response 
in most organ systems. If aberrantly regulated, it may lead to excess scar tissue formation, 
accumulation of collagen-producing cells and extracellular matrix (ECM) and eventually 
disrupt normal tissue structure and physiology. 
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In this thesis the homeostatic role of TGFβ is highlighted in three organ systems; liver, 
prostate epithelium and connective tissue (Fig.4).
Liver function is crucial for the homeostasis of the whole organism and is evident by the 
evolutionarily preserved regenerative capacity of mammalian liver. Under normal conditions, 
the liver is metabolically active but quiescent in terms of cell proliferation; cell division 
is minimal greatly due to cytostatic role of TGFβ among other factors. Overexpression 
of TGFβ1 in hepatocytes (liver epithelial cells) leads to increased apoptosis, fibrosis and 
reduced proliferative and regenerative response187,188. Liver fibrosis is associated with 
genetic polymorphisms of TGFβ gene leading to increased TGFβ1 serum levels189. The role 
of TGFβ in the liver is extensively discussed in Chapter 2. 
Prostate tissue is divided in proximal, distal and intermediate ducts and androgen hormones 
are the main regulators of its physiology190. Androgens have functional convergence with 
TGFβ191 which is expressed in a gradient form in prostate tissue. High levels of TGFβ signaling 
are present in the quiescent proximal region of ducts and androgen ablation reverses the 
proximal-distal TGFβ signaling gradient, leading to an increase in TGFβ signaling in the distal 
region192. Testosterone (5α-dihydro) decreases the level of TGFβ receptor II (TGFβRII) leading 
to suppression of the ability of TGFβ to down-regulate expression of Bcl-xL and cyclin D, 
activate caspase-3, and induce apoptosis193. Overexpression of dominant-negative form of 
TGFβ receptor type II in transgenic mice decreased apoptosis in the prostate epithelium194. 
Accordingly, in vivo injection of TGFβ1, in the ventral prostate, increases apoptotic events195. 
Connective tissue is an example of a non-epithelial system that is regulated by TGFβ 
signaling. Connective tissue is comprised of cells and ECM, and is found in different types 
in the body. ECM is composed by glycoproteins, fibrous proteins and glycosoaminoglycans, 
which are secreted by cells, mainly fibroblasts. Variations in the ECM composition determine 
the properties of the connective tissue (tendons, cartilage, eye cornea or if the matrix is 
calcified, it can form bone or teeth). Generally, connective tissue is either loose (adipose), or 
dense (tendons between muscles and bones), depending on the fiber arrangement. TGFβ 
plays an important role in the maintenance of the structural elements of ECM (collagen, 
elastin fibers) as well as the proliferation of fibroblasts and their transdifferentiation into 
myofibroblasts (MFBs). MFBs are crucial for wound healing as the main source of ECM 
proteins and maintain a vicious cycle of TGFβ production, responsiveness to TGFβ and 
ECM secretion. In fact, normal wound healing in adult animals is greatly regulated by TGFβ; 
initially TGFβ is secreted by platelets, which leads to recruitment of other immune cell types 
(neutrophils, macrophages) and fibroblasts196. Fibroblasts initially migrate into the wound 
area and secrete a collagen- and cellular fibronectin-rich ECM197. In fact, fibronectin cross-
talks with TGFβ signaling influencing activation of latent TGFβ in the matrix. Wound closure 
is achieved by ECM remodeling and angiogenesis; both processes are orchestrated by the 
pro-fibrotic and pro-angiogenic actions of TGFβ. 
Despite the plethora of biological processes that TGFβ signaling is involved in, from a 
clinical point of view, aberrant TGFβ expression/ downstream activation is often associated 
with connective tissue disorders198. Mutations in TGFβ receptors are linked with Marfan 












































































Fig.4. Homeostasis in distinct organ systems and their regulation by TGFβ signaling
(A). Liver disease progression from fibrosis to hepatocellular carcinoma (HCC), tissue cell types and morphology are 
depicted. Effects of TGFβ are summarized for the epithelial cells (hepatocytes and cholangiocytes) and the hepatic 
stellate cells (HSCs), precursors of myofibroblasts (MFBs) in the liver. (B). Prostate tissue morphology with proximal 
and distal ducts comprised by luminal and basal cells (neuroendocrine cells are not depicted here). TGFβ ligands 
exist in morphogenic pattern during homeostasis; highest concentration and signaling occurs in the proximal 
duct site (note that prostate stem cells reside in this area). Androgens promote cell proliferation by interfering 
with TGFβRII levels and androgen ablation therapy following prostate cancer detection leads to reversal of TGFβ 
distribution (distal instead of proximal). Transformed luminal cells cause adenocarcinoma development. Basal cells 
also contribute to prostate malignancy following a step of luminal differentiation. (C). Morphology and cell type 
distribution in the connective tissue underlying the epithelial barrier. Connective tissue is comprised by matrix 
(proteoglycans, hyaloronan, glycoproteins, elastin and collagen fibers) and a cellular component (endothelial 
cells, macrophages, mast cells and the most abundant, fibroblasts). 
1.5. TGFβ signaling in fibrosis
We discussed the structural role of the matrix in connective tissues in the previous section. 
However, the matrix is not a static element made by cellular proteins but it mechanically 
and biochemically influences basic cellular processes201. Bissell et al., firstly defined this 
phenomenon, as dynamic reciprocity between ECM, cell cytoskeleton and nuclear matrix202. 
This interplay of matrix and cells not only affects cell shape or motility but also actively 
alters signal transduction and gene expression pattern (mechanotransduction)203-205. TGFβ, 
a latent extracellular cytokine that regulates cellular processes by activating intracellular 
signaling is a key factor in the interface between cells and their ECM context206. For instance, 
the matrix can induce the expression of TGFβ1207. Moreover, the extracellular agonist of 
TGFβ ligands, DECORIN, is also a regulator of collagen maturation and assembly208. In this 
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section, we will discuss the implications of TGFβ in pathological fibrosis, in particular liver 
and Dupuytren’s fibrosis (DD). 
During the last decades fibrosis has accounted for up to 45% of deaths209 and yet there are 
no approved antifibrotic therapies available. Fibrosis is a pathological state characterized 
by the excessive deposition of ECM proteins commonly occurring during wound healing 
and tissue regeneration. Excess deposition of collagen and proteoglycans is associated with 
reduced tissue epithelization and cell death, and eventually disrupted cell functionality 
and tissue architecture (Fig.5). Fibrosis may affect most organ systems and lead to a variety 
of diseases including liver cirrhosis, connective tissue fibrosis, pulmonary hypertension, 
systemic sclerosis and heart fibrosis representing a major medical challenge. 
A complex set of genetic, immune response, epigenetic factors may lead to fibrosis by 
triggering constant activation of quiescent tissue fibroblasts to MFBs, the key pathogenic 
cells in fibrosis. The cellular and molecular phenotype of MFBs is highly dependent on TGFβ 
signaling pathway210,211. TGFβ stimulates ECM protein synthesis and secretion, decreases 
expression of proteases that cleave ECM (matrix metalloproteases, MMPs) and increases 
protease inhibitors (TIMPs)212. The outcome is a shift of balance towards ECM protein 
synthesis, secretion and deposition rather than degradation leading to scar tissue formation.
TGFβ family members and target genes include ECM and cytoskeleton proteins that are 
often deregulated in fibrotic and other diseases, such as plasminogen activator inhibitor 
1 (PAI-1)213, collagen type1α1 (COL1A1), COL1A2, COL4A2, COL5A1, COL5A2, α-smooth 
muscle actin (α-SMA, ACTA2) and fibronectin214-216. 
1.5.1. Liver fibrosis 
Liver fibrosis (cirrhosis) occurs in response to chronic liver injury due to alcohol intoxication 
or viral hepatitis Β and C infections (HBV, HCV)217. TGFβ plays a role in all the stages of liver 
disease progression from inflammation, cirrhosis to cancer formation 218. 
Cirrhosis often is a precursor to hepatocellular carcinoma (HCC), thus, the need for effective 
treatment is high. Collagen-depositing MFBs accumulate around the portal and central vein 
of the liver lobules. The source of MFBs in the liver is mainly the pericyte population of the 
liver, hepatic stellate cells (HSCs), transformed epithelial cells and fibrocytes from the bone 
marrow. The activation of HSCs and their transdifferentiation to MFBs is controlled by the 
pro-fibrogenic effect of TGFβ pathway, evident by multiple studies (reviewed extensively 
in218-220). Fibronectin modulates this response of HSCs to TGFβ during liver injury in a way 
that controls the extend of fibrosis221. In vivo deletion of SMAD3 results in improvement of 
liver fibrosis in mice222. 
Expression of fibrosis-related genes, such as collagens or PAI-1 in MFBs is induced by 
phosphorylation of SMAD2 and SMAD3 in the linker site by CDK4, p38 and JNK MAPK 
kinases223. In fact, the differential phosphorylation isoforms of SMAD2/3 (linker, cytoplasmic) 
may induce different levels of the inhibitor SMAD7223. SMAD2 and SMAD3 both are needed for 
induction of MMP2 and αSMA expression, however, it seems that SMAD2 mostly orchestrates 
the TGFβ-mediated cytostasis and maintains the epithelial phenotype while SMAD3 is 
indispensable for TGFβ-profibrogenic role224,225. SMAD7 blocks the fibrogenic response of 
HSCs in acute liver injury but not in chronic liver injury indicating that this negative feedback 
mechanism might be deactivated in liver fibrosis226. However, hepatocyte-specific deletion 
of SMAD7 in transgenic mice with chronic carbon tetrachloride (CCl4)-induced fibrosis 
ameliorates the fibrotic phenotype227. 
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TGFβ binds to both ALK1 and ALK5 in the liver, thus, a certain balance of ALK1/ ALK5 ratio 
is necessary to maintain the balance between protective, anti-fibrogenic action and pro-
fibrogenic activity of TGFβ. TGFβ/ALK1 signaling appears to directly antagonize TGFβ/ALK5 
signaling, while in other circumstances, the presence of ALK5 is an absolute requirement for 
efficient TGFβ/ALK1 signaling228. The role of BMPs in liver diseases is also being addressed 
by recent studies suggesting BMP9 as a pathological driver229 and BMP7 as an anti-fibrotic 
factor that antagonizes TGFβ pathway230-232.
1.5.2. Dupuytren’s fibrosis (part of this section is published in233)
Dupuytren’s disease (DD) is one of the most common connective tissue disorders with 
a higher prevalence in Caucasians of northern Europe234 and particularly in males234-236. 
DD is a fibroproliferative disease affecting the palmar fascia, and may lead to permanent 
flexion contracture of the digits237 (Fig.5). Current treatment of DD is symptomatic; surgical 
removal of the fibrotic nodules and cords leads to immediate relief of the contractured 
digits. Injection of collagenase enzyme obtained from Clostridium Histolyticum, has been 
approved by FDA (Xiaflex, Pfizer) as alternative treatment for DD238. However, the recurrence 
rate of the disease using the current therapeutic approaches remains high. 
Several environmental and genetic risks have been linked to DD supported by studies 
of familial cases, ethnicity and sex prevalence, occurrence in twins and postoperative 
recurrence239. However, the genetic mechanism is not fully understood and there is no 
evidence of a single genetic dysregulation as a cause of DD. Thus, the aetiology of DD 
remains unknown, although it is clear that TGFβ plays a role in the pathogenesis210,237. 
High TGFβ1, TGFβ2 mRNA and protein levels have been associated with DD fibrosis210,215,240. 
TGFβ2 shows intracellular localization within MFBs in the proliferative and involution stages 
of the disease241,242. In fact, transdifferentiation of quiescent fibroblasts into MFBs requires 
signaling by TGFβ243,244. Contractility of MFBs in increased after in vitro stimulation with low 
concentrations of exogenous TGFβ245-247. Presence of SMAD binding sites on the promoters 
of connective tissue growth factor (CTGF/CCN2), αSMA, fibronectin and collagens, Serpine-1 
(PAI-1) show that TGFβ directly controls the expression of MFBs-associated proteins248-253. 
The high proliferative properties of MFBs contradict the TGFβ proapoptotic and growth 
inhibitory role. However, it has been proven that in DD cells TGFβ induces expression of 
other cytokines such as platelet-derived growth factor (PDGF); in turn, PDGF activates ERK 
MAPK kinase pathway, induces expression of proto-oncogene c-MYC242 and promotes cell 
proliferation. Studies on BMP signaling have not proven a link between deregulated BMP 
pathway members and DD pathogenesis. BMP6 has a potential antagonistic role against 
TGFβ as shown by reduced in vitro contractility and SMAD/ ERK activation in fibroblasts 
treated with BMP6254.
Although much work has attempted to unravel the complex mechanisms underlying 
fibrosis, the current state of the art in DD and generally in fibrosis research fails to meet 
the demanding need for treatment255. Cell culture models for studying fibrosis currently 
include primary cells and/or cell lines as well as the use of different culture matrices and 
co-culture models. It is now evident that two-dimensional (2D) cultures of fibroblasts have 
distinctly different properties and gene expression profile than the intact tissue256,257. This 
can be, in part, attributed to the in vitro protocols and adaptation to culture conditions. 
For experimental reasons, connective tissue obtained from carpal tunnel tissue operations 
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Fig.5. Overview of the disrupted tissue architecture and the most common molecular aberrations associated 
with Dupuytren’s fibrosis
Fibrotic nodules consist of highly proliferative and contractile myofibroblasts (MFBs) that deposit matrix proteins. 
Normal matrix turnover and degradation are decreased due to molecular aberrations leading to fibrosis, tissue 
disfiguration and digit contracture. Adapted from 237.
control” while it may be molecularly very similar to DD258. All these describe one of the 
biggest limitations of the field, i.e. the lack of an in vitro/ex vivo model that allows molecular 
and genetic manipulation. A recent study proposes xenograft transplantation of human DD 
fibroblasts in the subcutaneous layer of the skin of mice as an in vivo model for DD research, 
but yet this model poorly recapitulates the human disease.
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1.6. TGFβ/ BMP signaling in cancer
In normal cells, growth inhibition mediated by TGFβ is usually dominant over growth 
stimulatory action of other factors. However, the situation is reversed in malignant situations 
that are characterized by hyperproliferation due to mitogens, action of mutated oncogenes 
and hyposensitivity to anti-proliferative action of TGFβ198,259. In normal conditions, TGFβ 
keeps normal epithelial tissues in a proliferation blockage, thus having tumor-suppressor 
role. Occurrence of oncogenic somatic mutations in epithelial cells leads to formation of 
primary carcinoma. Aberrant cell division without tight regulation of DNA synthesis and 
repair leads to additional accumulation of oncogenic mutations. 
The primary carcinoma may remain spatially confined if the TGFβ-mediated cytostatic cues 
are intact. However, if mutations in TGFβ/ BMP ligands, receptors and SMADs occur, then 
the cells acquire proliferative and migratory properties that facilitate cancer metastasis58. 
Apart from its cytostatic role, TGFβ regulates many other biological processes that are 
hallmarks of cancer, such as EMT, suppression of cytotoxic T lymphocytes and angiogenesis. 
Thus, malignant cells hijack TGFβ to obtain phenotypic characteristics crucial for cancer 
progression such as mesenchymal cell shape, increased motility and invasion through basal 
membranes into extracellular space and blood vessels (Fig.6). 
The tumor-promoting role of TGFβ in advanced carcinomas is mainly due to TGFβ signaling 
through the SMAD/1/5/8 machinery and inducing expression of ID proteins260, via non-SMAD 
pathways (circumventing the Ser/Thr kinase activity of TGFβ receptors or PTM regulation of 
linker and C-terminal SMAD phosphorylation) to activate the growth-stimulatory pathways 
ERK and AKT56,168,261. The essential role of TGFβ in stimulating metastasis262 and the high 
frequency of genetic mutations in TGFβ pathway leading to cancer263 highlight the necessity 
for TGFβ-targeting therapies. 
1.6.1. Epithelial-to-mesenchymal transition (EMT)
 
Polarized cells, positioned adjacent to each other via tight junctions, comprise epithelial 
tissues. Epithelial cells are stably in contact with the basal membrane forming a basal-
apical polarity and have epithelial- specific gene expression pattern (E-CADHERIN, ZO-1, 
LAMININS)264. However, epithelial cells are quite plastic under certain conditions such as 
tissue morphogenesis during development and would healing49. Plasticity allows them to 
progressively switch on the genetic program of mesenchymal gene expression that leads 
to loss of epithelial phenotype and acquisition of a mesenchymal one. This cellular process 
of epithelial cells disintegrating from the basal membrane, losing cell-cell contacts and 
becoming motile is termed epithelial-to-mesenchymal transition (EMT) and is reversible 
(MET) (Fig.6). Both EMT and MET are mechanisms of cancer metastasis; cancer cells undergo 
EMT to extravasate from the primary tumor into blood circulation or from blood vessels into 
other epithelia and reverse to MET program to invade and colonize the new sites259 (Fig.6). 
During EMT, epithelial proteins such as E-CADHERIN are downregulated and mesenchymal, 
cytoskeletal and ECM proteins are upregulated (FIBRONECTIN, VIMENTIN, NCADHERIN265). 
High motility group AT-hook 2 protein (HMGA2) via TGFβ/SMAD pathway regulates EMT 
master transcription factors SNAIL1/2, ZEB1/2 and TWIST, which repress epithelial genes 




Prostate cancer (PCa) arises from precursor lesions, defined as prostatic intraepithelial 
neoplasia (PIN), gradually progresses to locally invasive disease and ultimately to metastasis. 
Disease progression from PIN lesions or organ-confined PCa towards metastatic PCa involves 
multiple genetic and epigenetic events to take place. Each stage of this disease is associated 
with characteristic morphological and histo-pathological alterations. Associated with the 
human disease are also genetic chromosomal alterations, which have led to the identification 
of several tumor suppressor genes (for example, TP53, CDKN1B and PTEN) and androgen 
related gene fusions (such as TMPRSS2-ERG) of key importance in the early stages of the 
disease282, 283. Furthermore, the androgen receptor (AR) is required for maintenance of the 
prostate epithelium during normal organogenesis as well as carcinogenesis, including 
hormone-independent cancer. The androgen refractory stage is the final and most aggressive 
stage of the cancer, characterized by bone and lymph node metastases. As in most cancer 
types, TGFβ has growth inhibitory effects on primary PCa, but tumor-promoting role during 
advanced stages and leads to metastasis formation. In addition, stromal TGFβ can activate 
AR signaling in absence of androgens, which might contribute to hormone-independent 
growth of tumor284. 
ID1 activation, is implicated in MET and promotes metastasis260,269. TGFβ promotes EMT by 
interfering with RHO complexes in epithelial cell junctions; this mechanism is TGFβRI and 
SMAD-independent (TGFΒRII/PAR6/SMURF1/RHO)173. The reverse process (MET) is regulated 
by BMP signaling, in particular BMP7270. 
1.6.2. Tumor angiogenesis  
Deregulation of TGFβ and BMP pathways lead to vascular defects, such as pulmonary 
hypertension, hereditary telangiectasia (HHT)198,271. Deletion of TGFβ ligands or ALK1 in 
transgenic mice results in embryonic lethality due to vasculogenesis defects272,273. Vascular 
homeostasis relies on endothelial cells, smooth muscle cells and pericytes274. The key 
angiogenesis-related members are TGFβ ligands, ENDOGLIN, ALK1 and its ligands BMP9 
and BMP10, that synergize with proangiogenic factors such as vascular endothelial growth 
factor (VEGF), NOTCH pathway, PDGF, angiopoietins and basic fibroblast growth factor 
(bFGF)271,275,276. 
Angiogenesis determines normal and malignant tissue growth. The requirement for new 
vessels is high in primary tumors as the highly metabolic and proliferative cancer cells 
need oxygen, nutrients, and cytokines from the blood. As the epithelial cells cluster and 
proliferate forming a primary carcinoma, new vessels must be formed (Fig.6) in order 
for the blood flow to reach all the cells within the tumor (angiogenic switch). However, 
since tumor cells cannot perform de novo angiogenesis they have evolved to disrupt the 
existing normal vasculature and recruit endothelial cells into the tumor277. TGFβ promotes 
tumor angiogenesis by inducing expression of MMPs that degrade the basal membrane 
and assist endothelial cell migration278. TGFβ induces MMP2 and MMP9 in tumor cells279. 
Tumor angiogenesis is also influenced by MMP14 protease that releases membranous 
ENDOGLIN into its secreted form280. High TGFβ-expressing prostate cancer cells induce 
an angiogenic response when transplanted in vivo281 and inhibition of TGFβ activity by 
neutralizing antibodies decreases tumor angiogenesis282.  
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Fig.6. Stages of cancer progression and TGFβ/BMP signaling
Formation of primary carcinoma and phenotypic transition of epithelial cells into mesenchymal cells (EMT) are 
depicted. Tumor microenvironment (supportive stroma) consists of infiltrating immune cells and myofibroblasts 
(MFBs) derived by quiescent fibroblasts or by tumor epithelial cells via EMT. Crosstalk between the stroma and tumor 
cells, using cytokines and other signaling molecules, promotes acquisition of tumor vasculature (angiogenesis) 
which sustains tumor growth by delivery of nutrients and oxygenated blood. Tumor cells may disseminate from the 
primary tumor into the blood circulation, extravasate from the vessels through the perivascular and extracellular 


































EMT and migration of PCa cells are induced by TGFβ via MAPK kinase ERK2 and c-MYC 
expression285. BMP ligands also play a role in PCa286, in particular BMP2, BMP4, BMP7287, 288. 
Cell proliferation is increased in presence of BMP2 and BMP4, however, it not clear from 
the existing studies whether BMP7 is tumor promoter or suppressor in prostate289. BMP2 
expressed by osteoclasts might act as chemotactic factor for PCa cells to metastasize to 
the bone290. BMP9, the primary ligand of ALK1 in endothelial cells, might also play a role 
in PCa, as in other types of cancer as we will discuss in the next section. BMP9 is expressed 




Liver tissue can endure chronic damage and symptoms become evident in advanced disease 
stage making prognosis of liver diseases difficult. Hepatocellular carcinoma (HCC), one 
of the most frequent forms of cancer, is usually detected at a late stage, thus the current 
forms of therapy are often not curative e.g. tumor resection, treatment with sorafenib or 
eventually liver transplantation292.  
TGFβ plays a role in HCC development218,293 and one of the first indications was the finding 
that circulating levels of TGFβ1 in plasma from HCC patients are significantly higher than in 
patients with cirrhosis or viral hepatitis294. SMAD7 overexpression has tumor-suppressing 
role295. Liver expresses high amounts of BMP9 that are also secreted in the circulation296. 
HSCs and potentially also hepatocytes, express ALK1 and ENDOGLIN, the interaction partners 
of BMP9, under normal and pathological conditions. Apart from a role in endothelial cells 
and HSCs, BMP9 has been associated with HCC297. 
NODAL expression is shut down after embryonic development, but it is re-expressed in adult 
tissues, along with its co-receptor CRIPTO during malignant conditions. NODAL and CRIPTO 
are involved in plasticity of tumor cells, cancer-stem cell maintenance and metastasis298,49. 
In the liver, stem cell renewal transcription factor NANOG is reactivated during HCC and 
it mediates EMT by activating NODAL/ CRIPTO and SMAD3 expression158. Moreover, the 
interaction partner of CRIPTO, GRP78, has been associated with liver cell stress response 
and HCC299-301. Thus, both the canonical and the non-canonical NODAL pathway have a 
contributing role in HCC. 
1.7. Anti-TGFβ strategies (antisense oligonucleotides/ small molecule 
kinase inhibitors/ ligand traps)
Several components of the TGFβ pathway have been investigated for drug development; 
however, only a few compounds have proceeded into later stages of clinical trials302,303. TGFβ 
signaling is a key pathway for homeostasis and given its pleiotropic, cell-type and context-
dependent role, therapeutic interventions are beneficial for a particular tissue or cell type, 
at a specific stage of the disease. During cancer progression, if tumor cells are insensitive 
to growth inhibition by TGFβ, therapeutic enhancement of signaling might be useful to 
constrain their proliferation if the tumor is detected at an early stage304. Nevertheless, 
malignant cells quickly adapt and start using TGFβ to promote their metastatic spread. 
Given that cancer diagnosis does not detect micrometastasis events, it is more logic to 
preventively inhibit rather than induce TGFβ signaling when a primary tumor is diagnosed 
in order to stop the lethal consequences of metastasis. Moreover, expression levels of TGFβ 
pathway members are often elevated during conditions such as organ fibrosis and cancer; 
thus, inhibitory strategies are required to block the fibroproliferative role of TGFβ in MFBs 
(fibrosis), cancer-associated fibroblasts (CAFs) and to suppress tumor cell metastasis. 
A growing number of recent studies have tested TGFβ inhibitors as combination treatment 
with chemotherapeutics305, immune stimulatory agents (interleukin-2)303,306 or to minimize 
radiotherapy-induced carcinogenesis307. In the cancer field inhibition of TGFβ type I and 
type II receptors has been accomplished, while in the fibrosis field most of the anti-fibrotic 
drugs are designed to interfere at the ligand level of pathway transduction, therefore 
preventing their binding to the receptors308. The most successful TGFβ inhibitory strategies 
(Fig.7) used in experimental and clinical studies (table 3) are the antisense oligonucleotides 
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AONs targeting TGFβ ligand mRNA (Antisense Pharma), the competitive peptides against 
ligands (ligand traps, Digna Biotech), the neutralizing antibodies and the small molecule 








































































Fig.7. Schematic overview of different inhibitory strategies targeting TGFβ/BMP signaling activation 
TGFβ pathway activation can be inhibited by different compounds, which target mRNA/ protein expression or 
protein function and act at different subcellular compartments; (1) compounds that inhibit activation of latent 
TGFβ (DECORIN mimetic, THROMBOSPONDIN and αvβ6 INTEGRIN antagonists), (2) soluble type II/ III receptor 
ectodomain peptides that trap ligands and prevent interaction with a functional receptor, (3) neutralizing antibodies 
against TGFβ, BMP ligands and receptors, (4) small molecule kinase inhibitors that inhibit activity of type I or type 
II receptors , (5), antisense oligonucleotides interfering with mRNA translation of TGFβ2 mRNA, oligonuleotides 
that bind to gene promoters mimicking SMAD binding (pyrrole-imidazole polyamide, SMAD decoy ODN), (6) 
thioredoxin peptide aptamers for SMAD binding to co-factors FOXH1,LEF and CBP (TRX). 
1.7.1. Antisense oligonucleotides (AONs)
AON methodology is used to modulate gene expression in a sequence-specific way and 
has shown broad therapeutic applicability in many human diseases, particularly in the 
field of muscular dystrophies309 with very promising results reported in clinical trials310,311. 
The use of AONs in basic and translational research aims to either “partially correct” a 
non-functional protein or to disrupt a protein of interest as a way to inhibit its expression 
or functionality. AONs can be designed to interfere at the molecular level either during 
messenger RNA (mRNA) splicing or mRNA translation into protein. Splicing involves the 
Page | 26
Chapter 1
removal of non-coding sequences (introns) and “stitching” of the remaining coding DNA 
(exons). Particular exon(s) encoding protein domains crucial for protein function can 
become excluded from the mature mRNA; specific AONs bind to sites involved in exon 
splicing in the exon-intron boundaries and interfere with the splice machinery. Thereby, the 
particular exon is not integrated as part of the mRNA312. The resulting mRNA has an intact 
open reading frame and is translated into a protein that lacks only the particular peptide 
sequence encoded by the skipped exon. The advantage of this system is that no genetic 
alterations are introduced, since interference occurs exclusively at the pre-mRNA splicing 
process. Translation-blocking AONs function by forming a complex with complementary 
mRNA sequence; RNA-RNA or RNA-DNA dimers are then recognized by RNAse helicase 
(H), which leads to mRNA degradation313. Alternatively, AON binding to mRNA in the 5’ 
untranslated region might interfere with 5’ cap formation, ribosome binding and recognition 
of the ATG starting codon, thus hindering mRNA translation into protein314. 
AON-mediated inhibition of TGFβ ligand expression has been proposed and attempted 
as a novel cancer therapy for various malignancies. Interference with TGFβ1 production 
at the mRNA level by AON AP11014, developed by Antisense Pharma/Isana Therapeutics, 
significantly reduces TGFβ1 in prostate, lung and colon cancer cell lines315. TGFβ2 cytokine 
plays a key role in glioblastoma and pancreatic cancer. Trabedersen, interferes with TGFβ2 
mRNA translation and has reached the phase III of clinical trials for glioblastoma treatment316. 
The same company has developed TGFβ2-targeting AONs for glaucoma treatment (phase I 
trials). Another antisense TGFβ2 strategy has been developed for tumor vaccines (Lucanix, 
NovaRx)317,318. TGFβ2 AON sequence is transfected into lung cancer cells, which are used as 
anti-tumor vaccination. The vaccine has progressed into phase III clinical trials. 
A distinct type of gene therapy is the nucleic acid or peptide-based strategies that inhibit 
SMAD transcriptional activity at the DNA level; (1) the SMAD transcription factor- “decoy” 
double stranded oligonucleotides (decoy ODN) that block SMAD binding to SRE binding 
sites319,320, (2) pyrrole-imidazole polyamide compounds designed to bind to DNA minor 
groove in SRE binding sites, thus inhibiting SMADs to interact with gene promoters and 
other cis-regulatory elements321. 
1.7.2. Peptides that antagonize ligand function 
Ligand traps are peptides engineered to have the extracellular domain (ECD) of receptors 
or receptor-associated proteins, fused to stable region of an antibody (Fc of IgG). The logic 
is that the soluble receptor ectodomains will bind with the same affinity its ligands in the 
extracellular space and sequester them from binding to a functioning receptor on the 
cell membrane 322,323. Soluble receptor type II (TGFβRII-Fc) ligand trap was developed by 
Genzyme but did not progress into clinical trials324. 
Similar anti-TGFβ peptide mimicking the ECD of TGFβRIII receptor β-GLYCAN (Disitertide 
P144, Digma Biotech) is currently in phase II trials. P144  TGFβ1-inhibitor has been specifically 
designed to block the interaction of TGFβ1 with β-GLYCAN. It has shown significant anti-
fibrotic activity when applied topically in mice receiving repeated subcutaneous injections 
of bleomycin, a widely accepted animal model of human scleroderma325. Anti-fibrotic 
effects have been reported for liver fibrosis326, myocardial fibrosis327 and as combination 
therapy with antitumor immunotherapy328. Another compound of the same company is 
an antagonist based on the structure of THROMBOSPONDIN-1 (TSP-1) for the treatment 
of diabetic nephropathy329. The LSKL peptide binds to LAP domain of the latent complex 
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via the motif LSKL (Leu-Ser-Lys-Leu) and blocks TGFβ activation. αvβ6 INTEGRIN mediates 
release of latent TGFβ from LAP complex; anti-αvβ6 INTEGRIN antibody (STX-100, Stromedix) 
inhibits tumor progression in vivo by blocking activation of latent TGFβ ligands330. A similar 
peptide has been developed that mimics DECORIN binding to latent TGFβ; by blocking 
release of latent TGFβ the compound enhanced anti-tumor immune response in glioma331. 
Treatment with soluble ENDOGLIN ECD (ENDOGLIN-Fc) has beneficial outcome in inhibiting 
BMP9/ALK1 signaling and VEGF-mediated tumor angiogenesis and reducing tumor size in 
preclinical studies332. The ALK1-Fc ligand trap for BMP9 and BMP10 has anti-angiogenic 333-335 
effects with enhanced safety profile compared to VEGF inhibitors336. Treatment with ALK1Fc 
indicates anti-tumorigenic response of patients with solid tumors336 and is currently being 
tested in phase I clinical trials for recurrent ovarian and endometrial cancer (ClinicalTrials.
gov identifier; NCT01720173). Peptide aptamers (TRX-CBP, TRX-FOXH1, TRX-LEF1) have 
been engineered to inhibit SMAD binding to their transcription factor interacting partners 
CBP, FOXH1, LEF1337.
1.7.3. Neutralizing monoclonal antibodies 
Monoclonal antibodies are used for neutralization of excessive ligand or soluble receptors at 
the extracellular space. Due to their in vivo stability they can be administered less frequently 
however, administration is done intravenously, which remains a drawback. 
Neutralizing antibodies have been developed for binding to an individual or all TGFβ ligands 
(pan-TGFβ). TGFβ1-specific neutralizing antibody LY2382770 (Eli Lilly) was tested in phase II 
clinical trials for kidney fibrosis and although it was safe, it proved not sufficiently effective 
in ameliorating disease progression (ClinicalTrials.gov identifier; NCT01113801). CAT-192 
(Metelimumab) is a humanized antibody against TGFβ1. CAT-152 (Lerdelimumab) binds 
TGFβ2 (anti-scarring postoperative treatment of glaucoma)338. However, both antibodies did 
not show adequate efficacy and the studies did not proceed any further. A more effective 
neutralizing antibody is the pan-TGFβ compound Fresolimumab, which targets all three 
TGFβ ligands and showed promising anti-fibrotic and anti-cancinogenic potential. Single-
shot treatment with Fresolimumab against glomeruloschelosis is in phase I339 and is also 
being tested for malignant melanoma and renal cell carcinoma340. The antibody against 
human ENDOGLIN (TRC105) has anti-tumorigenic effects in advanced solid tumors341 and 
is currently in phase II clinical trials for glioblastoma342. Currently, TRC105 is also tested as 
combination therapy with VEGF inhibitors for prostate, breast, ovarian, and liver cancer (HCC). 
Phase II trials of TRC105 in combination with chemotherapy agents such as bevacizumab 
for recurrent glioblastoma (ClinicalTrials.gov identifier; NCT01564914), or sorafenib (VEGFR, 
PDGFR, RAF kinase inhibitor) for HCC (ClinicalTrials.gov identifier; NCT01306058) have 
shown promising outcome.  
1.7.4. Small molecule kinase inhibitors (SMIs) 
SMIs is a class of receptor kinase inhibitors which bind into the ATP pocket of the kinase 
domain, thus, preventing ADP to ATP conversion (phosphorylation) and receptor activation. 
During this mode of inhibition, TGFβ ligands bind to non-functional receptors (SMI blockage 
of the type I or type II receptor); thereby the signal is not transmitted downstream. SMIs have 
the advantages that are cell permeable due to their small molecular weight (as opposed 
to antibodies), however, they are less specific for a particular receptor because of the high 
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structural similarity of the ATP pocket among kinases. 
Several SMIs have been developed against TGF and BMP receptors with different selectivity 
for particular kinases or in vitro and in vivo performance343. A panel of frequently used SMIs 
(Fig.7) targeting the TGFβ branch (ALK4, ALK5 and ALK7) is the SB-431542, SB-505142, 
LY-364947 (selective for ALK5) and A-83-01. Potent BMP receptor inhibitors against ALK2, 
ALK3, ALK6) is the LDN-193189 and dorsomorphin (compound C).
Although several SMIs have shown promising results in in vitro and in vivo preclinical studies 
(SB-431542, SB-505124, GW788388, SD-208)344 they did not meet the pharmacokinetic 
stability criteria of clinical trials303. Currently, the SMIs being tested in preclinical studies 
are the LY-580276345, LY-550410346,347, LY-364947348 and LY-2109761349 for the treatment 
of various types of cancer. A study for HCC treatment with sorafenib (VEGFR, PDGFR, RAF 
kinase inhibitor) combined with ALK5 kinase inhibitor (LY-2157299) in patients with HCC 
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Abstract 
Adult organ regeneration occurs in many systems, such as in liver, skin, intestine and 
heart, indicating that postnatal life is not a static or quiescent state but a dynamic and 
complex process. The liver is a spectacular organ, exhibiting high regenerative capacity 
crucial for homeostasis and tissue repair: injuries induced mechanically or chemically, can 
be completely restored. Regeneration involves extensive cell division, inflammation and 
extracellular matrix remodeling processes. At the molecular level, one of the key mediators 
of regeneration response is the secreted cytokine transforming growth factor-β (TGFβ). TGFβ 
is a profibrogenic and anti-proliferative protein with pleiotropic functions depending on 
the cellular context. In this review, we discuss the role of TGFβ in the development of the 
liver and in adult liver regeneration, with particular emphasis on its role in regulation of 
hepatocyte regeneration and hepatic progenitor cell-induced regeneration. Finally, we give 
an overview of the current direction of liver research towards cell replacement therapies. 
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In the adult organism, the liver has a prominent role in maintaining homeostasis under both 
normal and pathogenic conditions. Cholesterol and glucose metabolism, lipoprotein, bile 
acid and serum protein synthesis and secretion are complex functions performed in the 
liver1,2. Dysregulation of these vital functions not only impairs the organ function itself but 
also affects all other organ systems; this may explain the phenomenal regenerative capacity 
of the liver throughout adult life. Following 60-70% partial hepatectomy (PH)3,4 the remaining 
intact part of the liver can compensate for the tissue loss by restoring the initial size and 
mass, while maintaining full liver functionality. Interestingly, hepatic progenitor cells (HPCs) 
are not required for this regeneration process; however, if liver function is impaired HPCs 
take over the regeneration capability5,6. PH is a standardized strategy to study regeneration 
of the entire organ within a time frame of 5-7 days in rodents7, in humans it is employed 
to enhance organ repair8. 
A unique feature of liver regeneration is that it does not depend on a single stem cell 
population as in other tissues such as blood, intestine, and skin9,10. All liver cell types 
are involved through rounds of mitosis and apoptosis: hepatocytes, stellate cells (HSCs), 
endothelial cells (ECs), biliary epithelial cells (BECs or cholangiocytes) and macrophages 
(Kupffer cells). Hepatic cells are organized in symmetric structures, liver lobules, which 
contain a central vein, in the centre of each lobule, and six surrounding portal triads 
(portal vein, hepatic artery and bile duct). From early response, through de novo synthesis 
of transcription factors to termination of proliferation and size adjustment, each step is 
tightly regulated. Cell-cell and cell-extracellular matrix interactions are crucial for the liver 
architecture. After injury, the hepatocytes, the main functional liver cell type, become 
apoptotic and release signals that stimulate cell proliferation of the remaining hepatocytes. 
Cell proliferation follows a consistent pattern, starting from the portal triads of the liver 
lobule and proceeding towards the central vein. Hepatocytes maintain high contact with 
sinusoidal cells during regeneration, a process named hepatocyte-sinusoid alignment11, 
ECs and BECs start proliferating, stellate cells progress from a quiescent to an activated 
state, differentiating to myofibroblasts (MFBs). MFBs contribute to the final stages of liver 
regeneration as they are responsible for extracellular matrix protein synthesis such as 
collagen, fibronectin, laminin, integrins12 and matrix protein remodeling. Only after chronic 
liver damage, when the hepatocyte proliferation is exhausted, the hepatic progenitor cells, 
also referred as HPCs in the mouse, become activated and can differentiate into both hepatic 
and cholangiocytic lineages.
Despite the high regenerative capacity of adult liver, compared to other organs, liver 
abnormalities such as cirrhosis and liver cancer still occur with high incidence. Epidemiologic 
data indicate that hepatocellular carcinoma is the fifth most prevalent type of cancer and 
the second cause of cancer death worldwide13. The puzzle of the molecular mechanisms 
controlling liver regeneration has only begun to assemble and our current understanding 
is that several signaling pathways are involved and act dependently to each other. One of 
the main orchestrators of the injury-induced response in the liver is transforming growth 
factor β (TGFβ) signaling pathway and in this review, we will discuss the recent advances 
regarding the function of TGFβ during regeneration and how this knowledge can be used 
in cell replacement therapies. Bone morphogenetic proteins (BMPs), also members of the 
TGFβ family, while important players in liver regeneration, will not be discussed and we refer 
instead to other reviews14,15. Moreover, fibrosis and hepatocellular carcinoma will not be 
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addressed in this review16. Finally, the role of other signaling pathways, such as Fibroblast 
Growth Factor (FGF) and Wingless/Integrated (Wnt) will be addressed by others in this edition.
2. Liver architecture and function
2.1. Hepatic development 
During embryonic development, the formation of definitive endoderm at gastrulation is the 
first step towards hepatogenesis. Endoderm germ layer forms a primitive gut tube consisting 
of three subdomains, the foregut, midgut and hindgut and gives rise to liver, pancreas, 
lungs and thyroid tissue17. The first hepatic formation, called the hepatic diverticulum, can 
be distinguished, around 9 dpc, adjacent to the developing cardiac tissue. Fetal hepatic 
progenitor cells or hepatoblasts, that will generate the main functional liver cell types, 
hepatocytes and BECs, delaminate from the epithelium at 9.5 dpc and migrate to the 
septum transversum mesenchyme (STM) to form the liver bud. During 10-15 dpc, the liver 
bud undergoes growth and eventually becomes the main site for fetal hematopoiesis until 
bone marrow takes over just before birth18. 
The embryonic liver originates from the ventral foregut19; however, liver tissue is in fact a 
mosaic of both endoderm and mesoderm-derived cell types. Epithelial cells (hepatocytes and 
BECs) derive from endoderm, while hepatic mesenchymal cells such as HSCs, Kupffer cells 
and blood vessels, have mesodermal origin20. Interactions among these two embryonic layers 
activate molecular pathways that are important for proper patterning of the liver.  Initially, 
inhibition of mesodermal Wnt and FGF4 signaling in the foregut enables liver and pancreas 
induction, whereas active mesodermal Wnt signaling in the posterior gut suppresses these 
tissue fates21. Retinoic acid signaling, produced from paraxial mesoderm cells, assists in the 
anterior-posterior positioning of liver and pancreas22. In the ventral foregut, FGF signals from 
cardiac mesoderm and BMP signals from septum transversum mesenchymal cells induce 
the liver program23,24. Mesodermal-derived BMPs affect the levels of  the endoderm specific 
gene Gata4, therewith blocking pancreatic and inducing liver specification, which is one of 
the key processes where TGFβ/BMP is required during hepatogenesis24.
2.2. Role of TGFβ during liver development 
TGFβ ligands (TGFβ1, TGFβ2 and TGFβ3) bind and activate TGFβ type I and type II Ser/Thr 
kinase receptors. Upon stimulation with TGFβ, the type II receptor phosphorylates the 
type I receptor which phosphorylates receptor-regulated SMADs (R-SMADs). The TGFβ 
pathway specific R-Smads, Smad2 and Smad3 subsequently form heteromeric complexes 
with the common co-SMAD or Smad4. These heteromeric complexes then accumulate in 
the nucleus, where they participate in transcriptional regulation of gene expression25,26. 
Inhibitory Smad7 antagonizes the activation of  R-Smads27. 
TGFβ is part of a large superfamily of proteins that includes, TGFβs, activins, nodal and 
BMPs. Activins and nodal, like TGFβ, signal via R-Smad2 and Smad3, whereas BMPs signal 
via R-Smad1, R-Smad5 and R-Smad825.
TGFβ/Nodal signals are present in the embryo already at onset of gastrulation, inducing 
endoderm formation17,28 and their disruption leads to abnormalities in all endoderm-derived 
organs. Regarding the liver, TGFβ ligands are expressed in the bud mesenchyme29. Embryos 
with double heterozygous mutations in Smad2 and Smad3 nuclear effectors of TGFβ 
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downstream signaling, have impaired liver organogenesis due to defective endodermal 
competence30. Proper dosage of Smad2 and Smad3 in the embryo is necessary for activation 
of Forkhead family member Foxa2 (Hnf-3) and Homeobox class protein (Hex) expression, 
two genes required for hepatic development31. Foxa2 is expressed early in development 
and regulates activation of hepatocytic gene expression program, including that of Hex 
and α-fetoprotein (AFP)31,32. In detail, Foxa2 binds to p53/Smad binding element sequences 
(SBE) of the AFP gene33,34 and the related Foxa1 transcription factor also interacts with TGFβ-
activated Smad2/Smad4 complexes to facilitate chromatin access and subsequent DNA 
binding and gene regulation35, suggesting the possibility of Smad proteins to cooperate with 
other transcription factors towards activation of AFP during development. AFP protein has a 
crucial developmental function and is expressed in fetal and neonatal mouse hepatoblasts 
but is silenced in adult hepatic progenitor cells or mature hepatocytes36. 
However, reactivation can occur in HPCs of adult regenerating rat liver following liver 
damage37. Also, in human hepatocellular carcinoma, postnatal silence of AFP is activated 
and facilitates re-entry into the cell cycle of differentiated hepatocytes34. Interestingly, once 
these cells are stimulated with TGFβ1, endogenous AFP protein expression is diminished34. 
TGFβ directly participates in the regulation of postnatal AFP repression and disrupting its 
signaling pathway leads to reactivation of AFP. Therefore, TGFβ signaling via Smad proteins 
is important not only for activation of developmentally important genes, such as AFP, but 
also for repression of these genes after birth. 
From another developmental aspect, studies on liver and pancreas organogenesis showed 
that progenitors of each lineage emerge from neighboring parts of the ventral foregut 
endoderm38. TGFβ/BMP and FGF signaling act in parallel and dynamic ways to restrict 
specification of hepatic and pancreatic progenitors39. Moreover, the TGFβ pathway plays an 
important role in hepatoblast specification40,41. Differentiation of bi-potential hepatoblasts 
to either hepatocytes or BECs fate follows a very distinct, spatial pattern. Hepatoblasts of 
liver parenchyma give rise to hepatocytes, while hepatoblasts located in the mesenchyme 
next to the portal vein, differentiate into BECs30,40. In particular, high activin/TGFβ signaling 
near the portal vein is needed for differentiation of BECs. On the contrary, activin/TGFβ 
must be suppressed in liver parenchyma by combined action of Hnf6/OC-1 and OC-2 
transcription factors in order to permit hepatocyte generation40,42. Thus, TGFβ is involved in 
multiple aspects of hepatogenesis, such as hepatic competence of endoderm and lineage 
specification of bipotential hepatoblasts and keeps hepatic gene expression tightly regulated. 
3. Liver regeneration 
Liver regeneration is a perfectly orchestrated process, able to restore liver architecture and 
mass within a very short period in rodents and human. Organ re-growth occurs in mammals 
and reptiles and usually recapitulates mechanisms of embryonic development43. Liver 
regeneration does not rely on an embryonic-like multipotential cell population, but mainly 
depends on the regenerative capacity of fully differentiated cells such as hepatocytes, HSCs 
and BECs. In the adult liver, mature hepatocytes are normally quiescent but they rapidly 
start proliferating after tissue damage. Their ability to reactivate telomerase activity prevents 
accumulation of mutations during cell divisions44. The combined action of all liver cell types 
is sufficient to reconstitute liver mass loss after liver damage induced by different causes 
such as viral infections, metabolic problems and 70% hepatectomy 8.
Adult liver regeneration and hepatogenesis are quite distinct processes, with differential 
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requirements regarding molecular signals, expression status and properties of the involved 
cell types. Although, regeneration is considered a postnatally-restricted process, recent 
studies43,45-48 discuss the potential capacity of embryonic liver for regeneration, in terms of 
cell proliferation and organ size growth as a response to injury or developmental defects. 
Such a paradigm was addressed in chimeric embryos generated with Hex null cells. The Hex 
gene is required for the formation of liver bud epithelium and thus, Hex chimeric embryos 
have disrupted integrity of the epithelium. Hex-null cells cannot form pseudostratified 
epithelium and were excluded from the epithelium by wild-type cells, which respond by 
increasing their proliferative rate in order to allow regrowth of the liver bud47. Therefore, 
hepatic endoderm cells can undergo compensatory growth to maintain the appropriate size 
of the developing liver bud, which indicates liver regeneration occurrence in the embryo. 
Another study has provided evidence of regrowth of developing liver following partial 
destruction of hepatic progenitor cells right after their emergence. Such elimination of 
progenitors was expected to lead to a smaller organ as it was observed with pancreas43. In 
contrast, by birth the liver had expanded up to the normal size, comparable to that of wild 
type animals. In addition, rat embryos that have undergone in utero partial hepatectomy 
have the potential to restore liver organ size within two days48. It is remarkable that not 
only adult liver has regenerative capacity but also embryonic liver can compensate for 
progenitor cell and growth factor deficiency, even at the crucial stages of embryogenesis. 
3.1. Molecular mechanisms controlling liver regeneration- implication of TGFβ 
signaling
The liver regenerative response is mediated by many signals. The main growth factors 
involved are hepatocyte growth factor (HGF), epidermal growth factor (EGF), interleukin-6 
(IL-6) and TGFβ49. TGFβ ligands play a controversial key role in adult liver regeneration. A 
summary of the genetic models of TGFβ family members and the liver developmental 
or pathologic phenotype can be found in Table 1. In early stages of regeneration, the 
hepatocytes must proliferate, therefore the inhibitory proliferation signals exerted from TGFβ 
are not needed, however, a few hours after liver damage, TGFβ is expressed in both liver and 
serum50, suggesting a central role for regeneration. TGFβ is also required at the end of this 
process for induction of EMT, inflammation, restoration of the original tissue architecture 
and cell-cell interactions51,52. The implication of TGFβ signaling in liver regeneration has 
been studied using different approaches, depending on the type of liver damage and cell 
type response (Table 2).
There is equilibrium among hepatic growth factors and mitoinhibition by TGFβ signaling. 
During regeneration initiation, cells must immediately divide in response to injury, thus, 
there is requirement for growth factors such as HGF and EGF. At this time point, TGFβ is 
upregulated, but the synchronous activation of HGF causes urokinase activation dependent 
removal of TGFβ. Urokinase protease degrades extracellular matrix proteins, in particular 
decorin, an inhibitory TGFβ binding protein53. TGFβ is, therefore, released from the liver 
matrix into the blood stream to allow cell proliferation and growth induction by HGF8,54, 
firstly removed from the portal area and progressively from the central area55, allowing 
hepatocyte proliferation56. 
A required signal for termination of cell proliferation is the shift of expression balance from 
HGF towards TGFβ-like factors. The purpose is to allow transfer of TGFβ back to the liver 
parenchyma to block further hepatocyte proliferation and restore cell-cell interactions and 
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extracellular matrix integrity57. The signals regulating inhibition of HGF and influx of TGFβ 
from circulation into the liver parenchyma are mainly unknown, but it is likely that a direct 
reciprocal antagonism between HGF and TGFβ components exists. In lung fibroblasts, TGFβ 
directly downregulates the expression of HGF58, which could also be the case in the liver. 
Molecular antagonism among HGF and TGFβ signals converges at the level of common 
miRNAs; HGF inhibits the fibrogenic action of TGFβ-induced myofibroblast transition and 
epithelial to mesenchymal transition (EMT) by upregulating miRNA-29. TGFβ itself aborts 
HGF inhibition by directly downregulating miRNA-2959. Other miRNAs have also been 
identified as regulators of TGFβ1/Smad3 activation during termination of regeneration60. 
The pro-fibrogenic and inflammatory action of TGFβ and its importance for regeneration 
termination has been extensively reviewed8. In this review we will highlight the role of 
TGFβ signaling in regeneration of both hepatocytes and hepatic stem/progenitor cells.
3.2. Regulation of hepatocyte regeneration by TGFβ signaling 
TGFβ-like factors, particularly TGFβ1, are produced at high levels in regenerating liver50 by 
nonparenchymal cells, such as HSCs, and act in a paracrine way exerting its antiproliferative 
effects by inducing apoptosis of mature hepatocytes (Fig.1A)61 via Smad and p38/ mitogen-
activated protein kinase (MAPK) dependent mechanisms62. Functional roles of Smad2 
and Smad3 in normal and regenerating adult liver was addressed by hepatocyte-specific 
inactivation of either or both Smads, which indicated that Smad3 is required for TGFβ-
induced apoptosis, whereas Smad2 is dispensable63. Administration of TGFβ1 and TGFβ2 in 
vivo after PH causes a reduction of the fraction of hepatocytes that progress from G1 to the 
DNA synthesis phase during regeneration64. This inhibitory effect is transient and reversible, 
causing a delay but not complete abolishment of regeneration. Enhanced proliferation of 
hepatocytes, observed in presence of dominant negative TGFβ receptor mutants65 and 
hepatocyte specific conditional deletion of TGFβRII57, supports the hypothesis that TGFβ1 
sustains quiescent hepatocytes in a differentiated state. Apoptosis induced by TGFβ is 
necessary as a growth stop signal for termination of regeneration process, but apoptosis 
must be circumvented at the early phase of regeneration, since hepatocytes must rapidly 
start proliferating at approximately 12-16 hours after injury66. Interestingly, during that stage, 
hepatocytes were described resistant to mitoinhibition of TGFβ either by downregulation of 
TGFβ receptors, TGFα, norepinephrine protective action67 or upregulation of transcriptional 
repressors68. Apoptotic signals induced by TGFβ in hepatocytes require reactive oxygen 
species (ROS) production mediated by NAPDH oxidase NOX469. Anti-apoptotic signals such 
as phosphatydilinositol-3-phosphate kinase or the MAPK/extracellular signal-regulated 
kinase (ERK) pathways inhibit TGFβ-induced NOX4 expression70. Such or similar mechanisms 
would secure normal liver regeneration even in case of TGFβ overrepresentation71. Disruption 
of TGFβ signaling by conditional knockout of TGFβRII affects hepatocyte proliferation57, 
but not termination of regeneration72. Downstream molecules Smad2 and Smad3 may 
operate even when TGFβ signaling is eliminated, due to stimulation from Activin A. Only 
combined inhibition of TGFβ and Activin A results in high proliferation of hepatocytes and 
delay of termination, implicating Activin A as a TGFβ equivalent regulator of regeneration72. 
Although it seems that presence of other signals (e.g. Activin A) will compensate for TGFβ 
ablation at the termination stage of liver regeneration, it should not be concluded that 
TGFβ signaling is not required.
A remarkable aspect of liver regeneration is the transdifferentiation capacity of differentiated 
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hepatic cells into other cell types. Transdifferentiation may occur among hepatocytes and BECs. 
Failure of BEC regeneration, due to bile duct damage, induces hepatocyte transdifferentiation 
into bipotential progenitors which give rise to BECs facilitating their regeneration73,74. 
Gradual loss of hepatocyte-specific and acquisition of BEC-specific transcription factors54 has 
been proposed as a mechanism for hepatocyte-to-BEC transdifferentiation. In the opposite 
direction, when hepatocytes are incapable of proliferation, BECs transdifferentiate into 
hepatocytes via an intermediate progenitor stage, by altering their molecular signature. 
Therefore, mature BECs and hepatocytes, both of which are embryonically derived from 
multipotent hepatoblasts, represent facultative stem cells for each other after cell damage75-77. 
This provides a paradigm of adult, fully differentiated cells, which retain and activate stem 
cell properties exclusively to replenish the needs of the adult organism. Indeed, the liver 
has evolved a unique regenerative capacity to guard its complex and vital functions and has 
fully capability to regenerate within. Studies on hepatocyte transdifferentiation towards BEC 
lineages suggest TGFβ1 signaling to participate in this process54. Cell tracking was performed 
in dipetidyl dipeptidase IV (DDPIV) chimeric rats that carry a DPPIV-positive population of 
hepatocytes transplanted from donor DPPIV positive rats. Hepatocytes and BECs of the 
recipient DPPIV negative rats do not express DPPIV. Following BEC injury by BEC-specific toxin 
administration and bile duct ligation, ~20% of the BEC population turned DPPIV-positive, 
indicating that they are derived from transdifferentiated DPPIV-positive hepatocytes54. 
An induction of TGFβ1 was observed in the hepatocytes at the area surrounding the 
repairing biliary ductules, resembling its expression pattern during development where 
high TGFβ1 signaling is also observed near the portal vein and is considered responsible for 
differentiation of hepatoblasts into biliary cells54. Thus, appearance of BEC clusters positive 
for the hepatocyte marker DPPIV provides strong evidence that BECs are derived from 
hepatocytes and that the apparent induction of TGFβ1 at the damaged portal area may be 
crucial for switching between hepatocyte, bipotential progenitor and BEC gene expression 
programs. However, the transdifferentiation concept of hepatocyte-to-BEC conversion was 
recently disputed by Malato et al.78 The authors used an in situ hepatocyte fate-tracing model. 
They assessed that all newly formed hepatocytes are derived from preexisting hepatocytes, 
that bile duct proliferation is necessary for the emergence of liver progenitor cell–derived 
hepatocytes and could not find evidence for hepatocyte-derived biliary epithelial cells or 
liver progenitor cells (double labeled EYFP and CK19 where not detected in this system, 
indicating that EYFP positive hepatocytes are not converted into BECs). 
TGFβ1 signaling may promote another transdifferentiation event, the conversion of fetal 
hepatocytes into a putative liver progenitor population, at least in vitro79. Fetal hepatocytes 
can circumvent growth inhibition and apoptosis by TGFβ1 if cultured in serum containing 
media. TGFβ-treated cells display a mesenchymal phenotype with loss of liver specific 
transcription factors (Hnf1α, Hnf4α, and Hnf6) and downregulation of gene expression 
signatures characteristic of differentiated hepatocytes, such as albumin and AFP. These 
cells are considered dedifferentiated cells, with induction of stem cell marker expression79, 
according to the authors representing a population of liver progenitors derived from 
hepatocytes under stimulation with TGFβ1. They further propose that such progenitors, in 
vitro retain differentiation potential back to hepatocytic cell fate, and could be used as a tool 
for isolation of such cells, although the molecular mechanisms behind this process remain 
unclear. Similar spontaneous hepatocyte mesenchymal transdifferentiation events that 
were enhanced with TGFβ have been reported for mouse hepatocytes that were cultured 
as monolayer. In an EMT-like process, hepatocyte features like albumin and transferrin 
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expression were lost with culture duration, whereas vimentin and collagen expression were 
established80-84. In this setting, TGFβ drives a so called late signature, including direct Smad 
target genes, like connective tissue growth factor (CTGF), plasminogen activator inhibitor 
-1 (PAI-1), Snail80,85, which has been associated with poor prognosis for HCC patients86. 
If, however, such scenario as described for cultured hepatocytes similarly occurs in vivo 
remains to be proven. 
Fig.1. TGFβ profibrogenic and mitoinhibitory action in (A) quiescent state and (B) after liver injury induction 
(A). Stellate cells (HSCs) produce TGFβ ligands, which in an autocrine manner promote transdifferentiation of HSCs 
into MFBs and in paracrine way acts upon hepatocytes and biliary cells (not indicated here). Other cell types also 
produce and secrete TGFβ, such as Kupffer cells and sinusoidal ECs. The anti-proliferative role of TGFβ on hepatocytes 
and HPCs is mediated by antagonism with HGF, EGF, TGFα mitogens. (B). HPC/oval cell-based regeneration for 
replenishment of non-replicative hepatocytes after extensive liver injury. TGFβ signals keep HPCs in quiescent 
state; however, there is evidence that TGFβ assists regeneration by promoting transdifferentiation of a subset of 
HPCs into HSCs. The production and remodeling of ECM by HSCs causes release of growth factors, which activate 
remnant HPCs to proliferate and differentiate into hepatocytic and BEC lineages. 
3.3. Regulation of oval cell response by TGFβ signaling 
Hepatocyte proliferation is the first key regenerative response; however, after extended 
and chronic liver damage replicative senescence leads to problematic cell regeneration87. 
Hepatocytes incapable of proliferating, such as in prolonged hepatitis infections, cirrhosis, 
non-alcoholic and alcoholic fatty liver diseases16, are replenished by hepatic progenitor cells 
(HPCs), which are not present in normal adult liver nor required for normal cell turnover78. 
HPCs or oval cells are believed to be bipotent epithelial cells that give rise to hepatocytes 
and BECs similarly to hepatoblasts. Such cells have been identified in the adult mouse and 
rat liver and there is debate concerning their identity, whether they comprise hepatic stem 
cells or transit amplifying cells78,88. 
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Following liver injury, HPCs emerge around the portal vein and the canals of Hering, they 
express both hepatic (albumin, transferrin) and BEC specific markers (CK19 and EpCam) and 
also unique markers such as OV-6 and Trop289. A population of Sox9-positive liver progenitors 
has been identified around the bile duct area during the regenerative process and is able to 
differentiate into hepatocytes in response to different types of hepatic injuries77, however 
it is not clear whether these Sox9-expressing progenitors comprise HPCs or precursors of 
HPCs. Further, cells expressing Oct3/4 stem cell markers have also been identified exclusively 
in the periportal tract during liver regeneration 90.
Spatial specification of adult stem or progenitor cells in the periportal area of the liver 
lobules and the canals of Hering suggest the existence of a stem cell niche or morphogenic 
signals that allow stem cell activation91,92. In regenerating liver, upon hepatic damage due 
to acetaminophen (APAP) administration, label retaining assays show the in vivo existence 
of four epithelial stem cell niches, that is the proximal biliary tree, intralobular bile ducts, 
periductal mononuclear cells and peribiliary hepatocytes91. It is conceivable to hypothesize 
that the liver regenerative capability is mediated by host stem/progenitor, located in intra-
hepatic niches that respond to microenvironment signals and contribute to the efficiency 
and flexibility of liver regeneration. Regarding TGFβ1 and its potential regulation of HPCs 
activation, it is essential to have insight on whether the spatial expression pattern of TGFβ 
and its downstream effectors coincide around the stem cell niches. 
Indeed, TGFβ1 is expressed in rat HSCs surrounding HPCs, which migrate from the site 
of emergence, the periportal area, towards the pericentral part while differentiating into 
ductile or hepatic cells93. To study the effect of TGFβ1 on HPCs, Park et al., used a model of 
PH combined with hepatocyte ablation by administration of acetylaminofluorene (2-AAF-
PH). A scenario was suggested as following; hepatocyte damage promotes HPC generation 
and HSC activation. HSCs secrete TGFβ1 which acts in a paracrine way to induce apoptosis 
of HPCs thus inhibiting their activation93.
The stem cell compartment of human liver, as identified by expression of stem cell markers 
Oct4 and Stat3, also expresses the TGFβ members TGFβRII and ELF94. Heterozygous Smad3-
adaptor protein β2-spectrin (β2SP)/ELF deficient mice have an expanded population of 
Oct3/4 positive progenitor cells residing in the periportal region, which highlights the 
inhibitory role of TGFβ on proliferation of progenitor cells90. Surprisingly, given the negative 
effect of TGFβ on HPC activation, disruption of TGFβ signaling, particularly of β2SP, does not 
enhance regeneration but instead causes a significant delay in regenerating human liver 
and in mice after PH95. Another aspect that highlights the role of TGFβ in liver regeneration 
is the increasing spatial expression of TGFβRI55 and β2SP from periportal to central areas, 
which is in line with the wave of proliferating cells. Undoubtedly, TGFβ is important for 
tuning liver regeneration but there is a dichotomy of the TGFβ effects on differentiation, 
emergence of stem/progenitor cells, apoptosis, cell proliferation, which is depending on the 
cell type and stage of damage or disease. For instance, TGFβ ligands affect the regeneration 
process by stimulating apoptosis of both hepatocytes and HPCs76 although both cell types 
may exhibit a differential response and sensitivity to TGFβ1, which is dependent on the 
cell physiological stage. Thus, in hepatocellular carcinoma, HPCs emerge and are highly 
proliferative in presence of the “growth inhibitor” TGFβ1. Interestingly, HPCs respond to 
TGFβ1, as seen by nuclear localization of phosphorylated Smad2, however they are insensitive 
to its mitoinhibitory actions (Ki67 staining), as compared to hepatocytes96. The difference 
in sensitivity between hepatocytes and hepatic progenitor cells in such settings has been 
attributed to the absence of inhibitory Smad6 in hepatocytes96. Thus, inhibition of hepatocyte 
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proliferation and the regenerative response mediated by TGFβ is circumvented by hepatic 
progenitor cell activation, thus providing a rescue mechanism to safeguard liver repair. 
This further indicates, that apoptosis and growth control exerted by TGFβ1 signaling on 
hepatic progenitor cells is only one aspect, since TGFβ1 may promote transdifferentiation 
or differentiation of hepatic progenitor cells into other lineages, e.g. towards the HSC 
lineage97. In presence of TGFβ1, hepatic progenitor cells not only upregulate ECM genes, 
such as collagen, matrix metalloproteases (MMPs) or tissue inhibitor of metalloprotease 
(TIMPs), but also induce expression of HSC markers such as desmin and glial fibrillary acidin 
protein (GFAP). Such conversion of epithelial hepatic progenitor cells to mesenchymal 
HSCs results from an EMT process that is at least partially orchestrated by TGFβ signaling97. 
Activation of HSCs is highly correlated with the hepatic progenitor cell response during injury, 
e.g. upon induction in the 2-AAF/PH model, when hepatocyte function is compromised. 
HSC activation requires TGFβ and the generated myofibroblasts can be detected around 
the portal vein area and in the proximity of hepatic progenitor cells. Stellate cells excrete 
MMPs and TIMPs, which by ECM remodeling cause release of bound growth factors that 
act on HPCs and, e.g., enhance their proliferation98. Selective inhibition of HSC activation 
causes diminished HPC activation (OV-6 and AFP positive) in the periportal area and thus, 
severely interferes with the regenerative response99. Hepatic rat stem cell lines when 
exposed to TGFβ increase the expression of differentiation markers such as albumin and 
tyrosine aminotransferase100, suggesting TGFβ as a signal required for differentiation of 
hepatocytes from HPCs.  
In summary, TGFβ has a direct negative effect on proliferation of hepatocytes and HPCs 
(Fig.1B). During regeneration, these cells lose sensitivity to the TGFβ cytostatic program 
and continue to divide in presence of TGFβ. The action of TGFβ in liver regeneration should 
not be reduced to its proapoptotic and growth inhibitory signal, as it is usually done. 
The contribution of TGFβ signaling in regeneration could be exerted by activating HSCs, 
which in turn promote HPC activation, directing them towards hepatocyte differentiation. 
Thus, TGFβ has pleiotropic functions depending on the cell type and the physiological 
situation of the organ. Therefore, the molecular mechanism of TGFβ action should be 
studied in detail in such context. Further knowledge on the supporting role of TGFβ during 
regeneration and dissecting its interplay with other signaling pathways such as HGF and 
EGF can provide insight on improved possibilities for manipulation of cell regeneration 
processes for therapeutic applications. 
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4. Hepatocyte reprogramming and liver regeneration- 
New prospective  
With liver transplantation being the only therapy and the reduced availability of liver donors, 
research has shifted focus on cell replacement therapies101. Regarding the liver, this is 
particularly promising because of the powerful regenerative characteristics of differentiated 
liver cells such as hepatocytes. In this respect, we do not need to rely on a limited number 
of stem or progenitor cells but can use a source of hepatocytes, the main functional cell 
types, as a therapy. A barrier to this approach, however, is the incapability of hepatocytes 
to be maintained or expanded in vitro. 
Several studies have managed to generate hepatic-like cells by different approaches, 
from embryonic stem cells, induced pluripotent stem cells or even from pluripotent germ 
cells102-106. Homogeneous populations of functional hepatic-like cells have been derived from 
human ES cells via a process mimicking endoderm development and hepatic specification107. 
Fetal liver stem/progenitor cells when transplanted into adult rat liver, display efficient 
differentiation into mature hepatocytes and high repopulating capabilities108. Cell lineage 
reprogramming of somatic cells into induced pluripotent stem cells (iPS cells) by modulation 
of transcription factor dosage is a promising therapeutic approach for liver diseases. Recently, 
direct reprogramming of mouse fibroblasts to hepatocytes (iHeps) by overexpression of 
two transcription factors in different combinations, Hnf4a together with Foxa1, Foxa2 or 
Foxa3109 or by transduction of Hnf1a, Gata4, Foxa3 and inactivation of p19Arf has been 
achieved110. Personalized medicine with a patient-specific hepatocyte source would limit 
the risk of organ rejection and eliminate the need of an external source of hepatocytes. 
However, in vivo functionality and stability of the properties of these cells have to be further 
validated before any clinical translation. Another recent study to address the importance 
of generating “self” hepatocytes for transplantation purpose has been carried out by Liu et 
al.111. The authors derived iPS cells from different cell types, which retained similar epigenetic 
signatures.  As proof of principal for retention of hepatic functionality of these differentiated 
cells, the authors intravenously infused mice after liver damage. Remarkably, the cells 
integrate in the regenerating liver with an efficiency of 8 to 15%, which is comparable 
to that of hepatocytes (11%)31. These encouraging observations point in the direction of 
“self”-derived hepatic like cells as clinically applicable in liver regeneration. 
Finally, hepatic generation by non-hepatic cell types has also been accomplished from 
human mesenchymal cells112 or by cell fusion with bone marrow derived cells113. 
An exceptional paradigm of the plasticity of hepatocytes is their potential to transdifferentiate 
into neurons (iN) after ectopic expression of neuronal transcription factors (Ascl1, Brn2, 
Myt1l)114. Interestingly, genes inducing iPS phenotype such as REST, Oct3/ 4, cMyc and 
Nanog are expressed in cultured primary hepatocytes and control cell proliferation and 
apoptosis in vitro, but may also control liver regeneration in vivo115. Another therapeutic 
option—relative to cell transplantation—would be to stimulate hepatic progenitor cells 
as a resident source, thus, avoiding the drawbacks of limited graft survival, restricted 
homing to the site of injury and host immune rejection. So, the hepatic progenitor cell 
population supported from the environment could possibly be induced to proliferate and 
transdifferentiate into major hepatocyte/ BDC by exogenous stimulation of stemness factor 
expression, to provide a resident cell based therapy, as previously successfully described 
for cardiomyocytes in adult heart injury116.
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Fig.2. Model of therapeutic approaches for liver diseases
Scheme of recent advances and possibilities in the field of induced hepatocytes (iHeps) and pluripotent stem 
cells (iPSCs). Hepatocytes are highly regenerative and plastic cells, which can be derived from iPSCs and ES cells, 
and in turn can give rise to iPSCs and directly transdifferentiate into neuronal-like cells (iNs). Human induced 
hepatocytes could be utilized for patient-specific disease modelling, drug toxicity trials and cell transplantation. 
Such studies would contribute to our understanding of the molecular mechanisms that control normal and aberrant 
liver regeneration. Activation or inhibition of the key signals can be manipulated in a therapeutic way in order to 
stimulate regeneration in vivo. Such approach could be applied to the treatment of several liver diseases, such 
as fibrosis, cirrhosis, hepatocellular carcinoma, as well as for regeneration of other tissues. 
The remarkable cell plasticity and regenerative ability of hepatocytes shows that they are 
an excellent tool for cell based therapies for liver diseases (Fig.2), however, efforts should 
also focus on the therapeutic use of hepatic progenitor cells as they have even higher 
proliferative potential than hepatocytes and are less susceptible to inhibition by TGFβ 
signals. Further knowledge of the intrinsic signals controlling liver regeneration is needed, 
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TGFβ component  Transgenic model Phenotype Organism/ Stage Reference
TGFβ1 Alb;Tgfβ1 (hepatocyte-
specific overexpression




TGFβ2, β3 Tgfβ2–/– ;Tgfβ3–/– 
Tgfβ2–/– ;Tgfβ3+/–
Early embryonic lethality, 
liver malformations
Mouse, embryonic 118




regenerating liver and 
increased liver mass: body 
weight ratio 
Mouse, adult 57
TGFβ-R-III TGFβR-III-/- Early embryonic lethality, 
liver defects
Mouse, embryonic 119
Activin βC, βΕ Actβc−/−; ActβE−/− No obvious defect in liver 
development, normal 
regeneration
Mouse, embryonic and 
adult
120






elf+/- Delayed hepatocyte 
proliferation followed by 
activation of progenitors 
cells  
Mouse, adult 95 






proliferation after CCl4 
injection and EMT 
transition
Mouse, adult 63
Smad3 Smad3-/- Viable, postnatal 
immunity defects at first 
few months 





Blockage of TGFβ-induced 
EMT and apoptosis
Mouse, adult 63
Smad2, Smad3 Smad2-/-;Smad3-/- Lethal, lack of mesoderm, 
gastrulation defects 
Mouse, embryo 126
Alb-Cre;Smad2 f/f Smad 
dex8/dex8
(Smad2, 3 double KO) 
High susceptibility to 
toxic liver injury
Mouse, adult 63
Smad2+/-;Smad3+/- Defects in definitive 
endoderm and liver 
development 
Mouse, embryonic 30,31
Smad4 Alb-Cr;/Smad4f/f Iron overload in liver 
and other organs and 
premature death
Mouse, adult 127,128
Smad7 Smad7-/- Promotes TGFβ fibrogenic 
action via CTGF 
upregulation
Mouse, adult 85
Table 1. Representative list of available animal models of TGFβ signaling components selected with regards 
to defective liver developmental, functional or regenerative phenotype
Alb; albumin, cre: cre recombinase, KO; knock out, EMT; epithelial-to-mesenchymal transition, CTGF; connective 
tissue growth factor, f/f; homozygous floxed (loxP containing) gene locus, CCl4; carbon tetrachloride, 
+/-; heterozygous mutant, -/-; homozygous mutant.
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Regeneration model Species TGFβ component Functional implication Reference
Transplantation Human β2-spectrin HPC/Oval cell response 90
Partial hepatectomy (PH) Mouse TGFβR-II Hepatocyte proliferation 57




Mouse SnoN, Ski inhibitors Activation status of Smad 
complexes, hepatocyte 
resistance to TGFβ 
mitoinhibition 
68
Rat TGFβ1 Inhibition of TGFβ1 by 
neutralizing antibody, 
hepatocyte mitosis, liver 
regeneration   
129





Mouse Endoglin Activation of HSCs, 
fibrogenesis 
130
Mouse SnoN, Ski inhibitors Activation status of Smad 
complexes, hepatocyte 
resistance to TGFβ 
mitoinhibition 
68
Mouse TGFβ1 Activation and 
transdifferentiation of  
HSCs, collagen and αSMA 
expression in HSCs 
131,132
Mouse Smad3 Smad3 induces collagen 
expression but is 
dispensable for HSC 
activation 
132






Mouse Smad2 Proliferation and 
sensitivity of HPCs to 
TGFβ1
96
Partial liver irradiation Rat TGFβ1 Stimulation of intrinsic 
regeneration by 





Rat TGFβR Anti-TGFβR molecular 
intervention and 




Table 2. Liver regeneration models reported to have elucidated functions on TGFβ family members
Different liver injury/ regeneration models are indicated, which have provided insight into the functional 
implementation of TGFβ ligands, receptors, R-Smads in the liver or in combination with therapeutic interventions 
such as neutralizing antibodies or small molecule inhibitors against TGFβ molecules.
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Abstract 
Liver exhibits a remarkable maintenance of functional homeostasis in presence of a variety 
of damaging toxic factors. Tissue regeneration involves cell replenishment and extracellular 
matrix remodeling. Key regulator of homeostasis is the transforming growth factor-β (TGFβ) 
cytokine. To understand the role of TGFβ during liver regeneration, we used the single-
dose carbon tetrachloride (CCl4) treatment in mice as a model of acute liver damage. We 
combined this with in vivo inhibition of the TGFβ pathway by a small molecule inhibitor; 
LY364947, which targets the TGFβ type I receptor kinase (ALK5) in hepatocytes but not in 
activated stellate cells. Co-administration of LY364947 inhibitor and CCl4 toxic agent resulted 
in enhanced liver regeneration; cell proliferation  (measured by PCNA, phosphorylated 
histone 3, p21) levels were increased in CCl4+LY364947 versus CCl4-treated mice. Recovery 
of CCl4-metabolizing enzyme CYP2E1 expression in hepatocytes is enhanced seven days 
after CCl4 intoxication in the mice that received also the TGFβ inhibitor. In summary, a small 
molecule inhibitor that blocks ALK5 downstream signaling and halts the cytostatic role of 
TGFβ pathway results in increased cell regeneration and improved liver function during 
acute liver damage. Thus, in vivo ALK5 modulation offers insight into the role of TGFβ, not 
only in matrix remodeling and fibrosis, but also in cell regeneration. 
Keywords 
Acute-Hepatotoxicity- CCl4- Regeneration- ALK5- LY364947- TGFβ- Smad
Introduction
Liver tissue has high regenerative capacity in response to damaging stimuli such as virus 
infections, chemicals, and alcohol intoxication1,2. Liver regeneration involves replenishment 
of dead epithelial and mesenchymal cells by proliferation and restoration of normal tissue 
architecture by fibrous scar formation3. Chronic organ damage leads to exhaustion of 
the cell pool and fibrosis, excess accumulation of extracellular matrix proteins (ECM) and 
eventually to clinical complications such as acute liver failure4. Thus, there is a need for 
better understanding of the mechanisms regulating innate tissue regeneration. 
Application of the hepatotoxin carbon tetrachloride (CCl4) is an established experimental 
animal model for liver regeneration since single administration of CCl4 in vivo leads to acute 
and reversible liver damage5. Liver regeneration occurs within 7-8 days without affecting 
any other organ system. Only a specific subset of hepatocytes, located around the central 
veins, appears to be damaged due to unique expression of CCl4-metabolising enzyme 
Cytochrome 450 (Cyp2E1)3,6. In turn, cytokines and stress signals derived from hepatocytes 
induce the activation of hepatic stellate cells (HSCs) into myofibroblasts (MFBs). The αSMA 
expressing MFBs7 appear in clusters around the central vein and assist tissue repair by scar 
ECM formation. Simultaneously, quiescent HSCs located in the space of Disse become 
activated by cytokines released from damaged hepatocytes, and concentrate in the central 
vein area, e.g. due to migration and/or proliferation. 
Transforming growth factor-β (TGFβ) signaling plays an important role in maintenance 
of liver homeostasis, terminal differentiation and apoptosis of hepatocytes8. Under liver 
damage conditions, TGFβ1 is up regulated and regulates parenchymal, inflammatory cells 
and HSCs6, 9,10. Although many cells in the liver may produce TGFβ1, Kupffer cells and recruited 
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macrophages are the major source of TGFβ. TGFβ1 is critical for activation of HSCs into MFBs, 
stimulates ECM production and inhibits ECM degradation11. Activated HSCs, and to lesser 
extent, sinusoidal endothelial cells (ECs), also contribute to increased TGFβ production4.   
However, TGFβ in the liver has additional actions, such as immunomodulatory properties 
and its cytostatic effects on epithelial cells (hepatocytes)12. The regenerative capacity of the 
liver is characterised by hepatocyte proliferation but also by increased TGF-β1 expression13. 
The level of DNA synthesis is maximal during the first 48 hours after CCl4 intoxication, 
coinciding with the TGFβ increase in the liver6,14. Thus, hepatocytes proliferate despite the 
presence of an antiproliferative stimulus; however, the exact mechanism of this process 
is unclear. Administration of TGFβ in vivo after partial hepatectomy reduces the number 
of hepatocytes that progress from G1 to the DNA synthesis phase15. It has been proposed 
that during early response after liver injury, hepatocytes become transiently resistant to 
TGFβ either by down regulation of TGFβ receptors14 and TGFα protective action15 or by up 
regulation of transcriptional repressors16. Levels of TβRI and TβRII mRNA expression in rat 
hepatocytes decreased from 12 to 48 hours and returned to normal by 72 hours after CCl4 
administration, while TβRI and TβRII mRNA were expressed constantly in non-parenchymal 
cells14. Thus, the function of TGFβ is cell-type specific and its role on liver regeneration 
remains largely unknown. 
TGFβ is synthesized and stored in the ECM as a latent complex with its prodomain, LAP 
(latency-associated peptide). Latent TGFβ is considered to be a molecular sensor that 
responds to specific signals by releasing active TGFβ17. These signals are often perturbations 
of the ECM that are associated with angiogenesis, wound repair, inflammation and, perhaps, 
cell growth18 . Changes in the cell’s environment are relayed to the sensor by a number of 
different molecules, including proteases, integrins and thrombospondin19. TGFβ functions 
by binding to cell surface receptors. Binding of free TGFβ ligands to its type II receptor 
causes the activation of the type I receptor, ALK5 and the assembly of a protein complex 
which further phosphorylates and activates the R-Smads, Smad2 and Smad3. Subsequent 
signal transduction occurs when the active Smad2 and Smad3 transcription factors form 
complexes with Smad4, and translocate from the cytoplasm to the nucleus20 to induce 
TGFβ target gene expression. 
Several studies have investigated the therapeutic potential of inhibition of TGFβ in lung, 
kidney and liver diseases and a number of compounds have reached the phase of clinical 
trials21. Smad3-deficient mice develop reduced dermal22,  renal23 and liver fibrosis24. However, 
the complexity of the TGFβ pathway, its involvement in a plethora of cellular processes and 
cell type specific effects impede the design of therapies in the context of liver diseases. For 
instance, loss of TGFβ signaling in fibroblasts causes intraepithelial neoplasia, suggesting that 
TGFβ controls the activity of fibroblasts as well as the oncogenic potential of neighbouring 
epithelial cells25. Experimental regeneration models such as partial hepatectomy indicate 
a role for TGFβ only at late stage of wound healing, mainly for restoration of ECM and new 
vessel formation1. The pleiotropic effects of TGFβ upon different cell types (hepatocytes 
and HSCs) and the time of action during liver damaging conditions remain yet unclear.
To study the mechanisms behind liver regeneration in regards to TGFβ signaling, in a 
time-dependent manner, we have selected the CCl4-induced acute liver damage model. A 
single dose of CCl4 leads to reversible centrizonal necrosis and steatosis
26, while prolonged 
administration leads to liver fibrosis, cirrhosis, and hepatocellular carcinoma. CCl4 impairs 
hepatocytes directly by altering the permeability of plasma, lysosomal, and mitochondrial 
membranes27. We investigated the effects of in vivo inhibition of the TGFβ receptor by the 
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small molecule inhibitor LY364947 (LY) during CCl4-induced acute liver injury in order to 
delineate its function on hepatocytes and HSCs. LY is an ATP-competitive, cell permeable 
inhibitor, selective for TGFβ type I Activin receptor-like kinases (ALK4, 5 and 7)28. In this study 
we show that, regarding in vivo TGFβ inhibition, the LY compound seems to be effective in 
epithelial cells, particularly centrizonal hepatocytes, and enhances their proliferation and 
regeneration in CCl4- acute injury model.
Materials and Methods
Acute liver damage model and administration of small molecule inhibitors
Animal protocols were in full compliance with the guidelines for animal care and were 
approved by the Leiden University Medical Center Animal Care Committee. Acute liver injury 
was induced in 5-6 weeks old male C57Bl6 mice weighing 20 - 25 g by intraperitoneally 
injecting a single dose of 1 ml/kg body weight CCl4 (mixed 1:1 with mineral oil), and mice 
were sacrificed after days 1, 2, 3, and 7 (n=2 per time point). LY364947 (5 mg/kg, Axon 
Medchem) was intraperitoneally injected 1 hour prior to CCl4 shot on day 0. Every 24 hours 
since the first injection, the compound was administered (day 0- day 3). From day 3 to day 7 
mice did not receive any compounds and were sacrificed after days 1, 2, 3, and 7 (n=3 mice 
per group and per time point). Control group received DMSO (1mg/kg mixed with PBS), 
LY364947 (5 mg/kg) received 4 injections every 24 hours. During day 3 to day 7, mice did not 
receive LY364947 and were sacrificed after days 1, 2, 3, and 7 (n=2 mice per group and per 
time point). From the liver tissues collected, one lobule was used for histology preparation, 
one lobule for RNA isolation and one lobule for protein isolation per individual mouse.
More information on Supplementary Materials and Methods.
Results
Phenotypic changes in acute CCl4-induced liver damage model
Induction of liver damage was performed by single injection of hepatotoxic agent CCl4 in 
5-6 week old male C57Bl6 mice. At several time points after vehicle control or CCl4 injection 
(day 1, day 2, day 3, day 7) mice were sacrificed and liver tissue was collected. Upon liver 
damage, hepatocytes located around the central vein area metabolize CCl4 and undergo 
functional and phenotypic changes, such as loss of hepatocyte marker HNF4α (Fig.1A). 
Dormant HSCs are distinguished by desmin expression and lack of αSMA staining, the latter 
being up regulated only upon activation of HSCs (Fig.1A). Highest expression of αSMA is 
reached during day 3 (Fig.1A) after single CCl4 injection. Increased collagen staining in the 
CCl4-injected livers (Fig.1A) represents the cell population of activated HSCs, which produce 
ECM proteins such as collagen type I and fibronectin. During mouse liver homeostasis, 
TGFβ is active, as nuclear phosphorylated Smad2 (pSmad2) protein is seen in hepatocytes 
of normal liver (Fig.1B) at various time points after injection with vehicle compound (day1, 
day2, day3, day7). Upon tissue damage active TGFβ ligands are released leading to activation 
of profibrotic gene expression and wound healing response in the activated HSCs. We have 
observed that pSmad2 nuclear localization follows a specific spatiotemporal pattern in the 
hepatocytes during the early time points after acute injury. Immunostainings for HNF4α, 
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pSmad2 and αSMA (Fig.1A-B) indicate that damaged hepatocytes adjacent to the central 
vein area transiently down regulate expression of HNF4α (Fig.1A) and pSmad2 (Fig.1B), 
almost immediately upon tissue damage. In turn, αSMA+ HSCs accumulate in the central 
vein between day 2- day 3 and activate pSmad2 (Fig.1B). This effect is transient, since 
pSmad2 expression is restored in the regenerated hepatocytes after seven days (Fig.1B). The 
distribution of HSCs at seven days after CCl4 shot is similar to the control liver tissue (Fig.1B).
A



































Fig.1. Acute CCl4-induced liver damage model
(A). From left to right: Picrosirius red staining for visualization of collagen fibers in liver tissues of control and CCl4-
treated mice (magnification: 10x). Immunofluorescence staining indicates protein expression of Kupffer cell marker; 
Fsp1 (magnification: 40x, scale bars=50μm). HSC markers; desmin (green) and αSMA (red), hepatocyte-specific 
marker HNF4α (grey) in control and CCl4-injected liver tissues (magnification: 100x, scale bars=250 μm). The marked 
area is shown at higher magnification (200x), scale bars= 10 μm. Nuclei (blue) were visualized by TOPRO-3 nuclear 
dye. Damaged central vein area is distinguished by expression of αSMA-positive HSCs (red) and loss of hepatocyte 
marker HNF4α (grey). Time point: day 3 (72 hours after CCl4). (B).Time course of pSmad2 (green) and αSMA (red) 
co-localisation by immunofluorescence during acute liver damage. Representative images of liver tissues from 
vehicle and CCl4- injected mice are shown (magnification: 20x. Scale bars=100, 250 μm). Bottom panel: image 
of higher magnification of the central vein (CV) (CCl4, 100x CV). Scale bars= 25 μm. Time course (1, 2, 3, 7 days).
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Effects of ALK5 inhibitor (LY) on TGFβ signaling and hepatic apoptosis in vivo
In order to interfere in vivo with TGFβ signaling activation we have used the small molecule 
inhibitor (LY364947), which selectively blocks kinase activity of ALK5. The LY compound 
was injected one hour prior to CCl4 administration, in order to inhibit the TGFβ pathway 
shortly before the induction of cellular damage (Fig.2A). Administration of the compound 
was performed every 24 hours for 4 days (day 0- day 3) in mice that also received a single 
shot of CCl4 or vehicle control at day 0 (Fig.2A). Mice injected with vehicle substance or 
LY compound have normal liver morphology (Fig.S1). Early response (24 hours) to tissue 
damage involves transient loss of nuclear phosphorylated Smads (pSmad2) specifically in 
damaged hepatocytes of the central vein area (Fig.2B). To further test this observation, 
pSmad2 protein levels were measured in whole liver homogenates in control (vehicle), 
CCl4 and CCl4+LY-treated mice (Fig.S2). In addition, reduced pSmad2 immunofluorescence 
staining is observed in livers that were treated only with LY (Fig.S1), suggesting that the 
LY inhibitor can attenuate the activation of ALK5/Smad2 pathway in hepatocytes. Time 
course of pSmad2 immunofluorescence in the damaged (CCl4) liver tissues, indicates further 
inhibition of pSmad2 signal after treatment with the inhibitor (Fig.2B). However, co-labeling 
of αSMA and pSmad2 (Fig.2B; Fig.S3) shows that HSCs still have active pSmad2 and may 
not be efficiently targeted by LY inhibitor when administered systemically. Hepatic mRNA 
expression of p21, enriched in hepatocyte population and TGFβ target gene, is down 
regulated after LY administration (Fig.2C); however expression of Collagen type I (Col1A1), 
that is enriched in the HSC population, is not effectively inhibited but even induced by the 
LY (Fig.2D). In addition, inhibitory role of LY on mRNA expression of Plasminogen activator 
type 1 (Pai-1) in whole liver extracts, is observed only at 48 hours after CCl4 intoxication 
(Fig.2E). Since, hepatotoxicity mediated by CCl4 causes centrilobular cell death in hepatocytes 
and TGFβ per se has a proapoptotic role on hepatocytes; we determined the occurrence of 
apoptosis. Two methods were used; terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) and activation of cleaved caspase 3, which occurs in apoptotic cells either 
by exogenous (death ligand) or endogenous (mitochondrial) pathways29. TUNEL positivity 
indicates cell death; however, it cannot distinguish necrosis from apoptosis events. TUNEL 
activity was observed earlier (24 hrs after CCl4) (Fig.3) than cleaved caspase 3 positivity 
(peak at 48 hours after CCl4, Fig.S4). TUNEL positive cells were quantified in all the mice of 
each group throughout the time course (day 1- day 3) of regeneration (Fig.3B). Only at the 
earliest time point (1 day after CCl4/ CCl4+LY), there is significant TUNEL activity (Fig.3A), 
compared to the positive control. CCl4+LY group has decreased number of dead cells 
compared to CCl4 group at day 1 (Fig.3B). Activation of pro apoptotic protein caspase 3 in 
hepatocytes as detected by immunofluorescence has slightly different pattern (Fig.S4A-B) 
than TUNEL activity. It remains uncertain whether cleaved caspase 3 is expressed only by 
hepatocytes or HSCs in the damaged central vein area as indicated by αSMA+ HSCs (Fig.
S4B). Quantification of cleaved caspase 3 positive areas during day 1– day 3 after damage 
induction shows a similar or slightly increased trend (non-significant at day 1, day 2) of 





















































































































































Fig.2. Dynamics of hepatic pSmad2 expression in the central vein area after LY364947 administration
(A). Scheme of experimental plan. Induction of acute liver damage by single shot of hepatotoxic agent CCl4 took 
place at day 0. ALK5 inhibitor LY364947 (LY) was administered every 24 hours (d0-d3). d; day. (B). Time course of 
pSmad2 (green) and αSMA (red) expression by immunofluorescence during acute liver damage. Representative 
images of liver tissues from vehicle control, CCl4, and CCl4+LY injected mice. Images are shown at magnification 
40x (scale bars= 50 μm). The marked area (dashed line) is shown at higher magnification (100x), scale bars= 25 μm. 
The non-dashed marked area is shown at higher magnification, scale bars= 22.7 μm. Time course (1, 2, 3, 7 days). 
(C). QPCR analysis of mRNA levels of p21, (D). Col1A1, (E). Pai-1; direct target genes of TGFβ pathway. Treatment 
groups: Control (n=2), LY (n=2), CCl4 (n=2), CCl4+LY (n=3). Error bars indicate S.E.M. Relative expression values 
were normalized to Gapdh expression. Time point: 48 hours after CCl4. LY; LY364947. **Statistically significant, 
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Fig.3. Effects of LY364947 on apoptosis in CCl4-induced regeneration in mice
(A). The presence of TUNEL positive cells was determined by immunofluorescence at 24 hours after CCl4 +/- LY. 
Representative images are shown per condition. Nuclei were visualized with TOPRO-3 (blue). Scale bars= 50μm. 
(B). Quantification of TUNEL immunofluorescence during day 1– day 3.  Values are expressed as mean percentage 
of positive cells measured in multiple areas of liver sections from 2 mice/ CCl4 group and 3 mice/ CCl4+ LY group. 
Error bars represent ± SEM. DNAse I-treated sections were used as positive control for DNA fragmentation and 
TUNEL activity. *Statistically significant, p<0.05. LY; LY364947
Effect of CCl4 and LY administration on expression of pericentral hepatocyte 
markers
Cytochrome 450 enzyme CYP2E1 and Glutamine synthetase (GS) are expressed exclusively 
in a subpopulation of hepatocytes of the mouse liver, specifically located around the 
central veins (pericentral hepatocytes). CYP2E1-expressing hepatocytes are affected by 
CCl4 because CYP2E1 converts it into a highly reactive radical (CCl3OO) which causes severe 
oxidative stress and might lead to apoptosis. Upon CCl4, Cyp2e1 (Fig.4A) and Gs mRNA 
levels (Fig.4B) are decreased, indicating either cell death of this subset of hepatocytes or 
temporary switching off of gene transcription. In fact, inhibition of Cyp450 enzyme activity 
may limit cell death and tissue damage. At seven days after CCl4 intoxication, mRNA levels 
of Cyp2e1 (Fig.4A) and Gs begin to recover (Fig.4B); however, they do not reach the levels 
of the control groups (Fig.4A-B). Recovery of the damaged hepatocytes seems improved in 
the LY treated group; mRNA expression levels of Cyp2e1 (Fig.4A) and Gs (Fig.4B) resemble 
the normal levels by day 7, in contrast to CCl4 d7 group. In view of these data, we assessed 
the CCl4-induced toxicity and recovery of CYP2E1+ hepatocytes by immunofluorescence in 
the damaged area in situ. Dynamics in protein expression of CYP2E1 (Fig.4C) follow similar 
pattern as the mRNA expression after CCl4 (Fig.4A), indeed confirming that normalisation 
of zonation in the CV area by day 7 (Fig.4C) is improved after LY inhibitor. Despite cell death 
events induced by CCl4 (Fig.3; Fig.S4), it is noteworthy that Cyp2E1 positive cells remain in 
the damaged area throughout the acute phase of injury (Fig.4C). Cells expressing αSMA, such 
as HSCs and smooth muscle cells, seem to intermingle with Cyp2E1+ hepatocytes (Fig.4C).
Inhibition of TGFβ in vivo enhances hepatocyte regeneration 
Cell proliferation is a mechanism for replenishment of hepatocytes as well as expansion of 
repair cells such as HSCs. We determined the expression of distinct proliferation markers (PH3 
and PCNA) in CCl4-induced liver damage (Fig.5). Histone 3 becomes phosphorylated only 
upon entry of the cell into mitosis; therefore phospho-histone 3 (PH3) expression is a marker 
of cell division (Fig.5A). Proliferating nuclear antigen (PCNA) is induced during duplication 
of DNA (S phase) prior to mitosis and also during DNA repair. Proliferation of hepatocytes 
is rare in the normal liver as they are quiescent cells (Fig.S5), however, upon injury they 
can re-enter cell cycle (Fig.5A-C). Quantification of PH3 indicates higher proliferation in 
presence of the LY inhibitor (Fig.5B). PH3 positive cells are mainly αSMA positive HSCs upon 
CCl4 (Fig.5A), however, proliferating αSMA-negative cells were also observed in the CCl4+LY 
liver tissues (Fig.5A), which are likely dividing parenchymal cells. Overview images of the 
same liver area were acquired with lower magnification for comparison (Fig.S6).  S phase 
marker PCNA is increased in the CCl4+LY group compared to the CCl4 group in HSCs and 
hepatocytes around the central vein area, adjacent to necrotic cells which express cleaved 
caspase 3 protein (Fig.5C). Proliferating cells that are distant from the central veins are 
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morphologically hepatocytes (Fig.5C). Quantification of overall number of PCNA positive 
cells as measured by immunofluorescence in the whole liver tissue showed increased trend 
of proliferation in the CCl4+LY group, particularly at day 2 and day 3 (Fig.5D). Western 
blotting analysis in whole liver extracts also confirmed that LY-treated samples had higher 
PCNA expression (Fig.5E). Administration of LY seems to inhibit the total levels (whole liver) 
of cyclin-dependent kinase inhibitor p21 (Fig.5E) which halts cell cycle progression in G1 
































































 αSMA CYP2E1 TOPRO










Fig.4. Hepatic CYP2E1 expression of central hepatocytes is sustained in the damaged area during acute 
liver injury 
Analysis of central hepatocyte-specific transcripts by QPCR in whole liver cDNA preparations. (A). cytochrome 450 
2E1 (CYP2E1, pericentral hepatocytes), (B). glutamine synthetase (Gs, pericentral hepatocytes). Treatment groups: 
Control (n=2), LY (n=2), CCl4 (n=2), CCl4+LY (n=3). Error bars indicate S.E.M. Expression values were normalized 
to Gapdh expression and to the control sample (vehicle DMSO/oil). Time point; d1: day 1 after treatment, d2: 
day 2 after treatment, d3: day 3 after treatment, d7: day 7 after treatment. *Statistically significant, p<0.05, 
**Statistically significant, p<0.01, *** Statistically significant, p<0.001 versus control, ns; non-significant difference. 
(C). Immunofluorescence staining of central hepatocytes (CYP2E1, green), activated HSCs and vascular smooth 
muscle cells (αSMA, red) in the central vein area. Nuclei are visualized with TOPRO-3 (blue). Time points: day 1, 
day 2, day 3 and day 7 after CCl4 or CCl4+LY. LY; LY364947. Magnification: 40x. Scale bars= 75μm.
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Fig.5. Increased cell proliferation after LY364947 administration in CCl4-induced regeneration in mice 
(A). Mitotic events after CCl4 and in combination with LY, as determined by immunofluorescence for phosphorylated 
histone protein 3 (PH3, green) in the damaged central vein area (αSMA, red). A representative image is shown 
per condition. Nuclei are visualized with TOPRO-3 (blue). Scale bars: 100μm. (B). Quantification of PH3 positive 
cells during day 1- day 3, expressed as mean percentage of positive cells from 2 animals/ CCl4 group and 3 mice/ 
CCl4+LY group. Error bars represent ± SEM. (C). Co-labeling of apoptotic and proliferating cells in the damaged 
central vein area; activation of proapoptotic protein caspase 3 in hepatocytes, as detected by immunofluorescence 
(cl.caspase 3, green) and DNA synthesis marker PCNA (red) after CCl4+/-LY administration. Scale bars: 50μm. (D). 
Quantification of PCNA positive cells as mentioned previously. (E). Protein expression of PCNA and p21 as measured 
by immunoblotting in whole liver tissue extracts. Treatment groups: Control (DMSO-oil), CCl4, CCl4+LY. Time course: 
day 1 (d1), day 2 (d2), day 3 (d3), day 7 (d7) after CCl4 injection and small molecule inhibitor administration (day 
0- day 3). β- actin was used as protein loading control. LY; LY364947. *Statistical significance, p<0.05.
In vivo interference of TGFβ pathway by LY does not inhibit activation of HSCs in 
the acute liver damage model 
To assess beneficial or adverse effects of LY on wound healing response, we have performed 
extensive histological analyses. Induction of αSMA is a reliable marker of liver MFBs (activated 
HSCs), as well as MFBs resident in other tissues and vascular smooth muscle cells. 
To distinguish HSC-enriched genes we measured the expression of αSMA and Ctgf which 
are enriched in HSCs. αSMA (Fig.S7A) and Ctgf (Fig.S7B) mRNA levels show a decreasing 
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trend of expression in the CCl4+LY compared to the CCl4 group. In the control groups, αSMA 
expression was only present in the smooth muscle cells lining portal and central veins 
(Fig.S1). Mice administered with CCl4 toxin show signs of wound healing response during 
the first 48 and 72 hours (day 2, 3), with up regulation of αSMA protein, as observed by 
immunofluorescence (Fig.S8A) and by western blot analysis (Fig.S8C). Tissue restoration 
after CCl4-induced damage takes place by day 7, when αSMA protein expression is decreased 
back to basal levels (Fig.S8A). However, expression of αSMA protein as measured by western 
immunoblotting in whole liver protein samples (Fig.S8C) is similar or slightly higher in livers 
of the CCl4+LY group over the CCl4 group. Quantification of positive staining in individual 
mice per group reflects a trend for higher induction of αSMA protein in the CCl4+LY group 
(Fig.S8B); therefore, HSC activation might not be affected by the LY treatment. 
In vitro effects of LY on TGFβ signaling
The differential in vivo responses of HSCs and hepatocytes to the LY were furthermore 
examined using established in vitro mouse cell lines. Mouse HSCs and AML12 (hepatocytes) 
cells were stimulated with TGFβ or with TGFβ+LY and the expression of TGFβ downstream 
targets was tested by QPCR and western blotting. As control, non-treated cells and TGFβ-
stimulated cells were used. TGFβ stimulation of HSCs up regulates mRNA expression of 
αSMA compared to non-stimulated HSCs (Fig.S9). TGFβ inhibition in HSCs is time- and dose-
dependent; at high doses LY (5 uM LY, 10uM LY) abrogates the effect of TGFβ stimulation 
on αSMA (Fig.S9). However, at lower dose (1uM) LY seems to induce, rather than inhibit, 
the TGFβ-mediated effect on αSMA expression, particularly at later (20 hrs TGFβ+1uM LY) 
time points (Fig.S9). We measured the expression of direct target genes Pai-1 and Ctgf on 
HSCs and hepatocytes; cell type- specific differences are observed during early induction 
by TGFβ (after 1 hour) (Fig.S10). LY treatment might be more efficient in inhibiting Pai-1 
expression in AML12 hepatocytes (Fig.S10C) rather than in HSCs (Fig.S10A). Similarly, Ctgf 
expression is efficiently down regulated in the AML12 cells as early as 1 hour (Fig.S10D) 
while Ctgf levels in HSCs remain high at 1 hour in presence of LY inhibitor (Fig.S10B). 
Furthermore, phosphorylation of Smad2 (Fig.S11A-B) and Smad3 (Fig.S11D-E) was analysed 
in a dose- dependent way after TGFβ stimulation (1 hour) and inhibition with LY (1uM, 
5uM, 10uM). HSCs (Fig.S11A, D) and AML12 cells (Fig.S11B, E) in vitro respond to addition 
of exogenous TGFβ by induction of downstream pSmad2 and pSmad3. Quantification 
of protein bands using densitometry was done in three independent experiments, and 
showed that decrease of phosphorylated Smad2 (Fig.S11C) and Smad3 (Fig.S11F) levels 
is analogous to the concentration of LY, with 10uM dose being the most effective for both 
HSCs and AML12 cell types. 
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Discussion
Acute liver failure is a severe condition of extensive hepatocyte necrosis and improper 
wound healing response, which occurs by exposure to intoxicants such as acetaminophen, 
thioacetamide, chloroform and CCl4. TGFβ is an inhibitory factor of liver regeneration by 
causing cytostatic response on hepatocytes and profibrotic effects on HSCs. Taking into 
account the deregulated levels of TGFβ in many fibrotic and malignant diseases we have 
investigated the impact of short term inhibition of TGFβ pathway on CCl4-induced acute 
damage and liver regeneration in vivo. 
In this study we assessed the distinct roles of TGFβ in cell death and regeneration of different 
cell types upon acute liver damage in mice. CCl4- induced toxification occurs mainly in 
the central vein area, probably due to the low oxygen pressure and high cytochrome 450 
enzyme levels3. Chemicals that induce cytochromes that metabolize CCl4 or delay tissue 
regeneration when co-administered with CCl4 will potentiate its toxicity, while appropriate 
CYP450 inhibitors will limit its toxicity6. Upon CCl4, TGFβ canonical pathway is activated 
and target genes p21, Col1A1, Pai-1, αSMA and Ctgf are induced.  However, histology of the 
liver tissues showed a local inhibition of pSmad2 early upon tissue injury, exclusively in the 
centrilobular hepatocytes but not in the activated HSCs.  This particular cell response may 
play a role in reentering of quiescent hepatocytes into the cell cycle and perhaps, initiation 
of the regenerative response. This observation is in line with previous studies12,14 describing 
transient desensitization of hepatocytes to TGFβ- mediated growth arrest. Inhibition of ALK5 
kinase activity by LY appears to have a potential stimulatory effect on hepatocyte proliferation 
during liver regeneration. Hepatocyte proliferation rate, indicative of the replacement of 
damaged cells by newly formed cells, was measured by PCNA immunostaining and western 
blotting. Proliferation is stimulated by LY co-administration with CCl4 as suggested by 
the increased PCNA levels as well as higher levels of the mitosis marker phosphorylated 
histone3. Mitotic events are very few after CCl4 intoxication, although this S phase marker 
expression is induced. A possible explanation for this difference is that hepatocytes are 
frequently binuclear cells since they progress through the DNA duplication phase but do 
not undergo cell division30. Higher proliferation rate after LY treatment is observed as early 
as 24 hours after injury, which may suggest that this compound leads to faster activation of 
innate repair and regeneration responses. Similar to our data, suppression of TGFβ induces 
transcription of regeneration factors (HGF, IL-6) in dimethylnitrosamine- induced chronic liver 
injury in rats18. Enhanced proliferation of hepatocytes, observed in the presence of dominant 
negative TGFβ receptor mutants18 and hepatocyte specific conditional deletion of TGFβRII31 
supports the hypothesis that TGFβ sustains quiescent hepatocytes in a differentiated state.
Cell death of a subset of hepatocytes occurs immediately due to CCl4 toxicity; however, 
there is clearly a subpopulation of Cyp2E1 hepatocytes that remain in the central vein zone 
at 24 hours after CCl4. The location of these cells adjacent to the central vein may suggest 
that the damaged cells have the capacity to survive and to sustain their initial location and 
hepatocyte specific gene expression. This observation is in line with Cyp2E1 mRNA presence 
in centrilobular hepatocytes as shown by in situ hybridisation in regenerating mouse liver32. 
Cyp2E1 zonal expression is normalized to the basal levels by day 7 in the LY-treated group, 
indicative of better recovery of the damaged area. LY may also possibly limit the damage or 
necrosis as suggested by the lower levels of TUNEL activity at 24 hours after CCl4 intoxication. 
However, cleaved caspase 3 levels are similar in CCl4 and CCl4+LY and peak at a later time 
point than TUNEL activity; the different pattern of terminal deoxynucleotidyl transferase 
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(TdT) and Caspase 3 expression suggests the presence of two different cell populations and 
functional processes. TUNEL positive cells, which are evident at early time points, possibly 
represent the cells undergoing necrosis due to the toxin, while activated Caspase 3 marks 
cells undergoing apoptosis. 
One consideration regarding HSCs is their activated MFB characteristics, such as αSMA 
and COL1A1 expression, which are sustained by autocrine TGFβ signaling, however, due 
to the terminally differentiated phenotype, HSCs might not act in response to exogenously 
provided TGFβ stimulation33. Furthermore, other studies have shown that ALK4, ALK5 and 
ALK7 receptors can be targeted by SB-431542 kinase inhibitor, which blocks TGFβ- induced 
nuclear translocations of Smad3 and Col1A1 levels in renal epithelial carcinoma, HaCat, 
NIH 3T3 and C2C12 cells28,34,35. Molecular ALK5 inhibition has been shown by the use of 
LY364947 compound30,36,37 or by other inhibitors, e.g. GW660438, GW78838839. Selectivity 
of the inhibitors is dose-dependent and inhibition of TGFβ receptor kinase activity may not 
inhibit non-Smad signaling response which may lead to adverse effects40.  
The in vivo co-administration of LY364947 in CCl4-mediated liver injury potently seems to 
decrease the mRNA expression of direct target genes, however since whole liver (hepatic) 
extracts have been used in this study, the cell type-specific enrichment of target genes 
cannot be determined. Ctgf, p21 are expressed by parenchymal and non-parenchymal 
cell types41-43.  Genes that are typically expressed in HSCs, such as Col1A1 and αSMA, have 
similar mRNA and protein levels in CCl4 and CCl4+LY-injected mice. Expression of Pai-1 
is not significantly different in CCl4+LY-injected mice compared to CCl4. In the model of 
acute hepatic injury used in this study, either HSC cell population is not sensitive to ALK5 
receptor inhibition33 after injury response is initiated or TGFβ inhibition is compensated 
by other signaling pathways (e.g.  PDGF 1, p38 MAPK34). In fact, αSMA is directly regulated 
by TGFβ and canonical Smad signaling12,15,16. Id1 target gene of BMP  signaling, which is 
also induced by TGFβ1/ ALK1/Smad1 branch, is important for activation of HSCs and actin 
polymerization44. Thus, TGFβ inhibition alone might not be sufficient to abrogate HSC 
proliferation and/ or accumulation of these cells. Enhanced fibrogenesis is beneficial for 
the regenerative response; however, if it becomes uncontrollable it may eventually lead 
to fibrosis. Thus, HSCs may require cell-specific targeting or longer treatment with ALK5 
inhibitor in order to invert their fibrogenic properties in fibrosis studies36,45. The study of 
van Beuge et al., 2013 showed that administration of LY without cell-specific delivery is 
less effective in decreasing the levels of fibronectin or collagen, similarly to our data. Other 
in vivo studies have provided evidence on the efficiency of the LY inhibitor in interstitial 
heart fibrosis46 and in lymphangiogenesis in a chronic peritonitis mouse model47. In cancer 
studies, combined administration of LY and Imatinib prolongs the survival of mice with 
chronic myeloid leukemia48. Nevertheless, specific targeting of a TGFβ inhibitor in any 
disease setting is definitely advantageous over systemic administration in order to prevent 
on target responses that might be disadvantageous due to the differential role of TGFβ 
depending on the cell type/ gene expression context. An interesting hypothesis that 
might emerge from the analysis of our data that requires further investigation is that the 
damaged hepatocytes survive and remain functional under acute toxin injury condition. 
Thus, cell damage might not de facto lead to cell death and massive hepatocyte necrosis 
and should be carefully characterised in the different experimental models of hepatic injury. 
In vivo TGFβ inhibition by systemic administration of the LY appears to enhance hepatocyte 
proliferation and regeneration of the liver, thus it could be therapeutically beneficial to 
explore cell type-specific targeting depending on the liver disease context e.g. hepatocyte 
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or HSC-specific delivery for hepatocellular carcinoma or fibrosis, respectively. 
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Fig.S1. LY364947 efficiently blocks Smad2 phosphorylation in normal liver
Staining for phosphorylated Smad2 (pSmad2, green) and alpha smooth muscle actin (αSMA, red) in control 
(DMSO-oil) and LY groups. LY; LY364947. 24 hours post injections. Nuclei were visualised by TOPRO-3 (blue). 
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Fig.S2. Phosphorylated and total Smad2 protein levels in whole liver homogenates 
Protein expression of pSmad2 and total Smad2 was measured by western immunoblotting in whole liver tissue 
extracts. Total Smad2 was detected using an antibody that recognizes the total Smad2 and Smad3 proteins. 
Treatment groups: vehicle (DMSO-oil), CCl4, CCl4+LY364947. Time course: day 1 (d1), day 2 (d2), day 3 (d3), day 7 




Fig.S3. LY364947 efficiently blocks Smad2 phosphorylation in hepatocytes but not in αSMA- positive HSCs 
Time course (day1, day2, day3) of Smad2 phosphorylation by immunofluorescence staining (green) in liver tissues 
from animals that received CCl4, CCl4+LY. αSMA staining (red) marks activated HSCs (liver MFBs) as well as vascular 
smooth muscle cells. Nuclei were visualized by TOPRO-3 (blue). Representative images are shown per treatment 
group and time point. Magnification 40x, Scale bars= 50 μm. LY; LY364947.
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Fig.S4. Apoptosis marker cleaved caspase 3 expression
(A). Activation of proapoptotic protein caspase 3 in hepatocytes as detected by immunofluorescence (cleaved 
(Cl) Caspase 3, green) after CCl4+/- LY364947 administration in the damaged central vein area as indicated by 
αSMA+ HSCs (red). Nuclei were visualised by TOPRO-3 (blue). Magnification 40x. Scale bars= 50μm. (B). Cleaved 
caspase 3 (red) and αSMA (red) immunofluorescence of sections at higher magnification (200x) on day 2 and day 
3 after CCl4-induced injury. cv; central vein Scale bars= 5 μm. (C). Quantification of cleaved caspase 3 positive area 
during day 1– day 3 after damage induction. Different fields of view in stained sections for every individual mouse 
were imaged and quantified. Graph indicates the mean percentage of positive stained area from 2 mice/ CCl4 









Fig.S5. PCNA and cleaved caspase 3 levels in quiescent control liver tissues
Time point; after 3 days of vehicle (left) or LY (right) administration. LY; LY364947. Cleaved (Cl) caspase 3; marker 
of apoptosis (green), PCNA; marker of proliferation (red). Nuclei were visualized with TOPRO-3 (blue). 
Scale bars= 100μm. 
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Fig.S6. PH3 immunofluorescence
Mitotic events after CCl4 or in combination with LY364947 (LY), as determined by immunofluorescence for 
phosphorylated histone protein 3 (PH3, green) in the damaged central vein area (αSMA+ HSCs and smooth muscle 
cells, red). A representative overview image is shown per condition. Nuclei were visualized with TOPRO-3 (blue). 
Magnification 40x. Scale bars = 50μm.
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Fig.S7. Hepatic αSMA and Ctgf mRNA levels after CCl4 administration in presence or absence of LY364947 
inhibitor
(A). mRNA levels of αSMA and (B). mRNA levels of Ctgf as measured by QPCR. Treatment groups: Control (n=2), 
LY (n=2), CCl4 (n=2), CCl4+LY (n=3). LY; LY364947. Error bars indicate S.E.M. Relative expression values were 
normalized to Gapdh expression. Time points: day 1- day 2- day 3- day 7 after CCl4. **Statistically significant, 



















d1 d2 d3 d7 d1 d2 d3 d7 d1 d2 d3 d7




























Fig.S8. In vivo inhibition of TGFβ receptor kinase activity in acute liver damage model by small molecule 
inhibitor LY364947
(A). Immunofluorescence staining of αSMA+ HSCs in CCl4 and CCl4+LY treated liver tissues. Representative images 
are shown per each time point; day 1, day 2, day 3 and day 7 after single CCl4 dose. Nuclei were visualized by 
TOPRO-3 (blue). Magnification 40x. Scale bars= 50 μm. (B). Quantification of αSMA immunofluorescence in liver 
tissues. Error bars represent S.E.M. Time points: day 1, day 2, day 3, day 7 after CCl4 shot. Treatment groups: control 
(n=2 per time point), LY (n=2), CCl4 (n=2) and CCl4+LY (n=3). ns; non-significant difference. (C). Protein expression 
of αSMA measured by western immunoblotting from whole liver tissue extracts. β- actin was used as protein 
loading control. Time points and treatment groups as described previously. LY; LY364947. 
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Fig.S9. High dose of LY364947 treatment is required to inhibit αSMA expression in HSCs in vitro
Quantitative PCR analysis of αSMA expression in HSCs. Cells were pretreated with increasing concentrations of 
LY364947 (LY 1uM, 5uM, 10uM) for 1 hour and stimulated with TGFβ3 (5ng/ml) for 1, 6 and 20 hours. Expression 
was normalized to the values of the control cDNA from non-stimulated cells. ****Statistically significant, p<0.0001 




































































































































































Fig.S10. In vitro effects of LY364947 on TGFβ target genes in HSCs and hepatocyte AML12 cell line
(A). Pai-1 mRNA expression and (B). Ctgf mRNA expression in mouse HSCs. HSCs were pretreated with increasing 
concentrations of LY364947 (LY 1uM, 5uM, 10uM) and stimulated with TGFβ3 (5ng/ml) for 1 hour. Fold induction 
(ΔΔCt) was normalized to the control sample (non-stimulated cells) and Gapdh expression values. (C). Pai-1 mRNA 
and (D). Ctgf mRNA expression in mouse AML12 hepatocytes. Cells were pretreated with increasing concentrations 
of LY364947 (LY 1uM, 5uM, 10uM) and stimulated with TGFβ3 (5ng/ml) for 1 hour. Fold induction (ΔΔCt) was 
normalized to the control sample (non-stimulated cells) and Gapdh expression values. *Statistically significant, 
p<0.05, **Statistically significant, p<0.01, ***Statistically significant, p<0.001, ****Statistically significant, p<0.0001 








































































































































































Fig.S11. In vitro effects of LY364947 on Smad2, Smad3 phosphorylation in HSCs and AML12 cell lines
Cells were pretreated with increasing concentrations of LY364947 (LY 1uM, 5uM, 10uM) for 1 hour and stimulated 
with TGFβ3 (5ng/ml) for 1 hour (n=3). Loading control; β-actin. (A). pSmad2 in HSCs (1h time point), (B). pSmad2 in 
AML12 hepatocytes (1h time point), (C). Quantification of western blotting pSmad2 signal by densitometry (n=3). 
Relative abundance over β-actin, (D). pSmad1, pSmad3 in mouse HSCs, (E). pSmad1, pSmad3 in mouse AML12 
hepatocytes, (F). Quantification of western blotting pSmad1, 3 signal by densitometry (n=3). Relative abundance 
over β-actin. *Statistically significant, p<0.05, **Statistically significant, p<0.01 versus TGFβ. 
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Supplementary Materials and Methods
Immunofluorescence
Liver tissues were fixed in 4% paraformaldehyde solution overnight, washed in PBS and 
processed for paraffin embedding. For every mouse, one of the liver lobules was embedded 
in a paraffin block and multiple serial sections (0.6 μm) were prepared. For antigen retrieval, 
sections were boiled 10- 30 min in antigen unmasking solution (Vector Labs) and were 
incubated in 3% H2O2 for endogenous peroxidases sequestering. Sections were blocked 
with 1% bovine serum albumin (BSA)- PBS-0.1% v/v Tween 20) and incubated with primary 
antibodies diluted in the blocking solution, overnight at 4°C or room temperature. Primary 
antibodies and dilutions used are as follows: anti-αSMA 1:500 (Sigma), anti-phospho-
Smad2 1:1000 (Cell Signaling), anti-Cyp2e1 1:500 (Biorbyt), anti-Fsp1 1:1000 (Millipore), 
anti-desmin 1:500 (Santa Cruz), anti-HNF4α 1:100 (Santa Cruz), anti-PCNA 1:10.000 (Sigma), 
anti-phospho Histone3 1:1000 (Millipore), anti-cleaved caspase 3 1:1000 (Cell Signaling). 
Sections were then incubated with secondary antibodies labeled with Alexa Fluor 488, 555, 
or 647 (Invitrogen/Molecular Probes, 1:250 in PBS-0.1% Tween 20). Detection of pSmad2 
and Cyp2e1 was enhanced using tyramide amplification (Invitrogen/Molecular Probes) by 
incubation of slides with horseradish peroxidase (HRP)-conjugated secondary antibody 
(1:100 dilution) (Invitrogen/Molecular Probes), followed by incubation with tyramide-4 
88 for 10 minutes. All sections were counterstained with TOPRO-3 (Invitrogen/Molecular 
Probes) at 1:1000 dilution in PBS-0.1% Tween20 for nuclei visualization, and mounted with 
Prolong G mounting medium (Invitrogen/Molecular Probes), which contains DAPI. Every 
immunofluorescence staining experiment was performed multiple times using different 
sections from the same lobule from every mouse. 
RNA isolation, RT-PCR and Quantitative PCR 
During liver tissue collection, one of the liver lobules of each individual mouse was snapfrozen 
in liquid nitrogen and stored at -80°C for RNA analyses. One liver part per mouse (100 μm) 
was homogenized using an UltraTurrax homogenizer (T25 basic, IKA) in TRIpure reagent 
(Roche) and directly processed for total RNA isolation according to the TRIpure RNA extraction 
protocol. Total RNA (0.5 μg) was used for first strand cDNA synthesis using RevertAid H 
Minus first strand cDNA synthesis kit (Fermentas). For quantitative PCR (Q-PCR) ten-fold 
diluted cDNA was amplified in a CFX Real Time Detection system (Bio-rad) using SYBR 
Green Supermix reagent (Bio-rad). Expression levels were normalized to housekeeping 
gene (Gapdh). 
Primer sequences: 
αSMA: for-ACTGGGACGACATGGAAAAG, rev- CATCTCCAGAGTCCAGCACA
Pai: for-GCCAACAAGAGCCAATCACA, rev-AGGCAAGCAAGGGCTGAAG
Cyp2e1: for- GGACATTCCTGTGTTCCAG, rev- CTTAGGGAAAACCTCCGCAC  
Ctgf: for- CAGACTGGAGAAGCAGAGCC, rev- GCTTGGCGATTTTAGGTGTC  
Gs: for- CTCCTGACCTGTTCACCCAT, rev- TTGCTTGATGCCTTTGTTCA   
Gapdh: for-AACTTTGGCATTGTGGAAGG, rev-ACACATTGGGGGTAGGAACA




During liver tissue collection, one of the liver lobules of each individual mouse was snapfrozen 
in liquid nitrogen and stored at -80°C for protein analyses. One liver part per mouse (100 μm) 
was homogenized in tissue lysis buffer (30 mM Tris pH 7.4, 150 mM NaCl, 0.5% Triton-X 100, 
10 mM NaF, 1mM Na3VO4, 10mM EDTA pH=8.0, 1%SDS, plus complete protease inhibitors, 
Roche) using an Ultra Turrax homogenizer (T25 basic, IKA). Following a centrifugation step 
(15 min, 4000 rpm, 4°C) to remove debris, the protein extract can be collected (supernatant) 
and further diluted 5-fold with lysis buffer. Whole protein extract by DC protein assay (Biorad) 
using BSA serial dilutions in tissue lysis buffer. A total of 20 ug was diluted in 4x Laemmli 
buffer, separated by SDS-PAGE and transferred to nitrocellulose membranes.  The following 
primary antibodies were used anti-αSMA 1:1000 (Abcam), anti-phospho-Smad1 1:1.000 
(Cell Signaling), anti-phospho-Smad2 1:1.000 (Cell Signaling), anti-Smad2/3 1:1000 (BD 
Biosciences), anti-PCNA 1:5000 (Sigma), anti-p21 (Santa Cruz), GAPDH 1:10.000 (Millipore), 
actin 1:10.000 (Sigma).  Appropriate secondary antibodies were used and detected by 
chemiluminescence (Biorad). 
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5.0 sofware (San Diego, CA) and 
two-way ANOVA test. Data is presented as mean±SEM. Significant differences are indicated 
with asterisks (* p< 0.05, ** p<0.01, *** p<0.001, ***p<0.0001). For quantitative PCR analysis 
experiments were repeated at least three times as technical replicates for every sample 
(different cDNA preparations using the RNA of one liver lobule per mouse) and the average 
value was calculated. The mean values obtained from individual animals for every group 
(n=2-3) were used for ANOVA statistical analysis. For quantifications of immunofluorescence 
signal; for every stained section (representing one mouse liver sample) multiple fields of 
view were imaged and quantified (see section Microscopy and Image analysis). The average 
of these values was calculated for every mouse sample. Statistical analyses were performed 
on the values of all the mouse samples per treatment group (n=2-3 in total). 
Cell lines 
Activated HSCs (Collagen1alpha1-GFP HSC cell line, David Scholten) and AML12 mouse 
hepatocytes were used. Cells were serum starved, pretreated with ALK5 inhibitor LY364947 
(5ug/ml) for 2 hours and stimulated with TGFβ3 (5ng/ml) for 1, 6 or 20 hours.  
Microscopy and Image analysis 
Confocal microscopy of labelled specimens was performed on a Leica TC-SP5 microscope 
with a 40Χ 1.4 NA oil-immersion objective Z series were collected and reassembled in Image 
J software (rsbweb.nih.gov/ij). Mean area fraction fluorescence was calculated in Image 
J software using threshold to select the root boundary and measuring the percentage 
of positive surface inside the intensity defined by the threshold. For quantifications of 
immunofluorescence signal, staining experiments were performed on all the samples 
simultaneously to reduce technical variation (each treatment group contains one sample 
from each mouse, n=2-3 in total). Experiments were repeated three times (three sections 
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per sample were analysed) and stained specimens in a given experiment were imaged 
using identical microscopic exposure and recording settings. 
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Chapter 4
Human Dupuytren’s ex vivo culture
for the study of myofibroblasts
and extracellular matrix interactions

Ex vivo fibrosis model
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Abstract 
Organ fibrosis or “scarring” is known to account for a high death toll due to the extensive 
amount of disorders and organs affected (from cirrhosis to cardiovascular diseases). There 
is no effective treatment and the in vitro tools available do not mimic the in vivo situation 
rendering the progress of the out of control wound healing process still enigmatic. To date, 
2D and 3D cultures of fibroblasts derived from DD patients are the main experimental 
models available. Primary cell cultures have many limitations; the fibroblasts derived from 
DD are altered by the culture conditions, lack cellular context and interactions, which are 
crucial for the development of fibrosis and weakly represent the derived tissue. Real-time 
PCR analysis of fibroblasts derived from control and DD samples show that little difference is 
detectable. 3D cultures of fibroblasts include addition of extracellular matrix that alters the 
native conditions of these cells. As a way to characterize the fibrotic, proliferative properties 
of these resection specimens we have developed a 3D culture system, using intact human 
resections of the nodule part of the cord. The system is based on transwell plates with an 
attached nitrocellulose membrane that allows contact of the tissue with the medium but 
not with the plastic, thus, preventing the alteration of the tissue. No collagen gel or other 
extracellular matrix protein substrate is required. The tissue resection specimens maintain 
their viability and proliferative properties for 7 days. This is the first “organ” culture system that 
allows human resection specimens from DD patients to be grown ex vivo and functionally 
tested, recapitulating the in vivo situation.
Introduction
Dupuytren’s disease (DD), a benign fibroproliferative disease causes permanent flexion of 
the fingers due to the formation of nodules and cords in the palm of the hand. Although the 
disease spread is particularly high among Caucasians of Northern Europe, the underlying 
genetic etiology of the disease remains unknown1. The main characteristic of DD is the 
excess production of extracellular matrix (ECM) proteins (e.g. collagen), which form a tough 
fibrous tissue occupying the space between the tendons and skin of the palm of the hand 
and fingers, permanently disrupting the fine movements of the hand2-3. The recurrence of 
the disease suggests underlying genetic alterations as a cause of fibrosis1, 4. An effective 
treatment could be to target directly the uncontrollable fibrotic mechanisms at the cellular 
and molecular level.
Our recent work on fibrosis has led us to the development of a novel 3D culture system 
that allows short-term culture of human fibrotic tissue with the potential of drug testing. 
This system has helped to overcome the limiting approach of 2D fibroblast cultures and to 
define a role for the partial down regulation, achieved by exon skipping, of TGFβ pathway 
activation in mediating fibrosis5.
We have developed a method to culture ex vivo human resection specimens from DD patients 
to study the interaction between myofibroblasts and the surrounding ECM5,6. The study of 
DD connective tissue fibrosis as well as other fibrotic diseases relies on histopathological 
analysis of the excised surgical specimens, isolation of fibroblasts from the tissue and 
establishment of primary cultures or cell sorting procedures. These approaches are quite 
static since they do not permit exogenous manipulation of the disease properties or 
therapeutic intervention by the experimenter. In addition, primary cell cultures tend to 
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adapt to the culture conditions and their gene expression properties differ essentially from 
the in vivo situation upon every passage, even during early passages (among passage 3 and 
6)7-8. We have managed to maintain the waste surgical material in ex vivo culture conditions 
for a time period that allows study of the patient-specific characteristics and screening of 
anti-fibrotic or anti-inflammatory drug compounds.
The system is based on a nitrocellulose membrane that permits contact of the tissue with 
the medium but not with the plastic, thus, preventing the alteration of the tissue upon 
attachment, as previously observed when culturing DD fibroblasts as well as other cell 
types9. No collagen gel or other ECM protein substrate is required, since the DD tissue itself 
produces large amounts of these proteins. This is advantageous for the maintenance of 
native ECM microenvironment and turnover since matrix substrates are important regulators 
of tissue architecture and function10-11. For instance, ECM proteins such as fibronectin, 
laminin and collagen, may influence front-rear polarity of fibroblasts as similarly shown for 
apical-basal polarity in epithelial cells12-13. Polarized cells have asymmetrical distribution 
of extracellular molecules which determines cell migration and gene expression, e.g. 
α1β1 integrin accessibility on the membrane affects cell adhesion to type I collagen14. 
Since a primary goal of this 3D model was to preserve the native microenvironment, no 
artificial ECM matrix substrate was used. In brief: resection specimens are equally cut in a 
sterile environment and placed on nitrocellular membranes. If treatment administrated via 
injection is required the tissues are injected after they have been placed on the membrane. 
If treatment does not require to be administrated via injection then the compound is added 
to the culture media (Dulbecco’s Modified Eagle’s Medium (DMEM), with 1% fetal calf serum 
(FCS), 1% penicillin-streptomycin (P/S)). The cultures are maintained for a maximum of ten 
days after which the tissue is fixed in 4% paraformaldehyde (PFA), processed through 30% 
sucrose solution, embedded in O.C.T. compound and stored at -80°C, as previously described5.
Protocol
This protocol follows the LUMC and AMC guidelines of human research ethics committee.
I. Surgical procedure and tissue collection
Note: Although various techniques for surgical excision of Dupuytren’s contracture exist, 
the current gold standard is the partial fasciectomy15. 
Most patients are treated in the day-surgery clinic.
1. 
2.
Perform surgery under general or regional anesthesia according to patient’s and 
anaesthesiologist’s preferences and to patient’s co-morbidities. These considerations 
are beyond the scope of this paper. Prior to incision, touch the skin with a sharp 
object to verify that anesthesia is satisfactory. Use a tourniquet to facilitate surgical 
visualization in a bloodless field.
After sterile prepping and draping, mark out the anticipated incision with a pen. 
Incise the skin with a scalpel under loupe magnification either longitudinally or 
using zigzag incisions in order to prevent additional contractures as well as to allow 
for sufficient exposure.
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Using scissor dissection, free the skin and subcutaneous layer from the underlying 
contracted fascia palmaris. Identify and protect the neurovascular bundle of the finger 
because the diseased cord can displace it toward the midline. Once the fibrotic tissue 
(nodule and/or cord) is outlined, excise it sharply and regionally (subtotal) using a 
scalpel. Perform meticulous hemostasis under tourniquet control at the end of the 
procedure to prevent hematoma formation.
To close the skin, use additional Z-plasties to obtain partial lengthening of the skin.
For these studies use only the nodule part of the fibrotic cord, the most active and 
cellular part of the disease. Have the surgeon perform macroscopic identification. 
The isolated nodules in the palm of the hand are often precursors of a cord but are 
hardly ever resected, as they usually do not cause symptoms. The ones we resected 
were the nodules that were part of a cord of the contracted finger. Identify these 
nodules by the hard thick part of the cords in the handpalm (Fig.1A).
Once the surgeon removes the tissue, immediately transfer it using sterile forceps 
to a 50 ml tube containing DMEM medium supplemented with 10% FCS and 1% 
(P/S). Keep the tissue for a maximum of 2 hrs in this medium on a box of wet ice (4°C) 
(e.g. transportation of the tissue from the operation room to the cell culture facility).
Keep the samples on wet ice (4°C) while preparing for the next step. Preparation of 
the materials and cell culture chamber requires 10-20 min.
II. Preparation of instruments, culture medium and culture inserts





Prepare 500 ml of DMEM supplemented with 10% FCS and 1% (P/S) and filter 
sterilize. Prewarm the medium at 37°C.
Autoclave forceps, a pair of curved-bladed Mayo scissors (150-170 mm in length) 
and a pair of Metzenbaum scissors and store in a sterile container.
Under laminar flow, open a sterile 12-well culture plate. Place a culture insert (0.45 
µm pore size, 12 mm diameter) in each well of the 12-well plate (Fig.1B, lower panel).
Fill the 12-well plate with 600 µl of prewarmed (37°C) culture media by pipetting 
on the well and not directly on the membrane of the insert. Place the plate into the 
incubator (37°C, 5% CO2) (Fig.1B, upper panel)
             1. Alternatively, use a 24- well plate and add 300 µl of medium per well. The 
volume of medium per well is optimal when a meniscus layer is formed 
between the liquid and the lower part of the membrane insert. Note: the 
medium at the bottom of the well diffuses through the nitrocellulose 




III. Tissue preparation and ex vivo tissue culture setup






Transfer the nodule part of the cord from the 50 ml tube on a 100 mm Petri dish and 
add 10 ml of prewarmed (37°C) medium. Ensure that the tissue is in contact with 
the liquid during the entire procedure.
             1. Remove the perinodular fat layer using the Metzenbaum scissors. Discard 
the fat tissue. With the use of forceps and the curved-bladed scissors, cut 
transversally the tissue into smaller pieces (maximum thickness 200 µm).
Transfer the 12- well plate from the incubator into the laminar hood. Check that the 
membrane of the insert has turned transparent (wet) and therefore is in contact 
with the medium.
Using forceps carefully lift a tissue part by touching the outer layer (do not apply 
tension on the tissue). Place one tissue part onto the membrane of the cell culture 
insert so that the tissue remains in the air-medium interphase. Culture a maximum 
of two tissue parts on the same insert/ well.
Ensure that the tissue is placed flat on the membrane, in longitudinal contact with 
the medium such that the tissue neither floats off the membrane nor is fully covered 
by medium. Avoid air bubbles.
Note: At this stage, it is possible to add growth factors or inhibitors of interest to the 
media; for instance, test compounds (A, B, C, D, E) in replicates and/or in concentration 
curve. Include at least 2 control (untreated) pieces of tissue under normal growth 
conditions to ensure that the experiment has been set up properly. Incubate tissues 
for 3-7 days in a tissue culture incubator.
Infect the tissue with either lentiviral or adenoviral construct if overexpression or 
knock down experiments of a gene-of-interest need to be performed 
(Fig. 2). Transfer a tissue part from the 12- well plate into a 35 mm dish using forceps.
             1. Use a maximum volume of 10 µl of high titer virus.
Perform the injection under a dissection microscope with an insulin syringe 
loaded with 50 µl PBS containing 10 µl of the selected virus. Place the 
needle perpendicular to the center of the tissue.
Slowly inject the content of the syringe. Do not retract the needle directly. 
When puncturing the tissue, do not let the needle go through the other 
side but maintain the needle within the tissue itself (around the center 
of the tissue).
Transfer the tissue back into the 12- well plate, close the culture plate and 
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PBS (phosphate-buffered saline) 8.00 g NaCl (0.137 M)
0.20 g KCl (2.7 mM)
0.20 g KH2PO4 (1.1 mM)
0.10 g MgCl2·6H2O (0.5 mM)
2.16 g Na2HPO4·7H2O (8.1 mM)
0.10 g anhydrous CaCl2 (0.9 mM)
H2O to 1 L
4% paraformaldehyde / PBS Dissolve 4 g of paraformaldehyde in a flask containing 
100 ml Phosphate Buffered Saline (PBS) in the fume 
hood, cover the flask. Place the flask on a heating-
stirring block and gently stir the solution. Monitor the 
temperature so that is reaches a maximum of 65°C. 
Avoid over-heating. Once the paraformaldehyde has 
dissolved and the solution appears clear, switch off the 
heat but leave to stir. Do not handle for safety reasons. 
Allow cooling. When cooled, aliquot the solution and 
store long term in -20°C freezer or in a 4°C refrigerator 
for maximum a week.
BSA (bovine serum albumin), 10% (w/v) Dissolve 10 g BSA in 100 ml H2O. Filter sterilize using 
a low-protein binding 0.22-µm filter. Store at 4°C.
DMSO/Methanol (20%) permeabilization solution Mix Dimethyl Sulfoxide with Methanol (1:4 analogies, 
total volume 100 ml).
Table 1. Buffer solutions
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fetal calf serum (FCS) Gibco high glucose, heat 
inactivated
penicillin-streptomycin Invitrogen 15070-063
Cell culture inserts Millicell PIHA01250 0.45 μm pore size, 12 
mm diameter
anti-α smooth muscle 
actin
Sigma A2547
anti-collagen type I Southern Biotech 1310-08
anti-collagen type III Southern Biotech 1330-01
Alexa Fluor555 Donkey 
Anti-Mouse IgG (H+L)
Invitrogen A-31570
Alexa Fluor 488 Donkey 






Tissue Tek OCT Sakura 25608-930
Microsccope glass 
coverslips
Menzel-Glaser BB024060A1 24 x 60 mm
Microscope SuperFrost 
slides




Leica TCS SP5 II confocal 
microscope
Leica Microsystems Argon-488, 514 nm and 
HeNe-633 nm laser lines
Zeiss 710 NLO upright 
confocal microscope
Jena, Germany Equipped with 
femtosecond Spectra 
- Physics Deep See MP 
laser (Santa Clara, United 
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IV. Whole-mount immunofluorescence staining and 3D reconstruction
Note: All procedures are performed at RT unless specifically stated. The protocol for whole 
mount immunostaining and imaging described below is an adaptation from previously 
reported methods used for other tissues16-19. 











Transfer tissues from the culture plate to 2 ml microcentrifuge tubes containing PBS. 
Wash 2x for 5 min in PBS solution on a rotating platform. Fix tissues in 4% buffered 
PFA (1.5 ml solution per tissue in 2 ml microcentrifuge tubes), overnight at 4°C on 
a rotating platform.
Remove PFA and wash 3x in PBS for 5 min each.
Dehydrate tissues by immersion in a 25% methanol solution for 2 hr at RT on a 
rotating platform. Increase the methanol percentage gradually (50%, 75%, 100%) 
with the tissues immersed at each solution for 2 hrs at RT on a rotating platform.
Transfer tissues in DMSO/methanol solution (permeabilization step) 
for 3 weeks at 4°C, as described previously18.
Note: At this stage, tissues can be stored long term in 100% methanol at -20°C.
Proceed with staining procedure16, 17; gradually rehydrate tissues (75%-50%-25%-0% 
methanol series). Perform each rehydration step for 2 hrs at RT or overnight at 4°C, 
under constant agitation.
Incubate samples with primary antibodies in PBS containing 1% bovine serum 
albumin (BSA) and 20% DMSO overnight at 4°C. Use antibodies at the following 
ratios using the commercial stocks in PBS: anti-α smooth muscle actin (1:500, mouse), 
anti-collagen type I (1:500, goat), anti-collagen type III (1:500, goat).
Wash extensively in PBS for 48 hrs at 4°C (change PBS solution 3 to 4 times).
Dilute appropriate secondary antibodies (Alexa 555 anti-mouse, Alexa 488 anti-goat) 
at 1:250 dilution in PBS containing 1% (BSA) and 20% DMSO. 
Incubate overnight at 4°C.
Wash extensively in PBS for 48 hrs at 4°C and incubate with nuclear counterstain, 
TO-PRO-3 diluted in PBS (1:500) was used at the final washing step.
Note: TO-PRO-3 is a far-red emitting DNA dye (with a He-Ne 633 nm laser line) and 
is combined for simultaneous imaging with other channels; in this case collagen 
type I / collagen type III (488 nm), α smooth muscle actin (555 nm), TO-PRO-3 (647 nm).
Transfer the tissues to a methanol series (25%-50%-75%) to slowly dehydrate 







Transfer tissues in polypropylene tubes. Clear tissues in methylsalicylate 
(handle under chemical hood)18 or as an alternative use BABB solution19. 
Incubate the tissues at RT, under constant agitation, until they become 
transparent. Mount between a slide and a coverslip sealed with hard set 
mounting medium (Fig.1C, upper panel). 
11. Image samples on an inverted confocal microscope equipped with high numerical 
aperture (NA) 63X and/or 100X oil immersion objectives (Fig.1C).
Clean the lens with cleaning solution provided by the microscope 
manufacturer.
Apply one drop of the oil on the objective lens. Place the slide with the 
specimen on the microscope stage and focus on the sample.
Set the configurations on the microscope for simultaneous imaging of three-channel 
fluorescence with laser lines 488 nm, 514 nm and 633 nm.
Acquire single XY images or multiple focal plane images (Z stack) (Fig.3A). Use 
increased width of Z stack for performing 3D reconstruction. To obtain a high-
resolution image use low scanning speed, number of average scans (≥ 3) and acquire 
16-bit images of 1.024 x 1.024 pixel resolution.
Analyze the Z stack acquired images: first rename and save image file (xyz). Using 
the software program of the confocal microscope, configure a maximum intensity 
projection of the Z stack images into a 3D reconstructed image.





Select the xyz file, in the “Process Tools”, click under “Visualisation” and “3D 
Projection”. Enter “Maximum” in the method of projection (or “Average” if 
the fluorescent signal is saturated). For a single projection do not change 
the X, Y, and Z planes, and apply the projection tool (Fig.3B, r1).
Use the Z stack images to create a 3D projection with animation (confocal software) 
for viewing purposes. Select the xyz file, in the Process Tools, click under “Visualisation” 
and “3D Projection”.
              1. Click on “Create Movie”. Enter the Start Rotation angle in degrees (e.g., 0° 
as starting point of the movie, Y axis) and click on “Set Start”. Enter the End 
Rotation angle in degrees (Y axis) as end point of the movie (e.g. 180° or 
360° for a complete rotation) and click on “Set End”.
Select “Maximum” as a method of projection (or “Average” if the fluorescent 
signal is saturated). Enter the ”Number of Frames” for the rotation of 
the 3D reconstruction (e.g. 20 rotations or higher to reduce the speed 
of rotation). Click on “Apply”. Export the movie as visual file (e.g. “avi”) 
(Supplementary Movie 1) or export as “tiff” file which creates an image 
file for each rotation angle (Fig.3B; rotation r4, r10, r18).
2.
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V. Combined second harmonic generation (collagen) and two-photon excited fluo-
rescence (elastin) imaging on ex vivo tissue during culture





Remove transwell plates from incubator and place a single (unfixed) tissue part in 
a 35 mm cell culture plate containing 500 µl of medium.
Position the tissue so that the long axis is flat on the plate. Keep tissue wet at all 
times however, not floating.
Place water-immersed objective of the multiphoton microscope directly in 
contact with the tissue (Fig.1C).
Obtain images with an excitation wavelength of 800 nm and collect emitted light 
between 371-425 nm (SHG, collagen) and 474-532 nm (autofluorescence, elastin) 
(Fig.3C). Perform two-photon microscopy in an upright confocal microscope that is 
equipped with a femtosecond laser using a 20X/ 1.0 NA water-immersion objective. 
Process confocal stacks with manufacturer’s software.
Note: Excitation with a near infrared laser of collagen molecules creates high contrast 
imaging of native collagen structures in different depths.
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Fig.1. Scheme of ex vivo 3D tissue culture system
(A). DD permanent flexion contracture in the hand of a patient prior to surgical removal. This figure has been 
modified from previous study5. (B). Example of ex vivo culture set up. (C). Examples of experimental approaches 




The method of ex vivo, 3D culture of connective tissue is an easy and robust set up system 
to understand the relation between ECM and other cell components constituting the 
DD tissue and potentially other types of fibrosis as well. Moreover this system provides a 
reliable method to test the effects of compounds on different cell types and their effects 
on the fibrotic load 20.
The steps from collection of surgical waste material derived from Dupuytren’s fibrosis, the 
assembly of the culture chamber and examples of analysis tools are presented in Fig.1. As 
illustrated in Fig.1, this method provides an experimental tool for large screens drug screens, 
e.g., antifibrotic drug compounds as well as the study of ECM modelling in a real-time and 
reproducible manner. Nodular parts of the fibrotic cord are equally sliced and placed in 
transwell plates; each tissue part (100-200 µm) is cultured on top of the membrane of a 
culture insert (0.45 µm pore size, 12 mm diameter). Culture medium is added at the bottom 
chamber, allowing contact with the tissue through the membrane. On average 30-40 tissue 
parts can be derived from a single resection specimen, which allows large-scale screening 
of drugs; compounds, small molecules or growth factors. Experiments addressing the 
concentration and/or time-dependent effect of drugs are feasible.
As shown in Fig.2, gene expression can be manipulated (overexpression/ knock down) by 
the use of adeno/ lentiviruses directly injected into the tissue. Fluorescently tagged viral 
transduction is performed in fresh thick tissue specimens by injection. Tissue remains in 
culture for 24- 48 hours post-injection and is subsequently fixed, embedded and sectioned 
in 0.7 µm cryosections. 
Moreover, to analyze the effect of different compounds or culture conditions the tissue 
parts are fixed and subjected to whole mount immunofluorescence as shown in Fig.3. 3D 
imaging of thick tissues is done by confocal microscopy (Fig.3A-B). Another method is 
the live 3D imaging on tissues maintained in culture; endogenous collagen remodeling is 
studied real-time in freshly dissected, non-fixed tissue parts by second harmonic generation 
(SHG) (Fig.3C). The effect of potential anti-fibrotic drugs is also followed in parts of the 
same tissue at different time points. Collagen structures of thick tissue are imaged using 
SHG in an upright multiphoton microscope. During imaging, tissue specimens are placed 
in medium and are imaged with a water-immersion objective. After imaging, the tissues 
can be transferred back to the culture system. Effects can be studied at the level of cellular 
and extracellular environment providing an advantage over in vitro cell-based assays. There 
are multiple possibilities for analysis of biological effects such as histology of fixed tissue 
sections, whole mount immunofluorescence and 3D reconstruction imaging by confocal 
microscopy, SHG and two-photon excited fluorescence imaging of endogenous collagen 
and elastin. Some of the advantages of the SHG imaging are the use of fresh, non-fixed 
tissue, that no antibody staining preparation is required and that the same tissue can be 
imaged multiple times (time course during culture conditions). SHG and two-photon excited 
fluorescence imaging has been described previously for muscle and connective tissue21-23 
and unstained arterial wall structure24, however, here we report an alternative application 
for the study of Dupuytren’s fibrosis.
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Fig.2. Proof-of-principle ex vivo viral-mediated gene expression modulation in whole mount tissue 
(A-C).Adenoviral transduction; (A). Nuclei are visualized with TO-PRO-3 dye (blue). Bars 75 µm. (B). Direct visualization 
of the fluorescent dye DsRed (red), post-injection with Adenovirus expressing-DsRed. Bars 75 µm. (C). Merged 
image (nuclear staining in blue, DsRed in red). Cytoplasmic localization of DsRed indicating adenoviral delivery in 
the cells within 24 hours. Bars 75 µm. (D-F). Lentiviral transduction; (D). Nuclei are visualized with TO-PRO-3 dye 
(blue). Bars 25 µm. (E). Direct visualization of GFP in tissue sections (green), post-injection with lenti-GFP particles. 
Bars 25 µm. (F). Merged image of D and E indicating intracellular localization of lenti-GFP. Bars 25 µm. (G-H). 
Example of lentivirus-mediated knockdown against gene of interest (designated as “A”); (G). Lentivirus carrying 
scrambled shRNA sequence was injected ex vivo into the tissue. Immunofluorescence staining for protein of interest 
(designated as “A”) shown in red. Bars 75 µm. (H). Lentivirus carrying gene A-shRNA sequence was injected ex vivo 


















Fig.3.3D reconstruction imaging, second harmonic generation and two-photon excited fluorescence imaging
(A). 3D imaging by confocal microscopy. Single (xy) images in focal planes along different tissue depths (z = 
50-200 µm). Whole mount immunofluorescence staining; myofibroblast marker α-smooth muscle actin (αSMA, 
red), nuclear staining (TO-PRO-3, blue). Bars: 500 µm. (B). 3D reconstructed image (Z stack 389 µm) of raw images 
as indicated in panel A at different 3D rotations indicated as “r1”, “r4”, “r10”, “r18”. Bars 500 µm. (C). Endogenous 
collagen content modeling by second harmonic generation (SHG) imaging in fresh, thick tissue parts (left panel, 
green). Two-photon excited fluorescence (TPF) of elastin structures of the ECM was captured by multiphoton 
microscopy (middle panel, red). Merged image of collagen (green) and elastin (red) (right panel). Bars: 100 µm.
Supplementary Movie 1. Representative 3D reconstruction movie of Dupuytren’s whole mount tissue
Confocal imaging of DD tissue was performed after seven-day ex vivo culture and processing for whole mount 
immunofluorescence staining;  myofibroblast marker α-smooth muscle actin (αSMA, red), nuclear staining (TO-
PRO-3, blue). Scale bar = 500 µm. Frames= 20. Z= 389 µm.
(http://www.jove.com/files/ftp_upload/52534/Movie%201.avi)
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Discussion
The most critical steps of culturing ex vivo human connective tissue are the immediate use 
of the tissue after surgical removal to ensure viability; the tissue should remain in medium 
or saline solution at all times; maintain a sterile culture; transverse sections of tissue should 
have maximum 200 µm thickness; set up of the ex vivo culture system is optimal when 
tissue is in contact with the medium but not fully submerged. Medium should be added 
only on the outside chamber of the transwell in a small volume (e.g. 500- 600 µl per 12-well 
plate surface area).
Connective tissue derived from Dupuytren’s is entangled in a tough structure with high 
content of ECM proteins such as collagen, proteoglycans, and elastin; due to these properties 
and additionally due to myofibroblast contracture it can be challenging to cut through 
the tissue. It is important to use appropriate surgical tools; curved bladed Mayo scissors 
for cutting larger parts in equal thickness and smaller surgical scissors for cutting smaller 
tissue parts (e.g., if more tissue parts are required use 24- well plates).
Methods for the study of DD are histopathological analyses of the excised fibrotic specimen, 
or derivation of primary fibroblasts. Cell derivation from the patient material is done is 
two ways; in one of the methods, tissue parts are cultured in plastic culture plates for a 
number of weeks until there is outgrowth of fibroblasts. The second method is enzymatic 
treatment of tissue with collagenase and trypsin. The first method is time consuming, 
fibroblast properties are altered due to culture conditions and there is passage-dependent 
variability among passages of the same cell line. The enzymatic method is faster and it can 
be used for cell sorting assays, however, in vitro maintenance of these cells out of the innate 
ECM does not reflect the in vivo properties. The model presented here is suitable for cell 
and ECM morphology studies and several techniques have been successfully utilized such 
as immunofluorescence, flow cytometry, RNA analyses, whole mount 3D imaging, and 
collagen deposition measurements (secreted in the culture media). However, total protein 
isolation from the tissue parts, cell signaling experiments and protein immunoblotting 
require optimization and are not as robust as the monolayer fibroblast cultures. Another 
drawback of the method is lack of mechanical tension engineered to the culture system. 
Most connective tissues exist under a constant or basal mechanical force, even during 
resting conditions, which not only provides mechanical support but also influences cell 
behavior and signaling25 (namely mechanoregulation and mechanotransduction). Loss 
of tension results in disassembly of αSMA fibers in MFBs in short period of time26. The 
abundance of αSMA in the ex vivo cultured tissues indicates MFB contractility. Nevertheless, 
our model could benefit from incorporation of an isometric force transducer27, 28. Regarding 
technical and biological variability, our method is reproducible (viability, ECM network) 
and less prone to tissue alteration due to short time of culture. For instance, the method 
of fibroblast outgrowth requires several weeks which may cause biochemical changes (e.g. 
accumulation of genetic mutations, replicative senescence). However, patient- specific 
genetic characteristics and biological variability are per se challenges in the DD research 
field and cannot be tackled with any of the current methods.
As shown in this protocol, fibrotic DD specimens after surgical removal are directly cultured in 
the ex vivo 3D system and/or snap frozen. Depending on the scientific question, modification 
of the tissue is possible by addition of growth factors, chemical compounds, virus- mediated 
gene delivery, antisense oligonucleotides and miRNAs. Compounds can be delivered in the 
media or with local microinjections of the tissue in the 3D culture chamber. After 3 (up to 
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7) days of culture the tissue can either be homogenized for cell isolation and FACS analysis 
or isolation of total RNA and proteins for expression profile analysis, as well as processed 
for histological analysis. The expression status of fibrous proteins (αSMA, collagen type I 
and II, fibronectin), tissue architecture of the nodule part of the cord and the consistency 
of the fibrous network is assessed before and after the treatments. In order to monitor the 
ECM rearrangements during the culture we combined the SHG (collagen) and two-photon 
excited fluorescence (elastin) imaging.
The extracellular rearrangements can then be quantified or modeled using an image 
quantification software. These parameters give an indication of the drug effects on fibrosis or 
the molecular alterations that have been induced during the culture. Moreover ECM arrays 
can also be performed on single slices to generate a better overview of the effects. Overall 
we have established a robust system that allows the study of fibrosis ex vivo.
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Chapter 5
Novel ex vivo culture method
for the study of Dupuytren’s disease:
effects of TGFβ type I receptor modulation
by antisense oligonucleotides

TGFβ type I receptor modulation by antisense oligonucleotides
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Abstract 
Dupuytren’s disease is a benign fibro-proliferative disease of the hand. It is characterized 
by the excessive production of extracellular matrix proteins, which form a strong fibrous 
tissue between the handpalm and fingers, permanently disrupting the fine movement 
ability. The major contractile element in Dupuytren’s disease is the myofibroblast. This cell 
has both fibroblast and smooth muscle cell-type characteristics and causes pathological 
collagen deposition. Myofibroblasts generate contractile forces that are transmitted to the 
surrounding collagen matrix. Μajor pro-fibrotic factors are members of the Transforming 
growth factor-β pathway which directly regulate the expression levels of several fibrous 
proteins such as collagen type I, collagen type III and alpha-smooth muscle actin. Molecular 
modulation of this signaling pathway could serve as a therapeutic approach. We, therefore, 
have developed an ex vivo “clinical trial” system to study the properties of intact, patient-
derived resection specimens. In these culture conditions, Dupuytren’s tissue retains its 
three-dimensional structure and viability. As a novel antifibrotic therapeutic approach, we 
targeted Transforming growth factor-β type I receptor (also termed Activin receptor-like 
kinase 5) expression in cultured Dupuytren’s specimens by antisense oligonucleotide-
mediated exon skipping. Antisense oligonucleotides targeting Activin receptor-like kinase 
5 showed specific reduction of extracellular matrix and potential for clinical application.
Introduction
Dupuytren’s disease (DD) is a common fibrotic disorder of the hand, found with high 
prevalence among Caucasians of Northern European descent1. This enigmatic benign 
fibro-proliferative disease affecting the connective tissue (Fig.1A) results from a complex 
interplay of genetic, anatomic and environmental factors2 with main clinical manifestation 
being the excessive collagen deposition. A disturbance of the heterogeneous mix of static 
and dynamic contractile elements located throughout the fascia of the palm and digits can 
lead to the development of flexion deformities (contracture). Although not associated with 
high morbidity, the impact on movement ability and quality of life of the patients affected 
by DD is major. Currently, the common therapy for DD is palmar fasciectomy, which consists 
of surgical removal of fibrotic tissue and results in immediate improvement of disease. 
However, due to the high recurrence rate and re-manifestation of fibrotic bands, surgery 
is not a permanent solution. 
Several studies have elucidated the aetiopathology of DD which is crucial for the design of 
novel therapies. Uncontrolled wound healing response leads to permanent extracellular 
matrix (ECM) deposition e.g. collagen. The cell responsible for ECM production in normal 
as well as in pathologic conditions is the myofibroblast (MFB), containing both fibroblast 
and smooth muscle cell-type characteristics3. MFBs generate contractile forces that are 
transmitted to the surrounding collagen matrix4 and are distinguished by alpha-smooth 
muscle actin (ACTA2) expression. In pathological conditions ACTA2 expression is persistent. 
Μajor pro-fibrotic factors are members of the transforming growth factor-β (TGFβ) pathway 
which directly regulate the expression levels of several intracellular and extracellular fibrous 
proteins such as  COL1A1, COL3A1 and ACTA23,5-7, fibronectin, matrix metalloproteases, 
integrins, all of which are aberrantly deregulated  in DD8,9. TGFβ ligands interact with TGFβ 
type I receptor (also termed Activin receptor-like kinase 5 (ALK5)/ TGFβRI and type II (TGFβRII) 
receptor complexes which subsequently activate by phosphorylation the SMAD2/3 effectors, 
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which form heteromeric complexes with SMAD4 and act as downstream transcriptional 
effectors of the pathway. Activation and transdifferentiation of DD fibroblasts towards 
MFBs is mainly controlled by TGFβ signaling10-13. Other cytokines, such as platelet-derived 
growth factor (PDGF), are induced by TGFβ14 and also enhance MFB differentiation. TGFβ and 
PDGF factors are aberrantly activated in DD10,15,16. In particular, in DD patient-derived MFB 
cultures, overactive TGFβ signaling causes spontaneous contraction and proliferation13,15. 
Contractility is attenuated by inhibiting TGFβ and TGFβ receptor (ALK5) function15,17,18. We 
have recently shown that the TGFβ/SMAD and PDGF/ERK1/2 MAP kinase pathways cooperate 
in mediating the enhanced proliferation and spontaneous contraction of DD fibroblasts15. 
Inhibiting the uncontrolled fibrotic mechanisms by directly targeting the overactivation 
of the TGFβ signaling, mediated via its ALK5 receptor, at the molecular level, could be an 
effective treatment.
A promising approach to deplete the cells from the function of key receptor of TGFβ signaling 
(ALK5) is by alternative splicing methodology. Particular exon(s) encoding protein domains 
crucial for protein function can become excluded from the mature messenger RNA (mRNA). 
Specific antisense oligonucleotides (AON) bind to sites involved in exon splicing to the splice 
sites of a targeted exon and interfere with the splice machinery; therefore the particular 
exon is not integrated as part of the mRNA19. The resulting mRNA has an intact open reading 
frame and is translated into a protein which lacks only the particular peptide sequence 
encoded by the skipped exon. The advantage of this system is that no genetic alterations 
are introduced, since interference is exclusive during pre-mRNA splicing process. AON 
methodology has broad therapeutic applicability in certain human diseases 20, particularly 
in the field of muscular dystrophies 20 with very promising results reported for clinical trials 
21,22. Based on this principle, we employed the AON-mediated exon skipping technology for 
disrupting the protein function of the ALK5, targeting in particular the extracellular ligand 
binding domain. AONs targeting splice sites of exon encoding extracellular ligand binding 
domain (exon 2) of the ALK523 have been developed and tested in vivo (D.U. Kemaladewi 
et al., manuscript submitted). This strategy ensures no loss of other important domains of 
ALK5, such as the transmembrane domain (encoded by exon 3) or serine-threonine kinase 
activity domain (exon 4- 9). ALK5 AON was administered directly to the DD patient-derived 
specimens by microinjecting it in the center of the tissue, and the effects on fibrosis and 
ECM deposition were assessed with various imaging and biochemical methods. In this 
study we show that DD resected specimens, which are discarded as waste material after 
surgery, can be maintained viable in defined culture conditions in our novel ex vivo model. 
Their study can provide us with useful information about the underlying patient-specific 
pathology and drug response.
Materials and Methods
Generation of 3D culture system
Specimens from DD surgeries are equally sliced and placed in transwell plates onto 0.4 
um nitrocellulose membranes (Greiner Bio One) in defined culture conditions (Dulbecco’s 
Modified Eagle’s Medium (DMEM, with 1% fetal calf serum (FCS), 1% penicillin-streptomycin) 
and allowed to grow (seven days). Nutrient exchange occurs by diffusion from the medium 
through the membrane while DD tissue remains continuously in contact with the liquid 
but is not immerged. Tissue resection specimens (N=9 DD and N=4 normal fascia palmaris) 
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were treated with a combination of activators and inhibitors of the TGFβ signaling pathway 
(e.g. TGFβ, 5ng/ml; SB-431542, 10ng/ml, Tocris). After culture, tissues were processed for 
RNA isolation or were fixed in 4% paraformaldehyde, incubated in 30% sucrose buffer, 
embedded in Tissue Tek- O.C.T. compound and stored at -80°C. 
Human tissue specimens
DD tissue was collected during a standard partial fasciectomy procedure. Indications for 
surgery were contracture(s) of the digit(s) with an inability to put the hand flat on the 
table (table top test). Only patients with first time occurrence of DD were included in this 
study. The range of age of patients was between 63- 88 years old, with 91% being males. 
Macroscopic identification (with surgical loupe magnification) of a nodule (representing most 
active disease) was done by the operating surgeon. Only nodules were used in our study. 
The nodules were defined as being the hard thick parts of the cord, mostly situated in the 
palm of the hand. This part was taken out of the cord after resection of the entire DD cord. 
The normal fascia palmaris tissue of the control group was collected during carpal tunnel 
release procedures. The included control patients did not suffer from DD. The operations 
were performed under local anaesthesia and under tourniquet control. After opening the 
skin through a longitudinal incision the fascia was identified and a small piece of fascia was 
harvested before incising the transverse carpal ligament. The tissue specimen was divided 
in two equal pieces, one of each was immediately processed for 3D culture and the other 
one was snap-frozen in liquid nitrogen and stored at -80°C. Oral consent for removal of the 
tissue for research purposes was obtained from the patients. Confirmation that the Medical 
Research Involving Human Subjects Act (WMO) does not apply to the present study was 
obtained by the local ethics committee (reference number W12_245 #12.17.0279) since 
the research was performed on “waste” material. 
Antisense Oligonucleotides
The antisense oligonucleotides (AONs) used to target ALK5 were developed and recently 
described in another study, in which in vitro and in vivo efficiency of the different AONs was 
extensively tested in the context of muscular dystrophies (D.U. Kemaladewi et al., manuscript 
submitted). In short, the AONs targeting ALK5 specifically bind to and induce exon skipping 
of exon 2 of the ALK5 precursor mRNA transcript. Exon 2 encodes for the ligand binding 
domain, which is, together with the type II receptor, essential in capturing the ligand to 
initiate signaling. Exclusion of exon 2 generate a transcript with intact open reading frame, 
while the resulting protein will lack the ligand binding domain and is therefore functionally 
impaired. Vivo-morpholino AONs with a morpholino backbone and an octaguanidine moiety 
to enhance cellular uptake were used in this study since they have been shown to increase 
exon skipping efficiency in animal models24. ViM AONs (0.5 nmol and 1 nmol, Genetools) 
were diluted in 1% FBS-DMEM or PBS and were microinjected in the tissue. The sequences 
(5’-3’) of the ViM AONs are the following: ALK5ViM: GCAGTGGTCCTGATTGCAGCAATAT, ScrViM: 
CCTCTTACCTCAGTTACAATTTATA. The 2’-O-methyl ribose AONs with phosphorothioate 
modifications (2’-O-Me) were obtained by Eurogentec. 
ALK5 2’-O-Me: UGUACAGAGGUGGCAGAAACA, Scr 2’-O-Me: GCAAGAUGCCAGCAGA
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RNA isolation, RT-PCR and Quantitative PCR 
See Supplementary Materials and Methods for details. 
Microscopy and Image analysis 
See Supplementary Materials and Methods for details. 
Immunofluorescence
See Supplementary Materials and Methods for details. 
Results
Human derived DD tissue can be maintained under ex vivo culture conditions
Fibroblast derivation from DD specimens requires a long culture period during which cells 
adapt to culture conditions (plastic surface, high oxygen, removal of ECM). Such changes 
of the native microenvironment may result in partial recapitulation of the disease state or 
fibro-proliferative characteristics of the tissue in fibroblast two- dimensional cultures 25,26. We 
have developed a three- dimensional (3D) culture system (Fig.1A-B), which allows human 
resection specimens to be grown ex vivo (up to seven days) in defined conditions. Longer 
culture periods (up to 12 days, data not shown) lead to increased cell death (cleaved caspase 
3 positive cells) and absence of proliferation, suggesting non viability of tissue after a certain 
time point (day 7). We show that DD resection specimens in the ex vivo “clinical trial” system 
maintain viability, proliferation (phosphohistone-3, pH3) and apoptosis levels (TUNEL) 
(Fig.1G). As control tissue we have used normal fascia palmaris from carpal tunnel surgeries, 
which is not affected by DD. Control tissue was successfully maintained in culture for up to 
seven days and is characterized by low levels of proliferation (pH3) and apoptosis (TUNEL) 
(Fig.S1, upper panel). Histological characterization of the cultured DD biopsies showed that 
the high expression of fibrotic proteins: ACTA2, COL1A1 and COL3A1 is preserved (Fig.1G, 
representative images), therefore they recapitulate the in vivo properties. Similar data were 
obtained from a number of biopsies (normal fascia palmaris, N=7, DD non cultured tissue, 
N=4, and DD tissue after seven days 3D culture, N=9) indicating the reproducibility of the 
method.  Quantification of immunofluorescence signal for COL1A1, COL3A1 and ACTA2 
(Fig.1D-F), in multiple patient-derived specimens showed that biopsies cultured ex vivo 
retain the expression characteristics with regards to fibrosis. 
Basal expression of ACTA2, COL1A1 and COL3A1 (Fig.1C-G), as well as TGFβ1 and PAI-1 mRNA 
levels (TGFβ target genes) (Fig.1C), are elevated in both cultured and non-cultured DD 
resection specimens compared to fascia palmaris (control, non- affected tissue). Moreover, 
the snap-frozen and the 3D cultured DD (matching) resection specimens similarly show 
areas of proliferating MFBs and low apoptosis (Fig.1G). All together, the above data indicate 
that DD tissue under culture conditions remains representative of the disease.
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Fig.1. Characterization of DD contracture tissue in the 3D ex vivo “clinical trial” system
(A). DD contracture in the hand of a patient; example of DD tissue prior and after resection. (B). Cartoon describing 
3D culture method: DD tissues are equally sliced (about 1mm), placed on a nitrocellulose membrane and cultured 
up to seven days. (C). Q-PCR on control normal fascia palmaris (N=7), DD non-cultured tissue (see DD tissue, N=4) 
and DD cultured tissue (see DD culture, N=9). Error bars represent ±S.E.M. ACTA2, TGFβ1 and PAI-1 mRNA levels have 
been quantified and normalized to ACTRT1. Fold induction values compared to DD non-cultured tissue are shown. 
(D-F). Quantification (described in methods) of immunofluorescence signal of COL1A1, COL3A1 and ACTA2 in normal 
fascia palmaris (N=7), DD non cultured tissue (see DD tissue, N=4) and DD tissue after seven days 3D culture (see DD 
culture, N=9). Multiple focal planes were quantified per sample, error bars represent ±S.E.M. Statistical significance 
was calculated by one-tailed paired t-test. *p<0.05, **p<0.01 (G). Immunohistochemical and immunofluorescent 
analysis of normal fascia palmaris, DD non-cultured tissue and DD cultured tissue. Hematoxylin and Eosin (H&E), 
proliferation marker phosphohistone 3 (PH3, green), apoptosis terminal deoxynucleotidyl transferase dUTP 
nick end labeling (TUNEL) assay (green), Collagen type I (COL1A1, green), Collagen type III (COL3A1, green) and 
smooth muscle actin, alpha 2 (ACTA2, red). Nuclei were visualized with TO-PRO3 (TOPRO, blue). Scale bars, 25 um. 
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Small molecule inhibitor of TGFβ type I receptor kinase (SB-431542) decreases 
expression of fibrotic proteins in DD specimens   
Our novel ex vivo culture method was further used to test the response of the DD tissue to 
stimulation with different factors directly after fasciectomy procedure. Main profibrogenic 
stimulus in DD is the TGFβ signaling; consequently we decided to interfere with the activation 
status of this particular pathway. Resection specimens (both control (Fig.S1) and DD 
(Fig.2A) ) were treated with TGFβ ligand as well as a pharmacological TGFβ type I receptor 
(ALK4, ALK5, ALK7) kinase activity inhibitor (SB-431542). Addition of TGFβ to cultured DD 
specimens resulted in increased expression of target genes ACTA2, COL1A1 and COL3A1 
in the majority of individual human samples tested or sustained the high levels (Fig.2B-D). 
This observation suggests high sensitivity of DD MFB cells to TGFβ, also confirmed by high 
expression of phosphorylated SMAD2 protein (pSMAD2) (Fig.2A). As expected, treatment 
with the SB-431542 inhibitor compound in our model suppressed the profibrogenic action of 
TGFβ and resulted in a trend reduction of the expression of fibrous proteins ACTA2, COL1A1 
and COL3A1 (Fig.2). Differential expression levels among individual samples after TGFβ 
and/ or SB-431542 treatments were observed. Proliferation (pH3) and apoptosis (Caspase 
3) were not significantly affected by the addition of either TGFβ or SB-431542 (Fig.2A). 
Treatment of control tissue with TGFβ cytokine caused an upregulation of ACTA2, COL1A1, 
COL3A1 expression (Fig.S1, middle panel), suggesting a responsiveness of the tissue to 
the treatment and underlining the profibrotic effect of TGFβ. The above observations may 
suggest that the 3D ex vivo culture system is suitable for chemical compound screening. 
Differences in the response of human specimens to growth factor or inhibitor SB-431542 
most probably derives from variation among different individuals which can be effectively 
observed and represented using our ex vivo culture system.  
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Fig.2. Inhibition and stimulation of TGFβ pathway in DD resection specimens cultured in 3D ex vivo 
“clinical trial” system
(A). Immunohistochemical and immunofluorescent analysis of 3D cultured DD resection specimens before treatment 
(untreated) and after seven-day treatment with TGFβ or ALK4/5/7 kinase inhibitor SB-431542. Hematoxylin 
and Eosin (H&E), proliferation marker phosphohistone 3 (PH3, green), apoptosis marker cleaved caspase 3 
(CASPASE3, green), Collagen type I (COL1A1, green), Collagen type III (COL3A1, green), smooth muscle actin, alpha 
2 (ACTA2, red) and phosphorylated SMAD2 (pSMAD2) (green). Nuclei were visualized with TO-PRO-3 (TOPRO, 
blue). Representative data from eight patient derived specimens (N=8). Scale bars, 25 um. (B-D) Distribution of 
fold quantitative values of ACTA2 (B), COL1A1 (C), and COL3A1 (D) among 8 patient-derived specimens after ex 
vivo culture. Quantification of fluorescent signal within certain area fraction was calculated in Image J software 
for every specimen in three different conditions; untreated (control, no exogenous factors), TGFβ cytokine and 
ALK4/5/7 kinase inhibitor SB-431542 compounds. Graph represents the values of positive signal of ACTA2, COL1A1, 
COL3A1, after treatment with TGFβ or SB-431542 compounds as a fold induction over the value of the control 
“untreated” sample (indicated by black line).
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AON- mediated exon skipping of ALK5 
While treatment with SB-431542 resulted in a promising downregulation of fibrotic pathways, 
this chemical inhibitor blocks the kinase activity of ALK4, ALK5 and ALK7 in a dose dependent 
way 27. Thus, in order to ensure higher specificity and less interference with other signaling 
pathways we have tested a novel strategy to selectively inhibit the function of the ALK5. 
We used vivo-morpholinos (ViM) based on previously developed AON sequence (D.U. 
Kemaladewi et al., manuscript submitted) that selectively target and disrupt the ligand 
binding domain of ALK5  by inducing exon skipping of mRNA transcripts. Microinjection 
(Fig.3A) of resection specimens with fluorescently labelled AON demonstrated efficient 
uptake (>90%) and transport to the nucleus throughout the tissue (Fig.3B-C). Similarly, the 
AON targeting ALK5 (ALK5ViM) was microinjected in the centre of the tissues after placing 
them on the nitrocellular membrane of the transwell culture plates (Fig.3A). At day 3 we 
validated the skipping of exon 2 by PCR (Fig.3D-E) and verified reduction of full length 
ALK5 mRNA expression (Fig.4B) compared to tissues injected with control scrambled ViM 
(ScrViM). No effect on the proliferation rate and apoptosis was observed by the use of 
ALK5ViM (Fig.4A). We performed a time course experiment to monitor the levels of full 
length ALK5 mRNA expression versus the exon skipped mRNA. Full length ALK5 mRNA is 
decreased by 70-75% during the first 48 hours after AON administration (Fig.S2A). These 
data indicate that high rate of exon skipping is achieved at early time points and maintained 
in the tissue explant cultures. We also determined the collagen expression in different time 
points and observed a gradual decrease of COL1A1 expression (Fig.S2B).
ALK5 AON causes a reversal of fibrotic phenotype ex vivo
Constant collagen deposition is the main feature of DD, thus, clinical attempts have been 
focused on direct induction of collagen degradation in vivo, such as by injectable collagenase 
treatment 28. Although very promising, this therapeutic approach is associated with several 
limitations (high morbidity), and cannot completely replace the surgical treatment29. 
Our objective was to interfere with the fibrogenic role of TGFβ in a clinically relevant 
manner. However, TGFβ is a regulator of many crucial processes such as inflammation and 
would healing in many organs and is secreted by many cell types including macrophages, 
endothelial cells, lymphocytes, epithelial cells. Thus, TGFβ should be tightly regulated and 
complete abolishment may lead to adverse effects. The process of exon skipping by AONs is 
advantageous because it results in partial and not complete blockage of the ALK5 receptor 
activity. Administration of the ALK5ViM directly to DD tissues (N=3) remarkably reduced 
the overall protein expression of ACTA2, COL1A1 and COL3A1 (Fig.4A) and activation of 
downstream pSMAD2 (Fig.4A, S3), rendering the tissue more similar to the control, normal 
fascia palmaris (Fig.S1). Quantification of the expression patterns among different specimens 
(N=3) confirmed a reproducible decrease observed after ALK5ViM treatment (Fig.4C-E). The 
spatiotemporal imaging of the endogenous extracellular distribution of collagen structure 
was determined by Second Harmonic Generation (SHG) on DD specimens during 3D culture, 
prior and after ALK5ViM application (Fig.4F). Reorganization/ degradation of collagen 
fibres, specifically at the site of injection with the ALK5ViM was observed with SHG (Fig.4F, 
white arrow) similarly to immunofluorescence signal (Fig.4A). In contrast, tissue injected 
with ScrViM retained the highly anisotropic collagen structures and did not exhibit signs 
of reorganization/degradation (Fig.4F). A partial reduction of available ALK5 molecules 
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Collection AON injection Analysis



















































Fig.3. Microinjection of AONs in DD resection specimen maintained in 3D culture and ALK5 exon skipping
(A). AONs coupled to a fluorochrome (AON-fluorescent) were delivered by microinjecting the center of the tissue 
on the nitrocellulose membrane as described in the cartoon. The tissue was then cultured for three days and 
sectioned in order to determine the presence of nuclei, which had taken up the AON. (B). Direct visualization of 
the AON-fluorescent (green) and nuclei (TOPRO, blue) in a DD tissue section. (C). Quantification of the percentage 
of fluorescent cells (AON) relative to total cell count. Scale bars, 50 um. (D). Description of exon skipping (exon 
2) of the ALK5 pre-mRNA. Primer position (exon 1 and exon 3) of primers used for detecting the full length ALK5 
and the exon skipped mRNA product are depicted here. (E). DD tissues were cultured and injected with either 
scrambled (ScrViM) or ALK5ViM. For comparison, treatment with TGFβ or SB-431542 compound was also combined 
with ViM administration. After three days of treatments, tissues were homogenized and used for RNA isolation 
and cDNA synthesis. Touchdown PCR was performed to validate the exon skipping and products were visualized 
by agarose gel electrophoresis. Full length ALK5 mRNA transcripts were detected in all conditions while exon2-
skipped ALK5 mRNA transcripts were only detected in tissues injected with ALK5ViM. CON: untreated condition; 
TGFβ: treatment with TGFβ cytokine, SB: treatment with SB-431542 compound; TGFβ+SB: treatment with both 
TGFβ and SB-431542 compound.
appears already sufficient to reduce the fibro-proliferative effect mediated by TGFβ in 
fibroblasts/ MFBs. Importantly; mRNA molecules that escape exon skipping do produce 
functional ALK5 protein able for ligand binding (TGFβ) and protein complex formation with 
type II receptors. Thus, application of AONs does not cause complete abolishment of the 












































































































Fig.4. ALK5ViM treatment of DD resection specimens cultured in the 3D ex vivo “clinical trial” system
(A). Immunohistochemical and immunofluorescent analysis of 3D cultured DD resection specimens after three-
day treatment with scrambled ViM (ScrViM) and ALK5ViM. Hematoxylin and Eosin (H&E), proliferation marker 
phosphohistone 3 (PH3, green), apoptosis marker cleaved caspase 3 (CASPASE3, green), Collagen type I (COL1A1, 
green), Collagen type III (COL3A1, green), phosphorylated SMAD2 (pSMAD2) (green) and smooth muscle actin, 
alpha 2 (ACTA2, red). Nuclei were visualized with TOPRO-3 (TOPRO, blue). (B). QPCR to detect expression levels of 
full length ALK5 mRNA was performed on tissues injected with ScrViM and ALK5ViM (N=3). Values were normalized 
to CAPNS1. Fold induction values compared to ScrViM condition are shown. Statistical significance was calculated 
by one-tailed paired t-test. ***p<0.001. (C-E). Quantification (described in methods) of immunofluorescence 
signal of COL1A1, COL3A1, ACTA2 from different patient-derived specimens (N=3) after three-day treatment with 
scrambled ViM (ScrViM) and ALK5ViM. Fold induction values compared to ScrViM condition are shown. Multiple 
areas were quantified per sample, error bars represent ±S.E.M. Statistical significance was calculated by one-tailed 
paired t-test. *p<0.05, **p<0.01. Scale bars, 25 um. (F). SHG images of endogenous DD tissue in the 3D culture 
system. Collagen distribution was imaged at control time point (SHG, t=0, upper panel) in adjacent parts of the 
specimen. The exact tissue parts were imaged at 72 hrs (SHG, t=72 hrs, bottom panel) after injection of ScrViM or 
ALK5ViM. Arrow indicates site of injection.
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Discussion
In the present study, we have developed a novel method for ex vivo analysis of human 
DD disease and we provide evidence of its suitability for molecular modulation by AONs. 
AONs were designed to target and inhibit a key profibrotic signaling pathway, which 
results in significant antifibrotic effects. Given the high risk of recurrence of DD, it would be 
therapeutically beneficial to reduce local collagen content in order to extend the symptom-
free period after surgery, needle fasciotomy and/or collagenase injection. Our ex vivo  “clinical 
trial” system allows the culture of DD specimens after surgical removal, without the need of 
fibroblast derivation, or grafting experiments30, while preserving the pathological status of 
the disease by maintaining the complex organization of the ECM and the 3D tissue structure. 
The main challenges in ex vivo culture methods are viability and preservation of the in vivo 
normal or pathological traits of the tissue to be studied. Several organ culture and precision 
cut tissue slice methods have been developed such as the submerged system31,34, the 
dynamic organ culture32 and the gas exchange method 31. Organ viability, functionality, 
metabolism and toxicity can be well studied in all these systems for complex organs such 
as liver, kidney, intestine, and lungs33,34. A limitation of these methods is the relatively short 
incubation time possible (approximately 24- 72 hours), depending on the tissue origin, as 
well as the challenge of organ/disease recapitulation. Our methodology is based on an 
enhanced setup where tissue parts are placed continuously and statically in contact with 
nutrients but are not fully immersed into medium, thus maintaining proper oxygenation 
and avoiding necrosis in the center of the tissue. Such setup appears suitable for culture of 
dense tissue such as DD fibrotic parts and facilitates viability for longer periods (up to seven 
days tested). Exposure of one side of the tissue to the medium is sufficient for diffusion and 
absorbance of nutrients throughout the tissue. Small tissue parts (<200um) are preferable 
in order to allow cell proliferation and longer viability35. Static incubation was performed, 
in contrast to most dynamic culture conditions, in order to maintain positional information 
and cellular sensing36,37. 
In addition, this particular setup allows for manipulation (e.g. AON injection) and direct 
visualisation of the effects on the ECM (SHG). Since DD tissue shows rapid production of 
ECM proteins, all tissues were cultured in absence of any exogenous matrix substrates. This 
is advantageous for the maintenance of native ECM turnover. Moreover, this culture setup 
is optimal for DD fibrotic tissue due to the content of highly proliferative MFBs and because 
the nodules and cords are in vivo quite isolated structures with autonomous characteristics 
(such as cell/ tissue growth and fibrosis). Due to these innate properties, it is likely that the 
tissues can be maintained ex vivo efficiently. 
In this study, we have exclusively utilized the nodule parts, which are the firm thickenings 
and are considered pathologically very active due to the high content of MFBs. Cord parts 
are mainly fibrotic flexions and contain few fibroblasts, which are in a dormant state38. It has 
been proposed that active nodules may progress into cord structures at more advanced stage 
of the disease39 therefore it is more clinically relevant to target the fibrotic characteristics 
of the node parts. TGFβ has been found to be expressed in both parts, as well as in the 
surrounding tissue4 (appearing not affected by the disease), which may play a role in 
promoting recurrence of fibrosis as part of wound healing response due to tissue damage 
from the primary surgery. The majority of the resection specimens we have analysed using 
this system respond to TGFβ stimulation by upregulation or maintenance of the expression 
levels of fibrotic proteins (Fig.2B-D). Decrease in COL1A1 and COL3A1 but not of ACTA2 has 
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been detected in two biopsies after TGFβ stimulation which may suggest the function of a 
negative feedback loop due to high levels of TGFβ40,41. Upon treatment of DD biopsies  with 
the SB-431542 inhibitor, expression of collagen and ACTA2 were decreased in the majority 
of biopsies or sustained the same levels as if untreated (Fig.2B-D).
Previous studies have attempted manipulation of TGFβ by neutralizing antibodies30 and 
kinase inhibitors15. TGFβ has been also targeted in indirect ways such as by cyclic AMP42, 
angiotensin inhibitors43, tamoxifen44, administration of Bone morphogenetic protein-615. 
Given the pleiotropic effect of TGFβ signaling, the aim is to normalize and not completely 
abolish its function. Therefore, in order to restore the balance of pathway activation 
without fully disrupting its function, we have selectively inhibited the ALK5- mediated 
profibrotic pathway by exon skipping technology. It is worth noting that AON approach 
provides the advantage of high specificity exclusively for ALK5 mRNA (exon 2 encoding 
ligand binding domain), while the SB-431542 compound targets activity of three kinase 
receptors (ALK4, ALK5, ALK7), all implicated in the activin/ TGFβ pathway. Moreover, SB-
431542 may not block TGFβ/ ALK5 induced non-SMAD signaling45,46 whereas ALK5 AON will 
inhibit both pathways. TGFβ/ p38 and ERK MAP kinases have been shown to be involved 
in fibro-proliferative response in Dupuytren’s disease15. Delivery of ALK5 AON by affecting 
SMAD and non-SMAD TGFβ signaling may thus achieve better inhibition than ALK5 kinase 
inhibitors by interfering with multiple pathways downstream of ALK5. Compared to regular 
oligonucleotides, small molecule inhibitors have better pharmacokinetic properties, due 
to the short half-life and inability to efficiently cross tissue membranes. However, currently 
there are many oligonucleotide modifications available that ensure improved stability, serum 
half-life and uptake of oligonucleotides. Our studies here use ViMs, which are antisense 
phosphorodiamidate morpholino oligomers covalently linked to a molecular scaffold that 
carries a guanidinium group at each of its eight tips to enhance delivery, to show proof-of-
concept for this approach. Efficacy of ViMs has also been shown by others in animal models47. 
However, further clinical development of this particular compound is hampered by toxic 
effects. Nevertheless, there is a plethora of chemical modifications available that can be 
studied further for clinical development48. In light of this, it is encouraging that we were 
able to obtain similar results with ALK5 AONs of the 2’-O-methyl phosphorothioate AON 
chemistry (Fig.S4, which is very similar to the chemistry approved by FDA (mipomersen49) 
and identical to drisapersen, which is in phase III clinical trials for Duchenne muscular 
dystrophy). TGFβ secretion might also play a significant role in the recurrence of fibrosis 
after surgical removal. In this context, a hypothetical therapeutic setting would be the 
administration of AONs prior to or instead of the surgical intervention to counteract the 
TGFβ signaling in the remaining MFBs. 
A challenge in the field of Dupuytren’s is the lack of in vivo modelling of the disease. Here, 
we have developed a very robust and reproducible ex vivo 3D culture method with a simple 
setup (no growth factors or matrix protein support required). By using the ALK5ViM AON 
in this system, we have showed significant decrease in collagen protein expression and 
degradation/reorganisation of collagen structures. Excessive collagen production is the 
main clinical symptom in this disease and here we provide proof of decrease in collagen 
deposition ex vivo. The average reduction of full length ALK5 mRNA achieved was 70-75% 
within the first 48 hours (Fig.S2A) and about of 30-60% by day 3 (Fig.4B, S2A). Our data 
indicate the potential of MFBs to reverse into a less fibrotic phenotype and to respond to 
growth factor inhibition even after advanced disease progression. In addition, we show 
the feasibility of a well-established ex vivo imaging approach, such as the SHG41,50, for the 
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study of ECM structure in native unstained tissue which to our knowledge has not been 
previously used for DD. The above observations may change the view of therapeutic 
approaches currently used for DD. Ultimately, the ex vivo “clinical trial” system can be applied 
for individualized therapy research after tissue resection as a drug screening method to 
test for specific responsiveness of DD tissues to a panel of growth factors and inhibitors 
and eventually lead to targeted therapy in case of recurrence. 
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Fig.S1. Normal fascia palmaris tissue cultures in the 3D ex vivo “clinical trial” system
Representative immunohistochemical and immunofluorescent analysis of 3D cultured normal fascia palmaris 
specimens (N=4). Hematoxylin and Eosin (H&E), proliferation marker phosphohistone 3 (PH3, green), apoptosis 
terminal deoxynucleotidyl transferase dUTP nick end labeling assay (TUNEL, green) in control normal fascia 
palmaris without any additional factors (untreated), after treatment with TGFβ and after treatment with ALK4/5/7 
kinase inhibitor SB-431542. Collagen type I (COL1A1, green), Collagen type III (COL3A1, green), phosphorylated 
SMAD2 (pSMAD2, green) and smooth muscle actin, alpha 2 (ACTA2, red) protein expression in control normal 
fascia palmaris without any additional factors (untreated), after treatment with TGFβ and after treatment with 
ALK4/5/7 inhibitor (SB-431542). Nuclei were visualized with TO-PRO-3 (TOPRO, blue). Scale bars, 25 µm. 
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Fig.S2. Time course of ex vivo delivery of ALK5 ViM AON 
Tissues were injected with ScrViM AON (scrambled sequence) or ALK5ViM AON and cultured for 1- 4 days. (A). 
Expression of full length ALK5 mRNA as measured by Q-PCR at different time points (day 1- day 4 after AON injection). 
Values were calculated as fold induction over the ScrViM (control) values for each time point. Error bars represent 
±S.D. Percentages indicate the decrease of ALK5 full length mRNA expression. (B). Immunofluorescent analysis 
of DD tissue specimens cultured in the 3D ex vivo system. Expression of Collagen type I (COL1A1, green), smooth 

























Fig.S3. Quantification of pSMAD2 immunofluorescence by image analysis. 
Number of pSMAD2 positive nuclei over total cell count (TO-PRO-3) after three-day treatment with scrambled 
ViM (ScrViM) and ALK5ViM. Fold induction values compared to ScrViM condition are shown. Multiple areas were 
quantified per sample (N=3), error bars represent ±S.E.M. Statistical significance was calculated by one-tailed 
paired t-test. **p<0.01.
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Figure S4. Ex vivo delivery of ALK5 AON with ViM and 2’OMe chemical backbones
Immunofluorescent analysis of DD tissue specimens cultured in the 3D ex vivo system. Tissues were injected with 
ScrViM AON (scrambled sequence), ALK5ViM AON or ALK5 2’OMe AON and cultured for 72 hours. (A). Expression 
of Collagen type I (COL1A1, green), smooth muscle actin, alpha 2 (ACTA2, red). (B). Collagen type III (COL3A1, 
green) and smooth muscle actin, alpha 2 (ACTA2, red) protein expression. Nuclei were visualized with TO-PRO-3 
(TOPRO, blue). Scale bars, 25 µm.
Supplementary Materials and Methods
Generation of 3D culture system
In order to bypass the need for exogenous ECM and the derivation of fibroblasts, we have 
developed a patient- derived specimen culture system. This is the first tissue resection culture 
system that allows human tissue from DD patients to be grown ex vivo and functionally 
tested, recapitulating the in vivo situation. The system is based on a nitrocellulose membrane 
that allows contact of the tissue with the medium but not with the plastic, thus preventing 
the alteration of the tissue upon attachment, as previously observed when culturing DD 
fibroblasts. No collagen gel or other ECM protein substrate is required, since the DD tissue 
itself produces large amounts of these proteins. In brief: specimens from DD surgeries 
are equally sliced and placed in transwell plates onto nitrocellulose filters. Tissues remain 
continuously and statically in contact with defined culture conditions (Dulbecco’s Modified 
Eagle’s Medium (DMEM, with 1% fetal calf serum (FCS), 1% penicillin-streptomycin) but 
without being entirely submerged and are allowed to grow (seven days). Tissue resection 
specimens (N=9 DD and N=4 normal fascia palmaris) were treated with a combination of 
activators and inhibitors of the TGFβ signaling pathway (e.g. TGFβ, 5ng/ml; SB-431542, 
10ng/ml, Tocris). After culture, tissues were processed for RNA isolation or they were fixed 
in 4% paraformaldehyde, incubated in 30% sucrose buffer, embedded in Tissue Tek- O.C.T. 




Hematoxylin and Eosin (H&E) staining were performed using standard protocols on 10-μm 
cryosections. Immunofluorescence staining was performed on 10-μm cryosections. For 
antigen retrieval sections were boiled in antigen unmasking solution (Vector Labs) and 
were incubated in 3% H2O2 for endogenous peroxidase sequestering. Primary antibodies 
and dilutions used: anti-ACTA2 1:500 (Sigma), anti-COL1A1 1:500 (Southern Biotech), 
anti-COL3A1 1:500 (Southern Biotech), and anti-phospho-SMAD2 1:1000 (Cell Signaling). 
Sections were blocked with 1% bovine serum albumin (BSA)- PBS-0.1% v/v Tween 20) and 
incubated with primary antibodies diluted in the blocking solution, overnight at 4°C or room 
temperature. Sections then were incubated with secondary antibodies labeled with Alexa 
Fluor 488, 555, or 647 (Invitrogen/Molecular Probes, 1:250 in PBS-0.1% Tween 20). Detection 
of pSMAD2, was enhanced using tyramide amplification (Invitrogen/Molecular Probes) by 
incubation of slides with horseradish peroxidase (HRP)-conjugated secondary antibody 
(1:100 dilution) (Invitrogen/Molecular Probes), followed by incubation with tyramide-488 
for 10 minutes. Sections were counterstained with TO-PRO3 (Invitrogen/Molecular Probes) 
at 1:1000 dilution in PBS-0.1% Tween-20 for nuclei visualization, and mounted with Prolong 
G mounting medium (Invitrogen/Molecular Probes), which contains DAPI. 
RNA isolation, RT-PCR and Quantitative PCR 
Nodule parts (100 μm) were homogenized using an Ultra Turrax homogenizer (T25 basic, 
IKA) in TRIpure reagent (Roche) and directly processed for total RNA isolation according 
to the TRIpure RNA extraction protocol. Total RNA (0.5 μg) was used for first strand cDNA 
synthesis using RevertAid H Minus first strand cDNA synthesis kit (Fermentas). 
For quantitative PCR (Q-PCR) ten- fold diluted cDNA was amplified in a CFX Real Time 
Detection system (Bio-rad) using SYBR Green Supermix reagent (Bio-rad). To detect full 
length ALK5 mRNA levels, primers flanking exon 2 and exon 3 were used. Expression levels 
were normalized to housekeeping gene (ACTRT1 or CAPNS1) and analyzed using the linear 
regression method. For exon skipping test, cDNA was amplified by touchdown PCR using 
ALK5 specific primers, which are designed to amplify both the full length and exon 2-skipped 
mRNA transcripts (forward primer in exon 1, reverse primer in exon 3). Primer sequences 
and detailed PCR protocol are available upon request. 
Microscopy and Image analysis 
Confocal microscopy of labelled specimens was performed on a Leica TC-SP5 microscope 
with a 40Χ 1.4 NA oil-immersion objective Z series were collected and reassembled in Image 
J software (rsbweb.nih.gov/ij). Mean area fraction fluorescence was calculated in Image J 
software using threshold to select the root boundary and measuring the percentage of 
positive surface inside the intensity defined by the threshold. Experiments were repeated 
three times and stained specimens in a given experiment were imaged using identical 
microscopic exposure and recording settings. Second-harmonic generation (SHG) was 
performed for imaging the organization of collagen fibers in native tissue. This type of two-
photon microscopy was performed on a Zeiss 710 NLO upright confocal microscope (Jena, 
Germany) equipped with a femtosecond Spectra-Physics Deep See MP laser (Santa Clara, 
United States) using a Plan-Apochromat 20x/1.0 NA water-immersion objective. The images 
Page | 137
TGFβ type I receptor modulation by antisense oligonucleotides
were obtained with an excitation wavelength of 750 nm and emitted light was collected 
between 371–467 nm. Confocal stacks were processed with the Zeiss ZEN2009 software.
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Abstract 
Prostate cancer is the second most common cancer in men worldwide and lethality is 
almost inevitable due to the consequences of metastasis. Therefore, targeting the molecular 
pathways that underlie primary tumor growth and spread of metastases is of great clinical 
value. Bone morphogenetic proteins (BMPs) play a critical role in prostate cancer. BMP9 and 
the closely related BMP10 signal via the transmembrane serine kinase receptors Activin 
receptor-Like Kinase 1 (ALK1) and ALK2 and the cytoplasmic proteins SMAD1 and SMAD5. 
The human ALK1 extracellular domain (ECD) binds BMP9 and BMP10 with high affinity and 
we show that a soluble chimeric protein consisting of the ALK1 ECD fused to human Fc 
(ALK1Fc) prevents activation of endogenous signaling via ALK1 and ALK2. We also show 
for the first time in prostate cancer that ALK1Fc reduces BMP9- mediated signaling and 
decreases tumor cell proliferation in vitro. In line with these observations, we demonstrate 
that ALK1Fc impairs angiogenesis and reduces tumor growth in vivo. Our data identify BMP9 
as a putative therapeutic target and ALK1Fc as a potential therapy capable of targeting 
tumor cells and the supportive tumor angiogenesis. Together these findings justify the 
continued clinical development of drugs blocking ALK1 and ALK2 receptor activity.
Introduction
Prostate cancer is the second most common cancer in men worldwide1. The survival rate 
of prostate cancer patients is mostly determined by the extent of the tumor. If the cancer is 
restricted to the prostatic gland the median survival is estimated up to 5 years2. If prostate 
cancer has metastasized to distant organs, the current therapies are not curative and the 
median survival drops to 1 to 3 years3. Currently prostate cancer, when still in its first phase 
of androgen dependency, can be successfully treated surgically. Follow up with androgen 
deprivation therapy will then contain the cancer and reduce the possibility of metastasis4,5. 
However, once the cancer develops in an androgen-independent state, therapy is no longer 
useful or successful5. Risk of lethality rate is high due to the consequences of prostate 
cancer metastasis6. Indeed, the prognosis for patients diagnosed with metastatic disease 
has not markedly improved in recent decades, and metastases remain the direct cause of 
approximately 90% of cancer deaths7. Therefore, understanding the molecular pathways 
that underlie the emergence and spread of metastases from primary tumors are of great 
biological and clinical value.
Different lines of research have highlighted the role of the type I activin receptor–like 
kinase-1 (ALK1) of the transforming growth factor-β (TGFβ) pathway as key regulator of 
normal as well as tumor angiogenesis8,9. Bone morphogenetic protein-9 (BMP9) and BMP10 
are high affinity ligands for ALK1, which is predominantly expressed by endothelial cells10. 
Alternatively, BMP9 signals through the BMP type I receptor ALK211-13. Binding of BMP9/
BMP10 to ALK1/ ALK2 results in phosphorylation and activation of downstream effectors 
SMAD1 and/ or SMAD512-14. BMP9 is produced in the liver, secreted in circulation15 and it 
promotes liver cell proliferation of primary hepatocytes and human hepatoma HepG2 cells16. 
In ovarian cancer, BMP9 can act as proliferative factor, promoting human epithelial ovarian 
cancer and human immortalized ovarian surface epithelial cell proliferation through ALK2/
SMAD1/ SMAD4 pathway13. Similarly, BMP9 stimulates cell proliferation of liver cancer cells17 
and osteosarcoma growth18. Among the BMPs, BMP9 is the most recently identified15 and 
least studied ligand. Current research has not only attributed a tumor promoter role to 
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BMP913,17,18 but also tumor suppressing properties19-21 in different types of cancer, including 
prostate cancer.   
Several studies have highlighted the role of BMP9/ ALK1 in the genetics and development 
of blood vessel formation, outlining its critical involvement in pathological and tumor 
angiogenesis22,23. Interestingly, alterations of signal transduction pathways that are important 
for blood vessel formation, such as the NOTCH pathway, have also been associated with 
arterio-venous malformations24,25. Recently, BMP9 and BMP10 signaling have been linked 
to NOTCH signaling, one of the major pathways involved in prostate cancer development, 
progression and bone metastasis26. Expression profiling studies have shown that members of 
NOTCH pathway are characteristic of high grade (Gleason 4+4=8) micro-dissected prostate 
cancer cells compared to low grade (Gleason 3+3=6)27. Moreover, inhibition of NOTCH1 
reduces prostate cancer cell growth, migration and invasion28. Interestingly, NOTCH signaling 
pathway activates ALDH1A1, a well- known marker of prostate cancer stem cells29-32. 
In order to understand the role of BMP9 in prostate cancer tumor progression, we have 
employed here the soluble chimeric protein (ALK1Fc/ ACE-041)33 containing the human 
ALK1 extracellular domain that binds with high affinity the ligands BMP9 and BMP1034, 
thus, reducing activation of endogenous ALK1, ALK2 and downstream signaling35. BMP9 
induces endothelial cell proliferation and vessel formation36 while ALK1Fc has previously 
been shown to inhibit vascularization and tumor growth of breast cancer in vivo in an 
orthotopic transplantation model34. ALK1Fc binds and neutralizes only BMP9 and BMP10 
ligands and not TGFβ34,35, which plays an important role in angiogenic processes. Phase I 
clinical trials have been completed using ALK1Fc as anti-angiogenesis therapy in myeloma 
(clinicaltrials.gov identifier NCT00996957). 
Here we show, for the first time in prostate cancer, that ALK1Fc reduces BMP9 signaling 
and decreases cell proliferation of highly metastatic and tumor initiating human prostate 
cancer cells in vitro. We further demonstrate that ALK1Fc reduces tumor growth by impairing 
angiogenesis and affecting cell proliferation of human prostate cancer cells in vivo. Taken 
together these data suggest BMP9 as a possible therapeutic target and thus justifies the 
continued clinical development of drugs blocking ALK1 and ALK2.
Materials and Methods
Cell line and culture conditions
Human osteotropic prostate cancer cell lines PC-3M-Pro4luc2 cells37 were maintained in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% FetalClone II (FCII) 
serum (Thermo Fisher, Waltham MA, USA), 0.8 mg/ml Neomycin (Santacruz, Dallas, USA) and 
1% Penicillin-Streptomycin (Life Technologies, Carlsbad, USA). C4-2B cells were maintained in 
T-medium DMEM (Sigma-Aldrich, the Netherlands) supplemented with 20% F-12K nutrient 
mixture Kaighn’s modification (GibcoBRL, the Netherlands), 10% fetal calf serum (FCS) 0.125 
mg/ml biotin, 1% Insulin-Transferin-Selenium, 6.825 ng/ml T3, 12.5 mg/ml adenine and 1% 
penicillin/streptomycin (all from (Life Technologies, Carlsbad, USA). Cells were maintained 
at 37°C with 5% CO2. 
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Luciferase reporter gene constructs 
PC-3M-Pro4Luc2 cells were seeded at a density of 50,000 cells in 500 µL medium in a 24-wells 
plate. Transient transfection of reporter constructs was performed with Lipofectamine2000 
(Life Technologies, Carlsbad, USA) according manufacturer’s protocol. For each well, 100 
ng of NOTCH reporter RBP-Jk-luc,10 ng CAGGS-Renilla luciferase, 100 ng BRE renilla and 
100 ng BRE-luc38 per well were transfected. After 24 hours, medium was replaced and cells 
were treated with BMP9 for 24 hours. The Firefly luciferase and Renilla luciferase levels in 
the lysates were measured using Dual Luciferase Assay (Promega, Madison, USA).
RNA isolation and Real-time qPCR
Total RNA was isolated with Trizol Reagent (Invitrogen, Waltham, USA) and cDNA was 
synthesized by treverse transcription (Promega, Madison, USA) according to manufacturer’s 
protocol. qRT-PCR was performed with Biorad CFX96 system (Biorad, The Netherlands). Gene 
expression was normalized to GAPDH or β-actin. (For primer sequences see Supplementary 
Table I). Total RNA from frozen section (5µm) was isolated with Qiagen Mini Isolation kit 
(Qiagen, the Netherlands) according to manufacturer protocol. Primer sequences are listed 
in Table 1. 
MTS assay
Cells were seeded at density of 2.000 cells/ well, in 96- well plates and treated with ALK1Fc 
or control-Fc (CFc) (10ug/ml, Acceleron, USA) allowed growing for 24, 48, 72 and 96 hours. 
After incubation, 20 µl of 3-(4,5 dimethylthiazol- 2- yl)- 5 -(3 -carboxymethoxyphenyl)- 2 -(4 
-sulfophenyl)- 2 H-tetrazolium was added and metabolic activity (absorbance of formazan 
product at 490nm) was measured after 2 hours incubation at 37°C. MTS absorbance values 
are positively proportional to total number of metabolically active cells providing an 
indirect correlation with cell proliferation rate39 (CellTiter96 Aqueous Non-radioactive Cell 
proliferation assay, Promega).
Animals
Male, 6-8 week-old, athymic nude mice (Balb/c nu/nu), purchased from Charles River 
(L’Arbresle, France), were used in all in vivo experiments (n=15 per group). Mice were housed 
in individual ventilated cages under sterile condition, and sterile food and water were 
provided ad libitum. Animal experiments were approved by the local committee for animal 
health ethics and research of Leiden University (DEC #11246), and carried out in accordance 
with European Communities Council Directive 86/609/EEC. After the experimental periods, 
mice were injected with hypoxia probe (6mg/kg, Burlington, Massachusetts, USA) and 
lectin-Tomato (1mg/kg, Vector Laboratories, USA) intravenously prior to perfusion and 
sacrified according to our mouse protocol. Tumors were dissected and processed for further 
histomorphological analysis as described below.
Orthotopic prostate transplantation and ALK1Fc treatment 
A total of 25.000 PC-3M-Pro4luc2 cells (10ul final volume) were injected in the dorsal lobe 
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of nude mice. In brief: after anesthetizing the mice with isoflurane, each mouse was placed 
on its back and a small incision was made along the lower midline of the peritoneum for 
about 1 cm. The prostate dorsal lobes were exteriorized and stabilized gently. A 30-gauge 
needle attached to a 1-cc syringe was inserted into the right dorsal lobe of the prostate 
and 10 µl of the material were slowly injected. A well-localized bleb indicates a successful 
injection. After retracting the needle a Q-tip was placed over the injection site for about 
1 min to prevent bleeding and spillage of material. The prostate was then returned to the 
peritoneum and the abdominal wall and skin layer was sutured. After establishment of the 
primary tumor, at 10 days after the orthotopic transplantation, mice were intraperitoneally 
injected with Control-Fc (CFc) or ALK1Fc compounds (1mg/kg) twice per week. 
Administration of compounds was performed for four weeks. ALK1-Fc is a fusion protein 
comprised of the extracellular domain of human ALK1 fused to the Fc region of IgG and 
was obtained from Acceleron Pharma, Cambridge, USA. The Fc domain of IgG1 was used 
as a control (MOPC-21; Bio Express, West Lebanon NH).
Whole body bioluminescent imaging (BLI)
Tumor growth was monitored weekly by whole body bioluminescent imaging (BLI) using 
an intensified-charge-coupled device (I-CCD) video camera of the in vivo Imaging System 
(IVIS100, Xenogen/Perkin Elmer, Alameda, CA, USA) as described previously40. Mice were 
anesthetized using isoflurane and injected intraperitoneally with 2mg D-luciferin (Perbio 
Science, the Netherlands). Analyses for each metastatic site were performed after definition 
of the region of interest and quantified with Living Image 4.2 (Caliper Life Sciences, Belgium). 
Values are expressed as relative light units (RLU) in photons/sec.
Immunofluorescence
Immunofluorescence staining was performed as described previously41. In brief, 5-μm 
paraffin embedded sections were used. For antigen retrieval, sections were boiled in antigen 
unmasking solution (Vector Labs, Peterborough, UK) and stained with following antibodies, 
CD31 (Sigma), ALDH1A1 (Abcam), phosphoHistone 3 (Millipore) and cleaved Caspase 3 
(Cell Signaling). Sections were blocked with 1% bovine serum albumin (BSA)- PBS-0.1% v/v 
Tween-20 and incubated with primary antibodies diluted in the blocking solution, overnight 
at 4°C or room temperature. Sections then were incubated with secondary antibodies 
labelled with Alexa Fluor 488, 555, or 647 (Invitrogen/Molecular Probes, Waltham, MA, USA) 
at 1:250 in PBS-0.1% Tween-20. Nuclei were visualized by TO-PRO-3 (Invitrogen/Molecular 
Probes, 1:1000 diluted in PBS-0.1% Tween-20) or DAPI which was included in the mounting 
medium (Prolong G, Invitrogen/Molecular Probes).
Western immunoblotting 
Proteins were extracted by using RIPA buffer (Thermo Scientific) and protein concentrations 
were quantified according to manufacturer’s protocol (Thermo Scientific). Proteins samples 
(20 µg per sample) were separated by 15% SDS- PAGE followed by transfer to a blotting 
membrane. The membrane was blocked with 5% Milk, dissolved in PBS-Tween-20 for 1 
hour at room temperature. The membrane was incubated with 1:1000 primary antibody 
(anti-NOTCH1, Cell Signaling, catalogue number 3608) at 4ºC overnight. Subsequently, the 
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ALK1Fc reduces primary prostate tumor burden in vivo
To investigate the role of BMP9 in prostate cancer progression, the BMP9- ligand trap, 
ALK1Fc, was administered in a mouse model of orthotopic prostate cancer. Orthotopic 
prostate tumor growth was induced by intra-prostatic inoculation of human prostate 
cancer PC-3M-Pro4luc2 cells in Balb/c nude mice and tumor progression was followed by 
bioluminescence imaging (BLI)37 (Fig.1A). Based on the BLI signal the mice were distributed 
between two treatment groups; ALK1Fc or CFc (n=15 per group). The compounds were 
injected twice weekly and tumor imaging and body weights were monitored weekly for 
5 weeks (Fig.S1). Tumor burden was quantitatively assessed for each animal during the 
course of treatment. The group of animals that received ALK1Fc exhibit smaller tumor size 
compared to the animals that received CFc based on the size after resection (Fig.1B) and 
bioluminescence quantification (Fig.1C, p<0.05). 
Fig.1. Effect of ALK1Fc in vivo
(A). PC-3M-Pro4Luc2 cells were orthotopically injected in the anterior lobe of prostate gland of nude mice (n=15 
per group). Detection of primary tumor burden was observed at 2 weeks after injection, time point designated 
as “week 1” at the start of treatment with ALK1Fc or CFc. Representative examples of bioluminescent images of 
tumor burden at the start of treatment with ALK1Fc/ CFc  (week 1) and at the end point (week 5). (B). Representative 
images of primary tumor size from a recipient of CFc versus ALK1Fc treatment after 5 weeks. (C). Quantification 
of bioluminescent signal (photons/sec) in mice treated with either CFc (n=14) or ALK1Fc (n=15) for 5 weeks. 
P value <0.001 (***).  
membrane was incubated with 1:10000 secondary horseradish peroxidase (HRP) antibody. 
All antibodies were dissolved in PBS-Tween-20. Chemi-luminescence was used to visualize 
the bands.
Statistical analysis
Statistical analysis was performed with GraphPad Prism 6.0 (GraphPad software) using t-test 
or ANOVA for comparison between more groups. Data is presented as mean ± SEM. P-values 
≤ 0.05 were considered to be statistically significant (* P < 0.05, ** P < 0.01, *** P < 0.001).
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Effect of ALK1Fc in vascular density, hypoxia and cell proliferation of the primary 
prostate tumor 
The acquisition of tumor angiogenesis promotes tumor growth beyond a few mm3 sizes. 
Intravital lectin perfusion was used to map the perfused elements of the tumor vasculature 
in mice. Fluorescent-conjugated lectin (lectin-Tomato) was visualized in tumor tissue 
sections and quantified. Vascular density, indicated by the overall lectin presence, was 
overall decreased in the tumors treated with ALK1Fc compared to the CFc group (Fig. 2A-
B; p value= 0.058 statistically not significant). We evaluated the presence of endothelial 
cells in tumor sections by CD31 immunofluorescence. CD31 expression in tumors showed 
decreased trend after treatment with ALK1Fc which could indicate fewer endothelial 
cells and vessels (Fig. 2C-D; p value= 0.052, statistically not significant). Hypoxia is an 
important component of angiogenesis and critical for tumor formation. A hypoxia-induced 
fluorescent probe was injected in tumor bearing mice prior to sacrifice and the hypoxic 
areas within the tumors were visualized after tumor resection (Fig.2E-F). Hypoxic areas are 
found in both treatment groups; however, the overall amount of hypoxia seems higher in 
ALK1Fc-treated, tumor-bearing mice over the CFc-treated groups (Fig.2E-F; p=0.05, non-
significant). We assessed the presence of total cell proliferation and cell death in these 
tumors by immunofluorescence for mitosis marker, phosphorylated histone 3 (PH3), and 
apoptosis marker, cleaved caspase 3 (CASP3). Dividing PH3 positive cells are predominantly 
located in normoxic areas (Fig.2E, left panel). Quantification of immunofluorescence signal 
shows that the number of dividing cells is significantly lower in the ALK1Fc-treated animals 
(Fig.2G; p<0.05). Total amount of apoptotic cells (Caspase-3 positive) is significantly higher 
in the ALK1Fc-treated tumors (Fig.2H; p<0.05). Histological analysis indicates localization 
of apoptotic cells mostly, however not exclusively, in the hypoxic areas (Fig.2E), suggesting 
a correlation between hypoxia and tumor cell death.
ALK1Fc decreases proliferation of human prostate cancer cells 
To investigate the effect of ALK1Fc on prostate cancer cells we first measured the mRNA levels 
of BMP9 type I receptors ALK1 and ALK2 in PC-3M-Pro4Luc237 human prostate cancer cell 
line and tested their response to BMP9. As previously reported in highly metastatic PC-3 and 
PC-3M prostate cancer cells42, qRT-PCR analysis in osteotropic PC-3M-Pro4Luc2 cells revealed 
undetectable levels of ALK1 mRNA and mRNA expression of ALK2 (Fig.S2A). Treatment 
with BMP9 showed a dose-dependent induction of BRE-Renilla luciferase activity (p <0.01 
and p<0.05 with 0.5nM and 1 nM BMP9, respectively) indicative of conserved and active 
signaling machinery (Fig.S2B). Using the 1nM BMP9 dose for subsequent experiments, we 
tested the individual effect of CFc and ALK1Fc or the combined effect of BMP9 with either 
ALK1Fc or CFc on BRE reporter assay (Fig.S2C). Treatment with ALK1Fc (10ug/ml) completely 
abolished the BMP9-mediated BRE luciferase (luc) activity (Fig.S2C; BMP9+ALK1Fc) to levels 
similar to the non-stimulated control (Untreated). Treatment with BMP9+CFc (10ug/ml) led 
to induction of BRE-luc activity of similar level as the BMP9 treatment (Fig.S2C; p-value 
<0.05). Taken together, these results indicate that ALK1Fc blocks ALK2-mediated BMP9 
signaling in PC-3M-Pro4Luc2 cells. The functional effect of ALK1Fc on human prostate cancer 
cells was investigated by measuring metabolic activity by accumulation of MTS substrate, 
indicative of cell growth rate (proliferation). BMP9 stimulation in vitro led to increase of MTS 
absorbance indicating higher cell number (Fig.3A). Treatment with 10ug/ml ALK1Fc, but not 
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with control Fc (CFc), reduced BMP9-induced PC-3M-Pro4Luc2 cell proliferation (p<0.001 
at day 4 comparing vehicle versus BMP9 or ALK1Fc treatment, respectively) (Fig.3A). Effect 
of only ALK1Fc or CFc on MTS assay was also assessed in absence of exogenously-added 
BMP9 and showed no influence of these compounds on the basal cell growth levels (Fig.
S2D). The BMP9 effect of was also tested in the C4-2B prostate cancer cell line; however no 
significant difference in MTS assay was measured (Fig.S2E). Additionally, BMP9 treatment 
in PC-3M-Pro4Luc2 cells combined with ALK2 functional inhibition by small molecule BMP 
type I receptor inhibitor LDN193189 (LDN) 43,44 showed abolishment of BMP9-induced 
proliferation (Fig.3B). LDN effectively blocked the activity of the BRE-luc reporter after 
BMP9 stimulation of PC-3M-Pro4 cells (Fig.S2F) and the effect of LDN showed minimal 
impact on basal cell proliferation levels in absence of exogenously added BMP9 (Fig.S2G). 
Finally, we evaluated the clonogenic ability of PC-3M-Pro4Luc2 cells after BMP9 treatment 
alone (Fig.S3A) and confirmed that BMP9 affects cell growth, strongly increasing the size 
of the colonies (Fig.S3B, p<0.05). However, BMP9 showed no effect on colony formation/ 
self-renewal ability of PC-3M-Pro4Luc2 since the total number of colonies formed is similar 
(Fig.S3C). Together, these data indicate that ALK1Fc strongly reduces BMP9-induced cell 
proliferation of human prostate cancer cells.
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Fig.2. Effect of ALK1Fc on vascular density, cell proliferation and apoptosis in vivo 
(A). Representative images of lectin detection in primary prostate tumor samples after perfusion with lectin-DsRed 
(red). TOPRO (blue) marks the nuclei. Treatment groups: ALK1Fc or CFc. (B). Quantification of lectin positive surface 
area in all tumor samples of each group (n=14 CFc group, n=15 ALK1Fc group) (C). Representative images of CD31 
(green) immunofluorescence staining in primary prostate tumor samples after 5 weeks of treatment with either 
ALK1Fc or CFc. (D). Quantification of CD31 positive surface area in all tumor samples of each group (n=14 CFc 
group, n=15 ALK1Fc group). (E). Representative images of hypoxia immunofluorescence staining (red) in primary 
prostate tumor samples after 5 weeks of treatment with either ALK1Fc or CFc. Hypoxia probe was injected prior 
to sacrifice and was detected by a specific fluorescent antibody. White lines are used to arbitrarily distinguish 
the hypoxic (red) area from the non-hypoxic one. Immunofluorescence images for colocalization of apoptotic or 
proliferating cells in hypoxic/ normoxic area within the prostate tumor area in ALK1Fc and CFc treated animals. 
pH3: Phosphorylated Histone 3 cell proliferation marker (green); cleaved caspase 3 apoptosis marker (green); 
Hypoxic probe-antibody; hypoxic area (red). (F). Quantification of hypoxia positive area in all tumor samples of 
each group (n=15 per group). (G). Quantification of total pH3 positive area in all tumor samples of each group 
(n=14 CFc group, n=15 ALK1Fc group). (H). Quantification of total cleaved caspase 3 positive (apoptotic cells) in 
all tumor samples of each group (n=14 CFc group, n=15 ALK1Fc group). 
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ALK1Fc in prostate cancer
Fig.3. Effect of BMP9 and ALK1Fc on proliferation and ALDH1A1 expression
(A). Cell proliferation MTS assay (24, 48, 72, 96 hours) was performed in PC-3M-Pro4Luc2 cells stimulated with 
recombinant BMP9 (1nM), BMP9 (1nM)+ALK1Fc (10ug/ml) or BMP9 (1nM)+CFc (10ug/ml). Accumulation of MTS 
was measured based on absorbance at 490 nm. Values are normalized to the basal measurements at 24 hours after 
cell seeding and treatments. Graph represents values for three independent experiments (n=3). Error bars indicate 
± SEM. P value < 0.01 (**) BMP9 versus Untreated and P-value < 0.001 (***) BMP9+CFc versus Untreated. (B). Cell 
proliferation assessed by MTS assay (24, 48, 72, 96 hours). PC-3M-Pro4Luc2 cells were seeded at low density in 96-
well plates and treated with BMP9 (1nM) and in combination with LDN (BMP type I receptor inhibitor LDN193189, 
120nM) (LDN+BMP9). (n=2). Error bars indicate SEM. (C). Representative images of ALDH1A1 immunofluorescence 
in prostate tumor samples from ALK1Fc and CFc treated animals. ALDH1A1: red; TOPRO: blue nuclear dye. (D). 
Quantification of ALDH1A1 mRNA by Q-PCR in tumor samples of each group (n=5 for CFc, n=5 for ALK1Fc). (E). 
Expression of ALDH1A1 in PC-3M-Pro4Luc2 cells. Relative mRNA expression was measured by Q-PCR from cDNA 
obtained from PC-3M-Pro4Luc2 cells treated with BMP9, BMP9+ALK1Fc, BMP9+CFc, for 48, 72 and 96 hours. Values 
are normalized to β-actin expression. Error bars are ±SEM (n=3).























































































































Expression of BMP9, ALK1 and ALK2 in human and murine prostate tumor tissues 
To investigate the BMP9, ALK1 and ALK2 expression in human prostate cancer samples we 
performed bioinformatics analysis using data mining platforms (R2: microarray analysis and 
visualization platform http://r2.amc.nl, source: GEO ID: gse29079) of mRNA expression of 
ALK1, ALK2 receptor and BMP9 ligand (Fig.S3D-F) in 48 benign tumors versus 47 malignant 
prostate tumors45. Levels of ALK1 transcripts are decreased in the malignant tumor group 
compared to the benign group (p<0.001). Interestingly, levels of ALK2 transcripts are 
significantly increased (p<0.01) in the malignant tumor group compared to the benign 
group, thus correlating with disease progression, while BMP9 mRNA expression is similar in 
both groups (p=0.28). Previously, cDNA microarray analysis was performed in the study of 
Bacac et al.,46 using laser-microdissected stromal cells from murine prostate intraepithelial 
neoplasia (PIN) and invasive prostate tumors. 
Analysis of ALK1, ALK2 and BMP9 expression (Fig.S3G-I) in this dataset indicated elevated 
mRNA expression of ALK1 and similarly increased expression of both ALK2 and BMP9 during 
the invasive stage of murine prostate cancer. 
ALK1Fc inhibits ALDH1A1 expression in vivo and interferes with NOTCH signaling
Finally, given the reduction of primary tumor burden and the in vitro effects of the ALK1Fc 
on cell proliferation we assessed the relative expression of the ALDH1A1 marker that is 
associated with cancer stem-like cells and poor patient prognosis31,32. Treatment with 
ALK1Fc affected the number of proliferative ALDH1A1 positive cells in the prostate tumor 
tissues both at protein (Fig.3C) and mRNA levels (Fig.3D). In vitro stimulation with BMP9 
of the same cell line used to induce tumors in xenograft mouse model, confirmed that 
BMP9 and BMP9+CFc upregulates ALDH1A1 expression, while BMP9+ALK1Fc treatment 
abolishes this effect (Fig.3E). Interestingly, ALDH1A1 is known to be regulated by NOTCH 
signaling29-31. The role of NOTCH1 in prostate cancer cell cell proliferation and migration has 
been extensively studied28,47-50. Larrivée et al., have shown that ALK1 and NOTCH converge 
on common downstream pathways and that BMP9 treatment alone upregulates JAG1 levels 
in human umbilical vein endothelial (HUVEC) non-transformed cells51. To verify the effect 
of BMP9 on NOTCH signaling activation in our cancer model, we quantified by qRT-PCR the 
expression of JAG1 after BMP9 stimulation in presence of ALK1Fc or CFc. Our transcriptional 
analysis showed that BMP9 and BMP9+CFc induce mRNA expression of JAG1 and that 
ALK1Fc is able to reduce the BMP9-mediated induction of JAG1 (Fig.4A). To assess the 
clinical relevance of BMP9/ALK2-mediated NOTCH pathway activation in human prostate 
cancer we performed bioinformatics analysis using data mining platforms (R2: microarray 
analysis and visualization platform http://r2.amc.nl, source: GEO ID: gse29079). Levels of 
NOTCH ligand JAG1 transcript show statistically significant enrichment in the malignant 
tumor group compared to the benign group (Fig.4B) and positively correlates with ALK2 
expression and disease progression (Fig.4D). In addition, expression levels of NOTCH1 
receptor in human prostate tumor microarray data indicate a positive correlation with 
progression to malignancy (Fig.4C) and with ALK2 expression (Fig.4E). Overexpression of 
JAG1 in PC-3M-Pro4Luc2 human prostate cancer cells seems to increase metabolic activity 
and total cell number as assessed by MTS assay (Fig.4F). 
Knockdown of the NOTCH1 receptor in PC-3M-Pro4Luc2 (shNOTCH1), validated by western 
immunoblotting for NOTCH1 protein detection (Fig.S4A) and NOTCH reporter (RBP-JK-
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luc) assay (Fig.S4B), showed reduced mRNA levels of JAG1 (Fig.S4C) and decreased cell 
proliferation, as compared to cells transduced with non-targeting shRNA lentivirus (p<0.05 
at 48 hrs) (Fig.4G). Stimulation of shNOTCH1-knockdown cell line with BMP9 increases 
their cell growth rate (Fig.4H) overcoming the knockdown of NOTCH1. Our data therefore 
suggest that BMP9/ ALK2 directly induces activation of NOTCH downstream target genes 
(JAG1) likely in a NOTCH1-independent way45,52,53 which leads to higher cell proliferation 
and is associated with tumor progression in PCa.
Fig.4. Effect of BMP9 and ALK1Fc on NOTCH signaling pathway and correlation study
(A). Expression of JAG1 in PC-3M-Pro4Luc2 cells. Relative mRNA expression was measured by Q-PCR from cDNA 
obtained from PC-3M-Pro4Luc2 cells treated with BMP9, ALK1Fc, CFc, BMP9+ALK1Fc or BMP9+CFc for 96 hours. 
Values are normalized to β-actin expression. Error bars are ±SEM (n=3). (B-C). Bioinformatics analysis of AMC 
OncoGenomics database (Sueltman transcript comparison) showing mRNA expression of JAG1 (B) and NOTCH1 
(C) and in prostate tissues among benign prostate tissues (n=48) versus tumor tissues (n=47). Values are expressed 
as 2log ratio tumor/ benign. ns: non-significant. P value < 0.001 (***).  (D). Correlation analysis of JAG1 and ALK2 
expression (p<0.0001) and (E). correlation analysis of NOTCH1 and ALK2 expression (p<0.0001) in prostate tissues 
among benign prostate tissues (n=48) versus tumor tissues (n=47). Bioinformatic analysis was performed using 
the AMC OncoGenomics database (Sueltman transcript comparison), values are expressed as 2log ratio tumor/ 
benign. ns: non-significant. (F). Cell numbers were assessed by MTS assay (0, 24 and 48 hours) in PC-3M-Pro4Luc2 
cells transfected with 1ug JAG1 or Mock expression vector (n=2). (G-H). Cell numbers were assessed by MTS assay 
(0, 24 and 48 hours). PC-3M-Pro4Luc2 cells were transduced with short hairpin RNA against NOTCH1 (shNOTCH1) 
lentiviral vector or non-targeting (NT) shRNA vector (mock) and plated at low density. Treatment with BMP9 
(1nM) was done once at cell seeding (t=0) MTS absorbance was measured. Values are normalized to the basal 
measurements t=0 after cell seeding and treatments. Graph represents values from four independent experiments 
(n=4). Error bars indicate SEM. P value <0.05 (*). 
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In this study, BMP9 was found to have a tumor- promoting effect on human prostate cancer 
cell in vitro and in vivo. We demonstrated here that blocking of BMP9 with ALK1Fc ligand 
trap efficiently diminished BMP9-driven cell proliferation in human prostate cancer cells 
and significantly reduced tumor growth in orthotopic model of human prostate cancer. 
BMP9 was first identified in the liver15 and active forms are present in serum13. BMP9 is a ligand 
for the ALK1 receptor in endothelial cells10 and has been shown to exert both stimulatory 
and inhibitory effects on endothelial cell type growth and migration36,54. Aberrant regulation 
of the TGFβ and BMP signaling pathway members often results in cancer progression55,56. In 
particular, BMP ligands, such as BMP9 as well as BMP type I receptors (e.g. ALK1 and ALK2) 
have been associated with tumor angiogenesis and cancer progression. In non-endothelial 
cells, BMP9 signals through ALK2 receptor such as in ovarian epithelium, where it has been 
shown to promote ovarian cancer cell proliferation13. Similarly, in hepatocellular carcinoma 
BMP9 has been reported to act as proliferative and survival factor17. In breast cancer few 
studies have highlighted the role of BMP9 in reducing breast cancer cells growth and 
metastasis57-59. However, the role of BMP9 and ALKs, in promoting or suppressing different 
cancer types, remains controversial. Collectively, these indicate that the effect of BMP9 on 
tumor promotion versus tumor suppression might be cancer-type specific, thus providing 
the rationale to elucidate the role of BMP9 in prostate cancer, for which little information 
is available to our knowledge. 
Using publicly available databases of human prostate cancer specimens, we found that 
ALK2 is significantly upregulated in malignant versus benign tumor tissue samples, whereas 
ALK1 is significant downregulated, supporting the notion that the tumor-promoting effect 
of BMP9 is mediated by ALK2 as in our model45. Additionally, microarray analysis of data 
from mouse prostate intraepithelial neoplasia (PIN) versus invasive cancer in a multistage 
model of prostate carcinogenesis showed upregulation of ALK2 and BMP9 at the invasive 
stage in the stromal compartment60. Taken together, these data suggest a tumor-promoting 
role of BMP9 produced by the supportive stroma during prostate cancer progression. The 
fact that the BMP9 transcript levels registered in the selected dataset are similar in benign 
versus tumor stage in human prostate tumor samples, suggest a paracrine effect of BMP9 
in human prostate cancer45. The significant increased expression of ALK2 in human prostate 
tumor tissue samples suggest that the BMP9 produced by the stromal compartment might 
be responsible for the tumor promoting effect that we documented here.
Our in vitro findings strengthen the afore-mentioned expression data and suggest that BMP9 
exerts a proliferative effect in human prostate cancer cells. Moreover, functional blocking of 
ALK2 activity by LDN193189 supports the notion that ALK2 is critically involved in mediating 
this BMP9 effect. As depicted in the supplementary data, ALK1Fc and LDN193189 alone 
did not affect cell proliferation of human prostate cancer cells, thus, suggesting a paracrine 
effect of stroma-derived BMP9 on tumor cells. BMP9 does not influence clonogenic ability 
of human prostate cancer cells but a significant stimulatory effect on the colony size was 
observed, suggesting an influence on colony expansion rather than on colony formation. 
In the orthotopic model of human prostate cancer used in this study, ALK1Fc significantly 
reduced the prostate tumor burden compared to control group. Strikingly, ALK1Fc treatment 
of tumor- bearing animals resulted in highly hypoxic tumors and a trend for decreased 
number of CD31+ tumor capillaries, thus supporting the notion that ALK1Fc could possibly 
block BMP9-induced neovascularization. Additionally, vascular density manifested by 
Page | 155
ALK1Fc in prostate cancer
lectin may suggest an overall reduced trend in lectin- positive area in animals treated with 
ALK1Fc versus CFc. Lectin distribution appeared to be less diffused, suggesting that ALK1Fc 
treatment contributes to vessel integrity and maintenance rather than angiogenesis. 
As expected, areas of tumor cell proliferation and apoptosis were found to be mutually 
exclusive distribution, with apoptotic regions highly, but not completely, overlapping with 
the hypoxic areas, suggesting that blocking of BMP9 by ALK1Fc might have an effect on 
cell proliferation and apoptosis of human prostate cancer cells besides targeting vessel 
maintenance34. 
SMAD1 and SMAD5 (effectors of BMP9 signaling) can directly interact with JAG1 promoter, 
following BMP9 treatment61. BMP9 stimulation of SMAD signaling induces transcription of 
NOTCH ligand JAG151. Transcriptional analysis revealed that ALK1Fc systemically blocked the 
induction of JAG1 mRNA in presence of BMP961 at latest time point. We hypothesized that 
the crosstalk between BMP9 and NOTCH has translational implications in prostate cancer. 
In silico analysis of previously published dataset of human prostate cancer specimens, 
confirmed upregulation of NOTCH1 and JAG1 at the tumor stage45. Database analysis in a 
multistage model of prostate carcinogenesis on mouse prostate intraepithelial neoplasia 
(PIN) versus invasive cancer also indicated that Jag1 is significantly upregulated in the 
stroma of invasive cancer stage60. 
Interestingly, NOTCH activates aldehyde dehydrogenase 1A1 (ALDH1A1), which is a well-
known marker of highly tumorigenic prostate cancer stem-like cells29-31. This subpopulation 
contributes to both initiation and progression of the cancer and when highly expressed in 
advanced-stage correlates with poor survival in hormone-naïve patients 31. ALK1Fc treated 
tumours showed significant reduction of ALDH1A1, which in combination with the data 
described above, suggest that ALK1Fc might potentially interfere with NOTCH signaling in 
the regulation of ALDH1A1. In conclusion, our findings provide novel information on the 
role of BMP9 in human prostate cancer and suggest the promising use of BMP9 targeting 





Fig.S1. Body weight of animals used in the in vivo experiment
Body weight (grams) of all the animals of treatment groups measured weekly during the course of treatment 
with either CFc (n=6) (A) or ALK1Fc (n=7).  
Fig. S2. Characterization of BMP9 response in vitro 
(A). Endogenous expression of ALK1, ALK2, ALK4 and ALK5 receptors in PC-3M-Pro4Luc2cells (mRNA level). Relative 
expression levels normalized to β-actin are shown. Error bars indicate +/-SD. (B). Dose dependent response of 
PC-3M-Pro4Luc2 cells to recombinant BMP9 (0.01, 0.1, 0.5, 1 nM). Downstream activation of BMP signaling was 
tested by transfection of BRE-renilla construct and measured by reporter activity assay. Graph represents values 
from three independent experiments; error bars indicate ± SEM (n=3). P value < 0.05 (*) and P value < 0.01 (**). 
(C). BRE reporter luciferase (BREluc) assay; Inhibitory concentration of ALK1Fc or CFc (10ug/ml) was determined 
in cells stimulated with 1nM BMP9. Graph represents values from two independent experiments; error bars 
indicate ± SEM (n=2). P value < 0.05 (*) and P value < 0.01 (**) compared to “untreated” control. P value  < 0.01 
(##) (D). MTS assay (24, 48, 72 hours) was performed in PC-3M-Pro4-luc2 human prostate cancer cell line treated 
with recombinant ALK1Fc (10ug/ml), CFc (10ug/ml). Accumulation of MTS was measured based on absorbance 
at 490 nm. Values are normalized to the basal measurements at 24 hours after cell seeding and treatments. Graph 
represents values from two independent experiments (n=2). Error bars indicate ±SEM. (E). MTS assay (24, 48, 72, 
96 hours) was performed in C4-2B human prostate cancer cell lines stimulated with recombinant BMP9 (1nM), 
BMP9 (1nM)+ALK1Fc (10ug/ml) or BMP9 (1nM)+CFc (10ug/ml). (n=3). (F). BMP transcriptional reporter assay (BRE-
luciferase). PC-3M-Pro4 were seeded and, transfected with BRE-luc and renilla plasmid DNA. After 24 hours the 
medium was replaced with 0.3%, 5%, 10% FCII serum containing media and treated with BMP9 (1nM), LDN193189 
(LDN, 120nM) and BMP9+LDN. Luc and Ren values were measured 24 hrs after treatment. RLU ratio values are 
shown (Luc/Ren). Error bars indicate ±SD. (G). MTS assay (24, 48, 72 hours) was performed in PC-3M-Pro4-luc2 
human prostate cancer cell line treated with LDN inhibitor (LDN193189, 120nM). (n=2). Error bars indicate +/-SEM.
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Fig. S3. Effect of BMP9 and ALK1Fc on clonogenicity and ALK expression in human samples
(A). Clonogenic assay of PC-3M-Pro4Luc2 cells. Low-density cultures (100 cells per well of 6well plate) were 
stimulated with BMP9, CFc, ALK1Fc, BMP9+CFc, BMP9+ALK1Fc. Colony formation was assessed after 10 days by 
crystal violet staining. Representative images are shown. (B-C). Quantification of surface covered by crystal violet 
positive colonies (colony area) and colony number. Graph shows percentage of positive surface normalized per 
condition (average of three independent experiments). P value < 0.05 (*), ns; non-significant. Error bars indicate 
SEM. (D-F). Bioinformatics analysis of AMC OncoGenomics database (Sueltman transcript comparison) showing 
mRNA expression of ALK1, ALK2 and BMP9 in prostate tissues among benign prostate tissues (n=48) versus tumor 
tissues (n=47). Values are expressed as 2log ratio tumor/ benign. ns: non-significant. P value < 0.01 (**) (G-I). 
Microarray cDNA analysis (adapted from Bacac et al., 46) of Alk1, Alk2 and Bmp9 expression in microdissected murine 
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Fig.S4.Characterization of NOTCH1 knock-down
(A). Western immunoblotting for NOTCH1 protein as validation of lentiviral shRNA-mediated knockdown of 
NOTCH1 intracellular domain (cleaved) in PC-3M-Pro4luc2 PCa cell line using five shRNA constrcuts. Based on the 
downregulation of cleaved NOTCH1 observed after lentiviral transduction and puromycin selection, the stable 
line expressing the shRNA #2 construct was selected for further experiments. NT; non-targeting shRNA lentiviral 
mediated transduction. β-actin was used as loading control. (B). NOTCH transcription factor RBP-Jk-luciferase 
reporter assay in non-targeting (NT) and NOTCH1 (shRNA#2) knockdown (KD) PC-3M-Pro4Luc2 cells. RLU: relative 
luciferase units (signal of luciferase normalised to renilla values). n=3, P value < 0.01 (**)
(C). QPCR for JAG1 mRNA levels in non-targeting (NT) and NOTCH1 (shRNA#2) knockdown (KD) PC-3M-Pro4Luc2 
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Discussion and Future Directions
TGFβ- the “Many-Faced God”
Cell signaling from members of the TGFβ pathway regulate homeostasis of many organ 
systems during embryonic development and adult life. TGFβ suppresses the proliferation 
of epithelial, endothelial and immune cells (tumor suppressor activity) and its action is 
under constant regulation. When the levels of TGFβ ligands or receptors are abnormally 
increased or decreased, due to occurrence of genetic mutations that affect gene expression, 
the cell homeostasis is disturbed; increased apoptosis/ proliferation, immune suppression/
hyperactivation, insufficient wound healing upon injury or excess ECM remodeling. In fact, 
in human pathological conditions, such as organ fibrosis and cancer, the circulating levels 
of TGFβ and BMP ligands are often found increased1. In particular, in many types of human 
cancer, TGFβ plays multiple roles2; at the initial stages of cancer formation it has tumor 
suppressing role. Upon establishment of a carcinoma TGFβ is considered to be a tumor 
promoter factor (mediated via linker phosphorylation of SMAD2/33 or non-SMAD pathways); 
tumor cells deactivate the cytostatic branch of TGFβ and maintain responsiveness to TGFβ-
mediated EMT transition, cell motility, migration, differentiation to MFB phenotype and 
ECM remodeling2,4,5. These processes facilitate the spread of tumor cells and metastasis to 
other organs. Given the increased lethality of cancer patients associated with occurrence of 
metastasis and the lack of therapeutic treatments for organ fibrosis, several drugs inhibiting 
the function of TGFβ pathway members have been developed as promising cancer and 
fibrosis targeted therapies6. 
Summary of Findings
Our studies focused on modulation of TGFβ pathway in homeostasis, human fibrosis and 
cancer by in vivo and ex vivo approaches in different organs (liver, prostate, connective 
tissue). Inhibition of TGFβ/ BMP pathway was performed using an antisense oligonucleotide, 
a ligand trap and a small molecule kinase inhibitor. Main goal of these different lines of 
research was to investigate the basic regulatory mechanisms during tissue regeneration 
(liver), fibrosis (Dupuytren’s disease), tumor angiogenesis and cancer (prostate) and potential 
therapeutic benefits of TGFβ/ BMP inhibition. 
The main findings of this thesis are summarized in Fig.1. 
1. Dynamics in TGFβ signaling activation regulates liver regeneration. Downstream 
effector SMAD2 mediates cell cycle arrest in hepatocytes and pro-fibrotic effects in 
HSCs (liver myofibroblasts). Systemic administration of small molecule TGFβ type 
I receptor kinase inhibitor LY-364947, selective for ALK5 inhibition, reduces basal 
SMAD2 signaling in hepatocytes, which leads to escape from cell cycle arrest (low 
p21, high PCNA and phosphorylated histone 3 levels). Hepatocyte proliferation due 
to ALK5 inhibition leads to improved cell replenishment during acute liver injury in 








Systemic administration of TGFβ type I receptor kinase inhibitor, LY-364947, is not 
sufficient to abrogate the fibrogenic response of HSCs in acute, reversible liver injury 
model (Chapter 3).
Human connective tissue from Dupuytren’s fibrosis is maintained in ex vivo culture 
for seven-day time period allowing real time study of fibrotic mechanisms by second 
harmonic generation imaging and three-dimensional reconstruction (Chapter 4).
Ex vivo delivery of ALK5 inhibitors SB-431542 and ALK5-AON have anti-fibrotic effects 
in human Dupuytren’s fibrosis (Chapter 5).
Inhibition of BMP9 by ALK1Fc ligand trap has potential tumor anti-angiogenic effects 
on human prostate cancer in mouse xenograft model (Chapter 6).
ALK1Fc diminishes primary prostate tumor size by inhibiting BMP9 pro-proliferative 
role directly on tumor cells. BMP9 mediates tumor growth via binding to ALK2 and 
inducing NOTCH signaling (Chapter 6).
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Fig.1. Summary of key findings of this thesis 
(A). Liver homeostasis and the effects of in vivo administration of small molecule kinase inhibitor LY364947 to 
inhibit ALK5 signaling (Chapter 3). (B). Connective tissue fibrosis (Dupuytren’s disease) and ex vivo tissue culture 
of human specimens (Chapter 4). Ex vivo inhibition of ALK5 using antisense oligonucleotide-mediated exon 
skipping showed anti-fibrotic effects on extracellular matrix protein deposition (Chapter 5). (C). In vivo inhibition 
of tumor angiogenesis and primary prostate tumor growth using the ALK1Fc ligand trap of BMP9/BMP10 in order 
to interfere with ALK1 and ALK2 downstream signaling.
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Modulation of TGFβ- Insight from In Vivo Liver Regeneration 
Several studies have thoroughly investigated the contribution of hepatic progenitor cells 
on liver regeneration (reviewed in Chapter 2). These normally quiescent cells (oval cells), 
reside in the bile duct area and upon chronic injury become activated (ductular reaction) 
and differentiate to replenish hepatocytes and biliary epithelial cells (cholangiocytes). 
Various cytokines and cell types (resident and recruited immune or bone marrow cells) play 
a dynamic role during liver regeneration. Recent studies have increased our understanding 
of how regeneration is regulated, for instance by transcription factor gene expression 
alterations7, contribution of hepatic stellate cells as either source of oval cells8 or collagen 
producing MFBs9, and bile duct (ductular) reaction and its the role was studied by in vivo 
lineage tracing 10. Preliminary data from this thesis (Appendix I) suggest a potential role 
for TGFβ type III auxiliary receptor CRIPTO in ductular reaction of oval cells during liver 
regeneration. However, the origin of these cells requires further characterization, considering 
that there are various other sources for MFBs11 during liver injury such as recruited bone 
marrow derived cells12, pericytes and endothelial cells13. Furthermore, CRIPTO-expressing 
cells are found in the microenvironment of hematopoietic stem cells14,15 while CRIPTO 
can function not only as membranous protein but also in a paracrine or systemic way as a 
soluble factor16. Thus, the origin and identity of CRIPTO-positive cells and their circulating 
or local role in the liver remain to be elucidated. 
Tissue injury causes changes in tissue architecture, different mechanical tension between 
the connective tissue, pH, altered levels of oxygen and nutrients delivered to cells17; all these 
factors trigger release of latent TGFβ from the matrix proteins and upon activation TGFβ 
dimer is then able to bind to its receptors on the cell surface and activate the pathway18. 
In Chapter 3, we studied different aspects liver regeneration after experimental injury 
in vivo; response of epithelial cells (hepatocytes), hepatic stellate cells (HSCs, MFBs) and 
liver functionality. We show that the levels and duration of TGFβ pathway activation are 
determinants of the regenerative response and that TGFβ has pleiotropic effects in different 
cell types. In vivo systemic administration of small molecule kinase inhibitor (SMI) LY-364947 
indicated that decrease of TGFβ/ALK5 pathway in the liver is applicable and has cell-type 
specific effects. Delivery of SMI and pathway inhibition is more efficient in the hepatocytes 
and less potent in targeting activated MFBs. It is known that TGFβ has a cytostatic role 
on hepatocytes (SMAD2-mediated) and a profibrotic and mitogenic role on the MFBs 
(SMAD3)19. In our study, inhibition of ALK5 activity induced proliferation of hepatocytes 
consistent with the TGFβ-mediated cytostasis. Regarding previous studies showing that 
soluble TGFβRII delivered in vivo reduces fibrosis20 we expected similar effects with the 
SMI LY-364947. Our data indicated that deposition of fibrous proteins by MFBs is not 
inhibited by SMI targeting ALK5. A variety of reasons may account for this response; (1) 
Kinetics and cell type specific delivery of the SMI21. (2) The acute liver injury model used 
is suitable for the study of regeneration and scar tissue formation (fibrogenesis) but not 
of pathological fibrosis22. Thus, to delineate the antifibrotic effects of LY-364947 different 
experimental models should be used such as chronic CCl4 fibrosis model. (3) Alternative 
non SMAD signaling mechanisms may become activated to compensate for ALK5/SMAD2/3 
inhibition23. Imatinib, a SMI of c-Abelson (c-ABL) kinase, is an FDA approved drug for chronic 
myeloid leukemia and also decreases lung fibrosis by inhibiting PDGF and TGFβ-non-SMAD 
mediated activation of c-ABL24. 
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Recent studies using similar SMI for ALK5, such as EW-7197, show reduction of TGFβ-induced 
reactive oxygen species production and promising anti-fibrotic outcome in liver fibrosis 
both in vivo and in vitro 25. Another inhibitor of ALK5, LY-2157299, has shown safety and 
efficacy in advanced human cancer such as glioma26 and in ex vivo studies of hepatocellular 
carcinoma27,28. 
Clinically approved kinase inhibitors are Imatinib (Gleevec), Efitinib (Iressa) and Erlotinib 
(Tarceva) for cancer treatment have paved the “translational” way of SMIs29. The main 
advantages of SMIs are the high cell permeability due to small molecular weight and 
decreased toxicity due to rapid metabolism and removal by the renal system. However, in 
vivo evaluation of SMIs requires frequent or periodic administration, since dosage-related 
and cell type-specific effects are difficult to monitor30 because the majority of these inhibitors 
bind to the ATP site of kinases. Cross-inhibition of multiple kinases is a consideration when 
using ATP inhibitors; however, experimental advances, such as high-throughput screening, 
have improved the specificity properties for a particular kinase30-33. Novel methodologies, in 
particular in Proteomics and Nanotechnology are needed to further improve the substrate 
specificity and delivery of SMIs to a particular tissue or cell type that is most likely to benefit 
from the drug and circumventing toxic effects to other tissues. 
Insight on TGFβ-mediated Fibrotic Mechanisms from an Ex Vivo 
Human Model 
Fibrosis is a pathological state characterized by the excessive deposition of connective 
tissue commonly occurring during wound healing and tissue regeneration34. It can affect 
most organ systems and lead to a variety of diseases including liver cirrhosis, pulmonary 
hypertension, systemic sclerosis and congestive heart failure, representing one of the major 
medical challenges of our time. To treat fibrotic disease, it is necessary to control the improper 
wound mechanism process and redirect it towards a pure regenerative/repair process35. 
Design of novel anti-fibrotic therapies can only be achieved after thorough characterization 
of the disease profile. Our aim was to improve the current methodology available for DD 
fibrosis in order to better study the molecular pathogenesis. In Chapter 4, we present the 
development of an ex vivo culture method for the maintenance of human fibrotic tissue from 
Dupuytren’s connective tissue disease. This model combines the near-in vivo, physiological 
microenvironment as equivalent to the in vitro method where culture conditions and gene 
expression can be modulated. Given the high rate of recurrence and surgical resection 
of fibrotic nodules being the main treatment to restore hand functionality, our model 
provides a patient-specific, preclinical platform for screening of anti-fibrotic compounds 
using surgical waste material. Fibroblast cell derivation remains the main method to study 
fibrosis; however it can only provide one-sided information excluding the influence of the 
microenvironment on cell behavior36,37. The advantage of this system is that we circumvent 
the need for fibroblast cell derivation and instead we study the three-dimensional context 
of cells and surrounding extracellular matrix35,38. 
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Novel Ex Vivo Culture Method of Dupuytren’s Fibrosis: Preclinical 
Translation for Human Anti-Fibrotic Drug Screening 
DD tissue composition consists mainly of fibroblasts, MFBs, with fewer subset of endothelial, 
smooth muscle cells and immune cells39 (Fig.2). ALK5 is expressed mainly in MFBs in DD, 
and not in endothelial cells, which express ALK140. In Chapter 5, using the ex vivo model 
of human fibrotic tissue we demonstrated how interference with the mRNA processing of 
ALK5 by AON exhibits altered gene expression in favor of fibrosis reversal. We have showed 
that AONs with two different chemical modifications, Vivo morpholinos and 2’-O-methyl 
(2’-O-Me), are effectively delivered in tissue and do not cause cell death or toxicity. In our 
system, the fibroproliferative properties of the disease have been hampered by ALK5 AON 
treatment, suggesting that partial reduction of the TGFβ signaling is sufficient to “decrease” 
the fibrotic content of the disease. One possible explanation of the strong anti-fibrotic 
effect of ALK5 AON observed in DD tissue may be attributed to the occurrence of “flywheel 
effect” upon downstream proteins. Although, the initial stimulus is removed (ALK5 exon 
skipping) there seems to be a continuous oscillation of downstream effects, such as protein 
expression of target genes (collagens, αSMA). Another consideration is that full skipping is 
not the goal for the treatment of DD especially since partial skipping already has beneficial 
effects of collagen deposition. Complete abrogation of ALK5 receptor activity might elicit 
compensatory mechanisms by other signaling pathways with no therapeutic benefit. 
Therefore, a more subtle and titrable regulation is required, which is one of the major 
advantages of the AON approach.
In addition, ALK5 kinase activity was effectively inhibited ex vivo by kinase inhibitor SMI SB-
431542, which is an ATP antagonist and blocks ALK4, -5, -7 kinase activity. In both strategies 
(SB-431542 and ALK5 AON) expression of fibrous proteins collagens type I and type III was 
decreased and the number of α-smooth muscle actin (αSMA)-positive MFBs was reduced. 
Since there was no increase in cell death events in our model, perhaps the existing MFBs 
were modulated in order to secrete fewer amounts of fibrous proteins. Moreover, degradation 
of collagen is induced by specialized enzymes MMP1, MMP8, MMP13 and MMP14. MMP13 
and MMP14 may indirectly also activate TGFβ (via MMP2 and MMP9) exacerbating fibrosis41. 
MFBs produce high levels of tissue inhibitor of matrix metalloproteases (TIMPs) to promote 
ECM deposition instead of degradation. Fibrosis resolution is associated with disappearance 
of MFBs and decrease in TIMP expression42. Reduction of fibrotic burden and MFBs in our 
model may be induced from the inhibition of TGFβ-mediated EMT process13. Quiescent 
fibroblasts are distinguished from activated MFBs by αSMA expression, thus, reduction of 
αSMA observed in real time due to TGFβ inhibition ex vivo (Chapter 5) may indicate reversal 
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The current opinion is that MFBs once activated and their function is no longer required, they 
undergo senescence43 or apoptosis44. Another hypothesis is that MFBs may reverse back to a 
quiescent fibroblast phenotype, which requires further experimental evidence11,45. Lineage 
tracing experiments are required to address whether this hypothesis is valid for DD, with 
genetic tools applied for tracing MFBs in liver and lung fibrosis in vivo (glial fibrillary acidic 
protein- Cre recombinase (GFAP-Cre)8, collagen 1 type I (Col-GFP)11. and PDGF receptor β 
(PDGFR β- Cre)46. MFBs in several organs are marked by PDGFRβ expression and deletion 
of αvβ6 integrin in those cells caused a reduction of TGFβ activation and subsequently 
of  fibrosis46.  Similar effects were observed by small molecule inhibitor targeting αvβ6 
integrin46. Given the recurrent properties of DD fibrosis the role of stem/ progenitor cells 
(for instance mesenchymal stem cells) that constantly differentiate towards MFBs might 
be a valid hypothesis for the origin of fibrosis. Thus, we need to identify the key regulatory 
proteins that trigger the start of fibrosis in DD and test whether their inhibition provides 
resolution of fibrosis. Performing drug screens on surgical waste, patient-derived tissue, 
instead of e.g. rodent models, could be an effective and quick way of drug categorization 
for further experimentation or dismiss, and thus it could reduce the number of animal 
studies35. Future research will focus on understanding the role of the immune system in DD 
contracture and ways of altering the immune response to trigger matrix degradation. (Pre)
clinical studies using the ex vivo culture method could potentially reveal immunological 
response triggered by candidate substances, and could be further used to delineate the 
exact mechanism of action of anti-fibrotic drugs.
Tumor Angiogenesis and Cancer 
Cellular and extracellular context (microenvironment) has a great influence on tumor growth 
and development of drug resistance47,48. Tumor microenvironment consists of tumor cells, 
and abnormally functioning, non-malignant stromal cells such as fibroblasts, endothelial cells 
and infiltrating immune cells. Initial experiments with viral oncogene Src showed induction 
of transformation in vitro but not when overexpressed in embryos49,50. Moreover, mutated 
stromal fibroblasts have the potential to oncogenically transform normal epithelial cells51. 
Thus, the extracellular matrix and cellular context exert powerful influence on the behavior 
of cancer cells despite the presence of mutated oncogenic proteins. From this prospective, 
properties of the microenvironment and its impact on both normal and tumor cells is highly 
similar during fibrosis (as discussed previously) and cancer, which should be considered 
in the study of both human diseases. A hallmark in the progression of solid tumors is the 
formation of blood vessels (angiogenesis) within the primary tumor, which paradoxically 
requires the contribution of non-malignant cells48. Tumors perform neovascularization to 
sustain their growth utilizing non-malignant cells from their niche. In contrast to the wound 
healing angiogenesis where new vessels integrate within the existing network, in tumors 
there is destruction of the vasculature and formation of immature, leaky vessels. Several 
factors induce angiogenesis such vascular endothelial growth factor, platelet derived 
growth factor, hypoxia, BMPs along with matrix degradating enzymes that disrupt existing 
vasculature in order to recruit pericytes, endothelial and smooth muscle cells. In our studies 
we investigated the contribution of a BMP ligand, BMP9, in ALK1-mediated angiogenesis 
and tumor growth of human prostate cancer. 
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Sequestering of BMP9 by ALK1Fc ligand trap reduced tumor angiogenesis in primary prostate 
cancer xenografts and led to decreased tumor growth. Along with the anti-angiogenic 
effects, a direct effect of BMP9 inhibition on tumor cells was observed. Thus, BMP9 levels 
from the circulation, stroma and possibly secreted also from tumor cells, have a dual role 
in prostate cancer; pro-angiogenic effects on ALK1 expressing endothelial cells and pro-
proliferative role on tumor cells via ALK2. 
BMPs plays role in prostate tissue homeostasis as well as in tumor formation and metastasis 
to the bone, which is the predominant metastasis site for prostate cancer (PCa)52. Most 
BMP ligands and receptors are regulated by androgens and are expressed in the normal 
prostate tissue while up/downregulation is associated with primary or metastatic tumor53. 
BMP2, 4, 6, 7 and GDF15 have been extensively studied in this context and have tumor 
suppressing role on the proliferation of androgen-sensitive cancer cells54. Loss of function 
of many BMP ligands, SMAD4, SMAD8 and type II receptors (ACVR2A, ACVR2B, BMPRII) is 
associated with hormone insensitive stage of PCa and bone metastases53-55. BMP9 seems to 
have dual effects in PCa; proangiogenic mediated via ALK1 in endothelial cells and tumor 
promoting role in ALK2-expressing PCa cells, similar to pro-proliferative role on ovarian 
cancer56 and hepatocellular carcinoma cells57. An explanation for the different PCa tumor 
effects between BMP9 and other BMP ligands, such as BMP758,59, may be the preference of 
BMP9 for ALK1 and ALK2 binding in different cell types, as opposed to BMP7 that utilizes 
ALK2, ALK3 and ALK6. Given the high affinity of BMPs to type I receptors this first binding 
step determines which type II receptor will be recruited to the complex causing different 
biological responses. Also, BMP9 binds to all three type II BMP receptors while BMP7 
binds to BMPRII and ACVR2A53. Autocrine or paracrine BMP9 exert proliferative effect on 
PC3 tumor cells via ALK2 supported by microarray data indicating elevated ALK2 levels 
in PCa versus normal or benign prostate tissues (Chapter 6). Constitutively active ALK2 
phosphorylates ENDOGLIN and promotes cell migration of PC3 cells60. Another potential 
mechanism is the synergy between BMPs and NOTCH signaling pathway; several studies 
prove that SMAD binding to transcription factors of NOTCH-intracellular domain class (NICDs) 
regulates  myogenic differentiation and the balance between endothelial cell migration 
and quiescence61. In Chapter 6, we provide evidence of synergy between BMP9 and NOTCH 
ligand JAGGED that enhances the proliferation of PC3 cells and positively correlates with 
tumor progression in human microarray data. 
Treatment with BMP9 ligand trap, ALK1Fc, showed promising anti-angiogenic and anti-
tumorigenic effects in xenograft model of human PCa cells in mice (Chapter 6) and is 
currently being used in clinical trials for recurrent solid cancers (head and neck, ovarian, 
endometrial)62. ALK1 is an effective target for angiogenesis given its expression in endothelial 
cells and the complex formation with other pro-angiogenic factors such as BMP9, BMP10, 
TGFβ, ENDOGLIN63-65. However, the outcome on vessel quiescence or activation is often 
contradictory due to TGFβ-functioning via both ALK5 and ALK1 in endothelial cells leading 
to codependence or between SMAD1/5/8 and SMAD2/3 pathways64. Activation of both 
ALK1 and ALK5 by BMP9 and TGFβ, induce expression of proangiogenic factor VEGF66. 
BMP9/ALK1 signaling may inhibit and promote endothelial cell growth depending highly 
on the cell context67. ENDOGLIN, the type III auxiliary receptor of TGFβ signaling favours 
signaling via ALK1 by binding to BMP9, BMP10 as well as to TGFβ1, 3 and preventing their 
interaction with ALK567-69. 
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However, ENDOGLIN associates with other type I receptors such as ALK2, ALK3 and ALK6, 
thereby influencing TGFβ and BMP signaling in various ways70. Inhibitors of ENDOGLIN 
have been developed as anti-angiogenic treatment (TRC-10571, ENDOGLIN-Fc72)based on 
the ability of soluble ENDOGLIN to bind to BMP9 and BMP10 and inhibit vessel formation 
and tumor growth73. Several other anti-angiogenic drugs are investigated in clinical trials 
for cancer therapy74; thalidomide (ClinicalTrials.gov identifier; NCT00083551), AG-013736 
(NCT00094107), Axitinib (NCT01321437), VEGF inhibitor SU5416 (NCT00006155), endostatin 
(NCT00518557). 
Clinical Applications and Future Prospective 
Deregulated TGFβ signaling is associated with disease progressio, for instance, chronic 
inflammation, cardiovascular disorders, organ fibrosis and malignancies, thus inhibition 
of this pathway is a promising therapeutic approach. Given the pleiotropic role of TGFβ 
signaling and its critical function in maintaining homeostasis of various tissues, therapies 
should tackle the pathogenic aspects of the signaling without interfering with homeostatic 
mechanisms. 
As evidenced in Chapter 3, short term TGFβ inhibition may be beneficial in enhancing 
cell proliferation after acute liver injury; however, it may eventually delay or exacerbate 
the fibrogenic response needed for appropriate regeneration. Thus, from a translational 
perspective TGFβ inhibition must be spatiotemporally controlled in particular cell type(s), 
during specific stages of during disease progression. Such approach comes from liver 
fibrosis studies where decrease of collagen chaperone expression was performed in vivo 
using siRNA delivered via liposomes that were coated with retinol protein75. Based on 
the retinol-storing properties of collagen producing HSCs11 the liposome-mediated drug 
delivery is beneficial in decreasing ECM protein secretion and limiting fibrosis76. Other 
studies performed HSC-specific drug targeting of ALK5 inhibitor LY-364947 utilizing the 
specific binding of mannose 6 phosphate human serum albumin (M6PHSA) on the insulin-
like growth factor II receptor, which is expressed in HSCs77. 
A hypothetical therapeutic setting for Dupuytren’s disease could be the administration of 
AONs (Chapter 4 and 5) prior to the surgical intervention or postoperatively, in order to 
counteract the TGFβ activity in the remaining MFBs. Early application of ALK5 AON could 
prevent destructive TGFβ action which is triggered by tissue damage during surgery, 
with consideration of the long term fibrotic effect that results from exposure to TGFβ78. 
Combination treatments targeting both the ECM and MFBs could be a promising approach; 
for instance treatment with matrix degrading enzymes, such as the FDA approved Clostridium 
Collagenase Xiaflex compound, would enhance the ability of TGFβ inhibitors (AONs or SMIs) 
to pass through the extracellular space and enter the MFBs. (Pre)clinical studies involving 
DD ex vivo culture method could potentially reveal anti-fibrotic candidate substances, that 
could be studied within a therapeutic context focused on patient-specific gene expression, 
drug and immune responses. Therefore, stratification of patients participating in clinical 
trials could be better monitored. 
Systemic administration of TGFβ inhibitors in humans might have detrimental effects due 
to inhibition of the cytostatic and immune suppressive role of TGFβ in many organs leading 
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to formation of carcinomas and inflammation. However, studies in transgenic mice (soluble 
TGFβRII fused to Fc is under the control of mammary specific promoter MMTV-LTR) showed 
that lifelong exposure to TGFβRIIFc does not induce toxic effects or have negative impact 
on homeostasis79 that is observed in mice with TGFβ gene deletion80. Most importantly, 
experimental induction of tumors in this mouse model showed that they are resistant to 
metastasis development79. A similar study showed beneficial effects in tumor apoptosis 
and migration in breast cancer after systemic administration of TGFβRIIFc, however no 
effect was observed on tumor angiogenesis81. Given the impact of the vasculature and 
surrounding stroma, combination treatment of TGFβ inhibitors with chemotherapeutics, 
immune modulatory agents or anti-angiogenesis factors6 have gained scientific and clinical 
interest as an approach for cancer treatment82-84. Monotherapy in cancer treatment often 
results in drug resistance, while combinations of drugs that target tumor cell proliferation 
but also the microenvironment are more likely to slow progression to metastasis. A major 
limitation and growing concern in cancer field is multidrug resistance (MDR), a process via 
which tumor cells acquire mutations that provide them synchronous resistance to different 
drugs when given in combination85. To stop this vicious cycle of drug resistance and cancer 
progression to metastasis, several chemosensitising compounds have been developed to 
interfere with MDR, such as steroids, channel blockers or stealth liposomes86. Moreover, 
drug resistance to anti-angiogenic compounds is less prevalent because of the genome 
stability of endothelial cells compared to tumor cells87. 
One of the drawbacks of chemotherapy or radiation is the induction of apoptosis of normal 
cells which are not replenished but rather replaced by fibrotic scar tissue. In this case long 
term inhibition of TGFβ might be beneficial to block the progression of fibrosis in cancer 
survivors88. ECM deposition in the tumor stroma and MFB contraction affect the influx and 
outflux of fluid from the interstitial space causing high interstitial fluid pressure (IFP)89; a 
property found in tumors which hampers the delivery of drug compounds into the tumor 
cells90. This is another aspect where TGFβ inhibition in the tumor microenvironment may 
enhance the delivery and benefits of chemotherapy91. 
Collectively, the studies in this thesis aimed to improve insight on the molecular mechanisms 
exerted by TGFβ in various tissues and in different disease stages. Inhibition of the TGFβ 
shows pleiotropic effects consistent with the plethora of biological processes regulated by 
TGFβ. Modulation of the gene expression or protein activity of key components of the TGFβ/
BMP pathway was performed using clinically releveant drug compounds. Our studies in 
homeostasis, fibrosis, tumor angiogenesis and cancer highlight the importance of a holistic 
view when interpreting the effects of TGFβ although therapeutic inhibitory approaches need 
to be cell type/tissue specific, administered at a specific stage of disease, in a controlled 
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Abstract
Hepatocellular carcinoma (HCC) is the third cause of cancer- related death with a growing 
incidence worldwide. A comprehensive view of the mechanism initiating the switch from 
liver regeneration to liver failure and tumor formation is needed. Here we report on studies 
regarding the potential role of a Transforming growth factor β (TGFβ) family member, the 
type III receptor for NODAL ligand, CRIPTO, in adult liver disease progression. We investigated 
the expression status of CRIPTO and its interaction partners in vivo in an acute liver injury 
mouse model and examined the in vivo effects on liver regeneration of adenoviral-mediated 
CRIPTO overexpression. Liver tissue specimens from HCC patients were evaluated for CRIPTO 
protein expression. Induction of Cripto was observed after experimental liver injury in mice 
and induction of Cripto overexpression caused bile duct reaction and hepatic progenitor 
cell activation. Both transient and stable CRIPTO overexpression in human hepatoma HepG2 
cells led to upregulation of liver progenitor cell activity, epithelial-to-mesenchymal transition 
(EMT), increased expression of EMT and cancer stem cell markers along with enhancement 
of cell proliferation and migration. The majority of human HCC tumor samples exhibit 
high levels of CRIPTO as compared to the non-tumorous counterpart tissue from the same 
patients. Overall, our preliminary data suggest CRIPTO as potential driver of liver progenitor 




Hepatocellular carcinoma (HCC) accounts for the majority of primary liver cancer cases and 
is the sixth common type of cancer1. HCC arises in the majority of cases on a background of 
cirrhosis, which may be caused by chronic exposure to damaging factors, such as  alcohol, or 
viral hepatitis (HBV, HCV)2. Systemic treatment available is the tyrosine kinase RAF inhibitor, 
sorafenib, which delays HCC progression and metastasis and is indicated for advanced tumors 
or tumors progressing upon loco-regional therapies3,4. There are no clinical or biochemical 
biomarkers available to identify responders to sorafenib 4. Many other compounds have 
been tested in recent years, but none of them has proven to be superior to sorafenib 
yet5. Circulating TGFβ and α-fetoprotein (AFP) levels have been explored as biomarkers 
in HCC6. AFP is reactivated in pathological conditions and is considered a marker of liver 
progenitor cells (oval cells)7. However, detection of high levels of AFP cannot be used for 
diagnosis or prognosis as it does not predict tumor size, stage and HCC progression and is 
absent in 30% of HCC cases 6. Signaling from Transforming growth factor β (TGFβ) pathway 
is an established regulator of liver homeostasis with tumor suppressor role during early 
tumor development8. As with other types of cancer, TGFβ exerts tumor promoter effects 
on established primary tumors and enhances epithelial-to-mesenchymal transition (EMT), 
cell motility and invasion contributing to metastases formation9. 
High levels of circulating TGFβ have been detected in HCC patients with a small HCC10 
although mutations in TGFβ pathway members have low prevalence in HCC. High levels 
of SMAD711, downregulation of TGFβ receptor type I and II expression12,13 and high levels 
of SMAD4 have been associated with poor prognosis in HCC patients14. SMAD3-mediated 
NODAL signaling has been linked to increased EMT and HCC cell invasion via a mechanism 
involving pluripotency transcription factor NANOG15. NANOG induces NODAL/CRIPTO 
expression and correlates with HCC metastasis and poor survival. NODAL and CRIPTO are 
involved in plasticity of tumor cells, cancer-stem cell maintenance and metastasis16,17. CRIPTO 
is an oncofetal protein suggested to partially promote tumorigenesis by inhibiting TGFβ 
signaling18-20 and is involved in the crosstalk of TGFβ/ NODAL pathways with p38/ c-Jun 
N-terminal kinase (JNK), sarcoma viral oncogene (c-SRC)/ Mitogen-activated protein kinase 
(MAPK)/ protein kinase B thymoma oncogene (AKT) and Wingless type (WNT) signaling 
pathways21-23. CRIPTO is silenced postnatally and re-expression is often associated with 
pathological conditions such as neoplasias of breast, lung, prostate, ovarian, bladder, colon, 
skin, lung and brain15,24-32. NODAL-independent CRIPTO signaling is mediated through the 
heat shock glucose-regulated protein (GRP78), which promotes c-SRC/MAPK/AKT activation. 
This pathway is oncogenically mutated in liver cancer33. Moreover, liver-specific deletion of 
GRP78 indicated a homeostatic and protective role during endoplasmic reticulum-stress 
response while elevated GRP78 levels are associated with HCC progression34-36. In the 
present study we investigated the role of CRIPTO-associated pathways NODAL and GRP78 
aiming to identify novel TGFβ-related regulators of liver regeneration and HCC progression.
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Materials and Methods
Human specimens
Liver tissue was obtained from resected livers during orthotopic liver transplantation. Paraffin 
embedded HCC and non-tumor tissue of anonymous patients transplanted for HCC in the 
setting of alcoholic liver disease (ALD) or viral hepatitis C (HCV) etiology were randomly 
selected.  Selection of tissues was performed in agreement with the “code of good practice”. 
Acute liver damage model and administration of adenovirus
Animal protocols were in full compliance with the guidelines for animal care and were 
approved by the Leiden University Medical Center Animal Care Committee. Acute liver 
injury was induced in 5-6 weeks old male C57Bl6 mice weighing 20- 25 g by intraperitoneal 
injection of a single dose of 1 ml/kg body weight carbon tetrachloride (CCl4) (Sigma, from 
a 50% solution mixed in mineral oil) or mineral oil (control). Mice were sacrificed at 3, 6, 24, 
48, 72 hours and day 6 (n=2- 3 per time point). 
Adenoviral constructs expressing β-galactosidase (lacZ) or Cripto were prepared using the 
Gateway adenoviral expression vectors pAd/CMV/V5-lacZ or pAd/CMV/V5-DEST, mouse 
Cripto expression plasmid was a gift from from Dr. Peter Gray 18. AdlacZ (AdCon) or AdCripto 
(1x10E+9 viral particles/ mouse) was injected intravenously via the tail vein to enhance 
delivery to the liver37. After 24 hours, CCl4 was intraperitoneally injected (day 0). Treatment 
groups were as follows: AdlacZ, CCl4+AdlacZ, AdCripto, CCl4+AdCripto. At day 1, day 2 and 
day 3 after CCl4 administration mice were sacrificed and liver tissues were collected for 
histology preparation, RNA/ protein isolation and analysis. 
Immunofluorescence
Liver tissues were fixed in 4% paraformaldehyde solution overnight, washed in phosphate 
buffer saline (PBS) and processed for paraffin embedding. For every mouse, one of the 
liver lobules was embedded in a paraffin block and multiple serial sections (6 μm) were 
prepared. From the human tissue, serial sections of 4 µm were prepared. For antigen 
retrieval, sections were boiled 10-30 min in antigen unmasking solution (Vector Labs) 
and were incubated in 3% H2O2 for endogenous peroxidases sequestering. Sections were 
blocked with 1% bovine serum albumin in PBS-0.1% v/v Tween 20 and subsequently 
incubated with primary antibodies diluted in the blocking solution, overnight at 4°C or room 
temperature. Primary antibodies and dilutions used are as follows: anti-CRIPTO 1:2000 and 
anti-GRP78 1:1000 (kindly provided by Dr. Peter Gray), anti-αSMA 1:500 (Sigma). Next day, 
sections were incubated with secondary antibodies labeled with Alexa Fluor 488, 555, or 647 
(Invitrogen/Molecular Probes, 1:250 in PBS-0.1% Tween-20). Detection of CRIPTO and GRP78 
was enhanced using tyramide amplification (Invitrogen/ Molecular Probes) as described 
previously38. All sections were counterstained with TO-PRO-3 (Invitrogen/Molecular Probes) 
at 1:1000 dilution in PBS-0.1% Tween-20 for nuclei visualization, and mounted with Prolong 
G mounting medium (Invitrogen/ Molecular Probes). All immunofluorescence experiments 
were repeated multiple times using different sections from the same lobule of every mouse.
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RNA isolation, RT-PCR and Quantitative PCR 
During liver tissue collection, one of the liver lobules of each individual mouse was snapfrozen 
in liquid nitrogen and stored at -80°C for RNA analyses. Tissue (100 mg) was homogenized 
using an UltraTurrax homogenizer (T25 basic, IKA) in TRIpure reagent (Roche) and directly 
processed for total RNA isolation according to the TRIpure RNA extraction protocol. Total 
RNA (0.5 μg) was used for first strand cDNA synthesis using RevertAid H Minus first strand 
cDNA synthesis kit (Fermentas). For quantitative PCR (Q-PCR) ten-fold diluted cDNA was 
amplified in a CFX Real Time Detection system (Bio-rad) using SYBR Green Supermix reagent 
(Bio-rad). Expression levels were normalized to housekeeping gene β-actin.
Primer sequences: 
β-actin (human): for-, AATGTCGCGGAGGACTTTGATTGC, 
rev- GGATGGCAAGGGACTTCCTGTAAA
β-actin (mouse): for- GGGGTGTTGAAGGTCTCAAA, rev- AGAAAATCTGGCACCCC
Ck19 (mouse): for- CCGGACCCTCCCGAGATTA, rev- CTCCACGCTCAGACGCAAG
Afp (mouse): for- CGATGTGTTGGCTGCAATGA, rev- GTGCCAGCAGACACTGATG
Cripto (mouse): for- CGCCAGCTAGCATAAAAGTG, rev- CCCAAGAAGTGTTCCCTGTG
GRP78 (human): for- GAACGTCTGATTGGCGATGC, rev- TCAACCACCTTGAACGGCAA
NODAL (human): for-CTTCTCCTTCCTGAGCCAACAAGAGG, 
rev-GGTGACCTGGGACAAAGTGACAGTG
N-CADHERIN (human): for- CAGACCGACCCAAACAGCAAC, 
rev- GCAGCAACAGTAAGGACAAACATC
E-CADHERIN (human): for- TTGACGCCGAGAGCTACAC, rev- GACCGGTGCAATCTTCAAA
VIMENTIN (human): for- CCAAACTTTTCCTCCCTGAACC, rev- CGTGATGCTGAGAAGTTTCGTTGA
OCT4 (human): for- GAGAACCGAGTGAGAGGCAACC, rev- CATAGTCGCTGCTTGATCGCTTG
NANOG (human): for- AATACCTCAGCCTCCAGCAGATG, rev- TGCGTCACACCATTGCTATTCTTC
BMI-1 (human): for- TCATCCTTCTGCTGATGCTG, rev- CCGATCCAATCTGTTCTGGT
CD44 (human): for- TGGCACCCGCTATGTCCAG, rev- GTAGCAGGGATTCTGTCTG
ALK4 (human): for- GCTCGAAGATGCAATTCTGG, rev- TTGGCATACCAACACTCTCG
LEFTY (human): for-CGAGTGGCTGCGCGTCCGCGA, rev- CGAGGCACAGCTGCACTTCTGCACC
ZEB-1(human): for- CCATATTGAGCTGTTGCCGC, rev- GCCCTTCCTTTCCTGTGTCA
ZEB-2 (human): for- GACCTGGCAGTGAAGGAAAA, rev- GGCACTTGCAGAAACACAGA
TWIST (human): for- GCCGGAGACCTAGATGTCATT, rev- TTTTAAAAGTGCGCCCCACG
SNAIL-2 (human): for- TGTGTGGACTACCGCTGC, rev- TCCGGAAAGAGGAGAGAGG
EPCAM (mouse): for- AGGGGCGATCCAGAACAACG, rev- ATGGTCGTAGGGGCTTTCTC
Cell lines 
The HCC cell line, HepG2, were maintained in Dulbecco’s Modified Eagle Media (DMEM) 
supplemented with 10% fetal calf serum and 1% penicillin/streptomycin. For adenovirus 
transduction, 200 multiplicity of infection (MOI) of high titer virus was incubated with the 
media for 24 hours. Migration, proliferation assays and mRNA analysis were performed at 
48 hours after transduction.
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Migration, measurement of metabolic rate MTS assay and wound healing assay
Transwell cell migration and aqueous soluble tetrazolium/ formazan (MTS) metabolic activity/
proliferation assay were performed as described in previous studies39. 
For the wound-healing assay 500.000 cells/ well of a 24- well plate were seeded. After 24 
hours, the wound was made and culture medium was refreshed. Subsequently pictures 
were taken (4x magnification) at at 0, 24, 48 and 76- hour time points. Size of wound was 
measured with ImageJ software.
Microscopy and Image analysis 
Confocal microscopy of labeled specimens was performed on a Leica TC-SP5 microscope 
with a 40Χ 1.4 NA oil-immersion objective. Series of Z stacks were collected and reassembled 
in Image J software (rsbweb.nih.gov/ij). Mean area fraction fluorescence was calculated in 
Image J software using threshold to select the root boundary and measuring the percentage 
of positive surface inside the intensity defined by the threshold. For quantifications of 
immunofluorescence signal, staining experiments were performed on all the samples 
simultaneously to reduce technical variation and imaged using identical exposure and 
recording settings. 
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5.0 sofware (San Diego, CA) and 
two-way ANOVA tests. Data are presented as mean±SEM. Statistically significant differences 
are indicated with asterisks (* P< 0.05, ** P<0.01, *** P<0.001, ***P<0.0001). For quantitative 
PCR analysis experiments were repeated at least three times as technical replicates for 
every sample (different cDNA preparations using the RNA of one liver lobule per mouse or 
HepG2) and the average value was calculated. The mean values obtained from individual 
animals for every group (n=2-3) were used for ANOVA statistical analysis. For quantifications 
of immunofluorescence signal every stained section (representing one mouse liver sample) 
multiple fields of view were imaged and quantified (see section Microscopy and Image 
analysis). The average of these values was calculated for every mouse sample. Statistical 
analyses were performed on the values of all the mouse samples per treatment group 
(n=2-3 in total). 
Results
Short term re-expression of Cripto after CCl4-induced liver damage
To assess whether Cripto is involved in liver homeostasis we analysed its expression in 
normal and injury-induced regenerating liver tissues from wild type C57Bl6 male mice. As 
previously reported for other tissues40, Cripto is not expressed postnatally in the liver under 
physiological conditions (Fig.1A). Cripto expression is induced during acute liver damage. A 
single CCl4 injection leads to acute liver damage and fibrogenesis within the first 72 hours but 
is completely reversible within 6-7 days. In this model, a series of time points was analysed 
and Cripto protein expression was observed at 24 hours (Fig.1A). mRNA expression was 
induced within the first 3 hours after CCl4 administration, with a peak of expression at 24 
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hours and a gradual downregulation from 48 hours onwards (Fig.1B). 
In vivo overexpression of Cripto indicates progenitor cell activation
Early induction of Cripto in response to tissue damage and localised expression around the 
damaged central vein area (Fig.1A) suggests a functional requirement. To further assess the 
function of Cripto we utilised the CCl4-induced acute liver injury model in combination with 
adenoviral-mediated overexpression of mouse Cripto. At 24 hours prior to CCl4 injection, 
the control adenovirus-lacZ (AdlacZ) or Cripto-adenovirus (Ad-Cripto) was administered 
to the 4 treatment groups AdlacZ, CCl4+AdlacZ, AdCripto, CCl4+AdCripto. Liver tissues 
were analysed at 24, 48 and 72 hours after CCl4 administration. Histological analysis after 
Cripto overexpression indicated an aberrant number of bile ducts in the portal triad area 
(Fig.1C). This area is not directly affected by CCl4 (due to lack of metabolising enzymes) and 
is the site of residence of hepatic stem/progenitor, also termed as oval cells41. Each portal 
triad normally consists of the portal vein, the hepatic artery and one bile duct. The newly 
formed bile ducts indicate bile duct proliferation, and a process termed bile duct reaction 
due to liver progenitor (oval cell) activation42. In particular, the additional bile ducts (basal 
number is one bile duct; only the additional ducts are indicated) are positive for α-smooth 
muscle actin (αSMA) and were exclusively observed in liver tissues of the AdCripto and 
CCl4+AdCripto groups (Fig.1D).
Cripto upregulation was detected at 24 hours in AdCripto or CCl4+AdCripto mice (Fig.1E), 
exponentially upregulated at 48 hours (Fig.1F) and normalised back to the basal levels in 
all treatment groups (Fig.1G). Next, we evaluated the expression of oval cell markers (AFP, 
cytokeratin 19 (CK19)) to test whether bile duct proliferation may be attributed to presence 
of oval cells. AFP expression (Fig.1H-J), measured in whole liver mRNA extracts, showed a 
pattern of transient upregulation similar to Cripto expression (Fig.1E-G), i.e., upregulated at 
24 hours following AdCripto administration (Fig.1H), overall induced at 48 hours in all the 
treatment groups (Fig.1I) and reduced again after 72 hours. At this time point (72 hours), 
AFP levels remain elevated only in the CCl4+AdCripto group (Fig.1J). CK19 expression was 
induced transiently early after CCl4 administration at 24 hours (Fig.1K-M), preceding, but 
not after, the Cripto expression. 
Further, transient overexpression by AdCripto was also validated in vitro in the HCC cell line 
HepG2. Upregulation of Cripto (Fig.2A) in the HepG2 led to induction of both interaction 
partners NODAL (Fig.2B) and GRP78 (Fig.2C), mesenchymal markers N-CADHERIN and 
VIMENTIN (Fig.2D-E) as well as pluripotency/cancer stem cell (CSC) markers, Octamer 
binding transcription factor 4 (OCT4), homeobox transcription factor (NANOG), polycomb 
ring finger protein (BMI-1) and cell surface glucoprotein (CD44) (Fig.2F-I), were increased 
upon transient Cripto overexpression.
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Fig.1. Cripto is re-expressed during early response of CCl4-induced regeneration in mouse liver and may 
stimulate oval cell (progenitor) activation 
(A). Immunofluorescence staining for Cripto (green) and αSMA (red) in liver tissue at 24 hours after vehicle or CCl4 
injection. Central vein area of the liver is depicted. Nuclei are stained with TO-PRO-3 (blue). Scale bars 50 μm. (B). 
Cripto mRNA expression in liver homogenates at different time points after CCl4 treatment; 3 hours, 6 hours, 24 
hours, 48 hours, 72 hours, 6 days. Values are normalized to β-actin and time point 0 hours (DDCt fold). Error bars 
indicate SEM (n=3). (C). In vivo overexpression of Cripto was induced by adenovirus transduction in the acute CCl4 
liver injury model. Bile duct (oval progenitor cell-driven) reaction in the periportal area after overexpression of 
Cripto in the liver is depicted using immunofluorescence for αSMA (red) in livers administered with CCl4+AdlacZ, 
CCl4+AdCripto or AdCripto. Nuclei are stained with TO-PRO-3 (blue). Scale bars 75 μm. (D). Quantification of the 
additional bile ducts observed in the periportal vein area. Total number of additional bile ducts in 5 areas per 
section was averaged. Error bars indicate ±SEM (n=2). (E). Cripto mRNA expression in liver homogenates at 24 hours, 
48 hours (F), 72 hours (G) after CCl4 injection. Treatment groups: AdlacZ, CCl4+AdlacZ, AdCripto, CCl4+AdCripto. 
Values are normalized to β-actin. Error bars indicate SEM (n=3). (H). A-fetoprotein (Afp) (oval cell marker) mRNA 
expression in liver homogenates at 24 hours, (I). 48 hours and (J). 72 hours after CCl4. (K). Cytokeratin-19 (Ck-19) 
(oval cell marker) mRNA expression in liver homogenates at 24 hours, (L). 48 hours and (M). 72 hours after CCl4. 
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Fig.2. Effects of transient CRIPTO overexpression in EMT and stem cell marker induction 
(A). Confirmation of expression of the CRIPTO adenoviral construct used previously in vivo and transient 
overexpression of CRIPTO in HepG2 cells;  quantitative mRNA expression of CRIPTO and its interaction partners 
NODAL (B) and GRP78 (C) in HepG2 cells 48 hours (hours) after transduction with control Adenovirus (AdCon) 
or CRIPTO expressing Adenovirus (AdCRIPTO). Error bars indicate ±SD (n=3). (D-E). mRNA expression levels of 
mesenchymal markers NCADHERIN and VIMENTIN. (F-I). mRNA expression levels of cancer stem cell (CSC) markers 
OCT4 (F), NANOG (G), BMI-1 (H), CD44 (I) and in HepG2 cells 48 hours after transduction with control Adenovirus 
(AdCon) or CRIPTO expressing Adenovirus (AdCRIPTO). Error bars indicate ±SD (n=3).
CRIPTO and GRP78 expression in human HCC
Based on the induction of CSC and EMT markers in vivo and in vitro, the expression levels 
of CRIPTO and GRP78 in human HCC liver specimens were evaluated. Aetiopathological 
heterogeneity in HCC was taken into account during the selection of HCC patient material; 
in this study we assessed specimens from HCV infection-driven HCC (HCV-HCC) or alcoholic 
liver disease-driven HCC (ALD-HCC). Adjacent tissue to the resected tumor, derived from the 
same patient, was used for comparison (control). We found that CRIPTO protein levels are 
lower in the adjacent non-tumor tissue compared to the tumor area  in 50% of the patients 
with HCV-related and in all ALD-related HCC patients (n=4 per group) (Fig.3A-B, 3D-E). In 
tumor tissue areas, higher CRIPTO expression levels were observed at the vicinity of the 
stroma (Fig.3A, 3D). For comparison, samples from patients with only HCV infection and 
without detected signs of cirrhosis or HCC were also analysed and revealed low to none 
CRIPTO and GRP78 expression (Fig.3B-C). GRP78 is upregulated in HCC tissue areas in 25% 
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of the analysed HCV-related HCC patient samples (Fig.3A,C) and in 50% of the analysed 
ALD-related HCC tissues compared to adjacent non-tumorous tissue (Fig.3D,F).  
To assess functional effects exerted by CRIPTO in HCC, we generated a stable HepG2- CRIPTO 
cell line by lentiviral transduction (LV-MOCK, LV-CRIPTO). The overexpression of CRIPTO was 
confirmed at the mRNA level by quantitative PCR (Fig.4A). Associated NODAL pathway 
members (NODAL, ALK4, LEFTY) and GRP78 were also upregulated in the LV-CRIPTO HepG2 
(Fig.4B-E). Moreover, proliferation (MTS assay), migration (transwell assay) and wound 
closure assay showed that the HepG2-CRIPTO cells become more proliferative (Fig.4F) and 
motile (Fig.4G-H). Consistent with the acquisition of invasive and mesenchymal properties 
CRIPTO overexpressing cells show downregulation of E-CADHERIN (Fig.5A), upregulation 
of EMT markers (VIMENTIN, ZEB-1, ZEB-2, TWIST and SNAIL-2)  (Fig.5B-F) and increased 
CSC marker (EpCAM, BMI-1 and CD44) expression  (Fig.5G-I).
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Fig.3. Expression of CRIPTO and its interaction partner GRP78 in human HCC liver tissues
(A). Representative immunofluorescence images of CRIPTO and its interaction partner GRP78 staining in human 
liver sections from HCV-derived HCC tissue (HCV infection-driven) and adjacent non-tumor control tissue from 
the same patient. Nuclei are stained with TO-PRO-3 (blue). Scale bars 75 μm. (B). Quantification of CRIPTO and (C). 
GRP78 protein expression as assessed by immunofluorescence in tumor HCC HCV (Tumor) and in adjacent non-
tumor tissue (Control) from the same patient (n=4). Liver tissue from patients with HCV infection but absence of 
cirrhosis (non-cirrhotic HCV, n=4) was used for comparison. The percentage of positive pixel area was an average 
from two-four focal areas per section. Each bar represents values from each patient. Error bars indicate ±SD. (D). 
Representative immunofluorescence images of CRIPTO and its interaction partner GRP78 protein expression in 
human liver sections from alcoholic liver disease (ALD)-derived HCC tissue and adjacent non- tumor control tissue 
from the same patient. Nuclei are stained with TO-PRO-3 (blue). Scale bars 75 μm. (E). Quantification of CRIPTO 
and (F) GRP78 protein expression as assessed by immunofluorescence in tumor HCC ALD (Tumor), adjacent non-
tumor tissue (Control) from the same patient (n=4). The percentage of positive area (pixels) was the average from 
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Fig.4. In vitro effects of stable overexpression of CRIPTO in HepG2 cells
(A-E). Quantitative PCR for mRNA expression of Cripto associated members of the NODAL and GRP78 pathways 
in wild type HepG2 cells; control, stably overexpressing Mock construct after lentivirus transduction (MOCK) 
and stably overexpressing CRIPTO (CRIPTO). (A). CRIPTO, (B). NODAL, (C). GRP78, (D). ALK4 and (E). LEFTY mRNA 
expression (n=3, ±SEM). Values are normalized to β-actin and to control sample (ΔΔCT fold expression). (F). 
Metabolic activity MTS assay (24, 48, 72, 96 hours) was performed in control, MOCK and CRIPTO overexpressing 
HepG2 cells. Accumulation of MTS was measured based on absorbance at 490 nm. Values are normalized to the 
basal measurements at 0 hours after cell seeding. Graph represents values for three independent experiments 
(n=3). Error bars indicate SEM. p value < 0.001 (***), < 0.0001 (****). (G). Transwell migration assay of LV-MOCK 
and LV-CRIPTO overexpressing HepG2 cells; quantification of percentage (%) of positive area of migrated cells 
(Crystal violet cell dye) was performed in two independent experiments. Error bars indicate ±SEM. (H). Cell 
motility was assessed in wound healing (scratch) assay. Wound size was quantified in a time-dependent manner 
(0, 24, 48 and 72 hours) in two independent experiments. Error bars indicate ±SEM.
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Fig.5. Expression of EMT and CSC markers in HepG2 cells upon stable overexpression of CRIPTO
(A-F). The levels of mRNA expression of epithelial-to-mesenchymal (EMT) markers in control, MOCK and CRIPTO- 
overexpressing HepG2 cells was assessed by quantitative PCR; (A). E-CADHERIN, (B). VIMENTIN, (C). ZEB-1, (D). 
ZEB-2, (E). TWIST, (F). SNAIL2. (G-I). mRNA expression levels of cancer stem cell (CSC) markers; (G). EPCAM, (H). 




The ability of quiescent hepatocytes to become proliferative and replace the damaged cells, 
both of the hepatocyte and cholangiocyte lineage, is at the foundation of liver regeneration41. 
In addition, hepatic stellate cells and Kupffer cells orchestrate wound healing response by 
the secretion of cytokines, removal of dead cells and extracellular matrix restoration. The 
general perception is that liver progenitor cells (oval cells) reside in the bile duct (at the 
portal triad) and their role is largely compensated by hepatocytes, bone marrow- derived 
fibrocytes and possibly hematopoietic stem cells. Oval cells typically are only detectable 
upon chronic liver injury or carcinogenesis and not upon acute CCl4 damage
43. However, 
in our model we observed reactivation of CK19 and AFP, markers of oval cells, followed 
by bile duct proliferation, a process associated with oval cell activation usually observed 
after partial hepatectomy or bile duct ligation42,44,45. Oval cell marker AFP has important 
functions during embryogenesis, it is postnatally silenced and re-expression often drives 
clonal expansion of oval cell-derived tumors43,46. AFP has been discarded from diagnostic 
schemes in recent guidelines due to the limited sensitivity4,47. 
Here we report preliminary evidence that (1) pluripotency-associated protein CRIPTO is 
reactivated in vivo at early stages after acute liver injury, (2) CRIPTO overexpression induces 
bile duct reaction and AFP upregulation, (3) acute liver injury may also elicit the activation 
of oval cells. The rapid dynamics of CRIPTO and AFP expression and downregulation in vivo 
suggest that their expression levels are tightly regulated in order to induce a short-term 
cellular response; in this case perhaps a beneficial role in regenerative response. We speculate 
that due to the oncogenic role of high AFP levels in the liver and of CRIPTO in other tissues, 
both proteins are silenced in the adult organism to prevent abnormal activation of oval 
cells and tumor formation. 
In the majority of human HCV- related HCC and ALD-related HCC tissue samples, the levels 
of CRIPTO were elevated in the tumor area compared to adjacent non-tumorous tissue from 
the same patient. CRIPTO- GRP78- mediated AKT signaling has been found to contribute to 
tumorigenesis24, thus, we assessed the expression levels of GRP78 in human HCC specimens. 
Indeed, higher levels of GRP78 were detected in 50% of the tumor tissues of the ALD-HCC 
group and in 25% of the HCV-HCC group, similar to CRIPTO. However, 75% of HCV-related 
HCC showed reduced GRP78 expression that coincides with previous findings showing that 
GRP78 has a protective role in the liver, against steatosis and cancer. 
The location of CRIPTO in the hepatocytes, in particular those at the border between tumor 
nodule and stroma, has led us to the hypothesis that CRIPTO may promote invasiveness. 
Stable overexpression of CRIPTO in HepG2 cells induces their proliferative and migratory 
potential and is associated with an increase of EMT transcription factor and mesenchymal 
marker expression. Transient and stable overexpression of CRIPTO upregulates NODAL, LEFTY 
and GRP78, thus more aggressive, EMT-like phenotype of these cells may be attributed to 
either or both GRP78 and canonical NODAL signaling, however, further investigations are 
required. 
In summary, this study provides supportive evidence for a novel role of developmental 
protein Cripto during progenitor cell activation during acute liver injury, suggesting that 
common developmental programs also regulate liver development and adult liver injury 
response. CRIPTO expression correlates with progression to human hepatic carcinogenesis in 
response to HCV hepatitis infection and alcoholic disease. The implication of fetal oncoprotein 
Cripto in the early response to acute liver injury and in advanced liver cancer may indicate 
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that CRIPTO is part of the missing link between acute and chronic liver injury, progression 
to cirrhosis and further to cancer formation. 
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Cancer and chronic fibrosis are devastating diseases of high mortality rate with limited 
curative therapies available. Both of these diseases may influence the function of one or 
multiple organs while the extracellular microenvironment is a contributing factor in the 
pathogenesis of both disorders. Considering the increasing number of cases per year, a 
better understanding of the biological drivers of these diseases is fundamental in order 
to develop effective therapeutics. At the molecular level, signaling pathways control cell 
growth, differentiation or apoptosis during development and adult life of the organism 
ensuring homeostasis. In a paradox, the same signals are often implicated or even drive 
disease progression. Environmental or genetic factors have impact on gene functions by 
direct gene alterations or indirect epigenetic factors that change the function of signaling 
members. One of the signaling pathways with key regulatory functions in homeostasis, 
tissue fibrosis and cancer in many organs is the TGFβ/ BMP pathway. 
In this thesis we have addressed the role and therapeutic potential of TGFβ/ BMP pathway 
inhibition using different drug compounds that are currently towards the clinic or being 
tested in clinical trials. Three distinct types of inhibitors were used; small molecule inhibitors 
of the ALK4, 5 and 7 TGFβ receptor kinases, an antisense oligonucleotide interfering with 
ALK5 mRNA splicing and an ALK1 ligand trap; a peptide that contains the extracellular 
domain of ALK1 fused to Fc and sequesters BMP9 and BMP10. These inhibitors were used in 
an ex vivo human fibrosis model or in vivo mouse models of various human diseases (acute 
liver failure/ liver regeneration, Dupuytren’s fibrosis) and cancer (prostate, liver). 
Chapter 1 introduces the basic aspects of the TGFβ/ SMAD signaling pathway, including 
its regulation, crosstalk with other pathways and the role during homeostasis of liver, 
prostate and connective tissue. Moreover, the impact of TGFβ and BMP deregulation is 
introduced in relation to common abnormalities; liver wound healing, Dupuytren’s fibrosis 
and prostate tissue malignancies. Advances in drug development have provided researchers 
with therapeutic strategies with potential clinical application. In this Chapter we address 
the properties of individual classes of drugs targeting (mainly inhibiting) the TGFβ pathway 
and their status on ongoing or completed clinical trials. 
In Chapter 2 the current knowledge on TGFβ signaling in relation to its contribution in liver 
regeneration is reviewed. Different aspects are addressed such as embryonic development, 
the molecular mechanisms regulating hepatocyte and oval cell regeneration, plasticity of 
hepatic lineages, and induced reprogramming of hepatocytes as cell based therapies for 
human liver diseases. Repeated tissue injury leads to unrepairable cell regeneration and 
a shift towards scar tissue formation (fibrosis). The end stage of excess fibrosis in the liver 
(cirrhosis) is a risk factor for hepatocellular carcinoma development. In order to understand 
the progression of liver disease further investigation of the mechanisms that balance cell 
replenishment and fibrosis is needed. Excess activation of TGFβ leads to epithelial cell 
apoptosis (acute liver failure), epithelial-to-mesenchymal transition, liver cirrhosis and 
eventually cancer. Thus, in vivo inhibition of TGFβ may prove a beneficial therapeutic 
strategy in liver diseases. 
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In Chapter 3 we investigated the in vivo applicability of a drug compound, the small molecule 
inhibitor (LY364947) targeting the kinase activity of TGFβ type I receptor (ALK5), in a mouse 
model of acute injury-induced liver regeneration. Administration of LY364947 in mice that 
received hepatotoxin carbon tetrachloride (CCl4) enhanced the proliferation of hepatocytes 
and recovery of the liver enzyme expression pattern, showing overall improved wound 
healing compared to mice that did not receive the ALK5 inhibitor. The possible mechanism 
of this effect is inhibition of the cytostatic effect of TGFβ by downregulation of p21, and/or 
upregulation of proliferating nuclear antigen and phosphorylation of histone 3. 
In Chapter 4 and 5 we addressed the limitations to study the effects of TGFβ inhibition using 
the current methods available in the field of fibrosis (primary fibroblast cultures). For this 
we developed novel ex vivo culture methodology that allows us to maintain human fibrotic 
connective tissue from palmar fascia (Dupuytren’s fibrosis). The proof-of-principle for this 
ex vivo method is introduced in detail in Chapter 4 along with further applications, such as 
biochemical and imaging techniques to be used for studying patient-specific pathogenesis 
and responses to candidate antifibrotic drugs. In Chapter 5, we have used the ex vivo culture 
system to assess the anti-fibrotic potential of TGFβ inhibitors. Antisense oligonucleotide 
and small molecule kinase inhibitor-mediated ALK5 inhibition diminished the number of 
collagen-producing myofibroblasts and decreased the expression of extracellular matrix 
proteins indicating an amelioration of fibrosis ex vivo. Such preclinical studies highlight the 
importance of TGFβ inhibition as monotherapy or in combination with other substances, 
such as anti-inflammatory agents, for the treatment of fibrosis. 
In Chapter 6 we explored the effect of the anti-angiogenesis compound ALK1Fc (ACE-041, 
Acceleron), which acts on different fronts; tumor microenvironment (matrix and vasculature) 
and tumor cells. Administration of ALK1Fc exhibited in vivo anti-angiogenic and tumor 
suppressive effects in a primary prostate cancer mouse model established by orthotopic 
transplantation of human prostate cancer cells. ALK1Fc ligand trap is currently being tested 
in clinical trials for solid tumor treatment as tumor angiogenesis inhibitor. ALK1Fc reduced 
the tumor volume of primary prostate cancer (formed by aggressive prostate cancer cell 
line PC3-M-Pro4) possibly due to reduced tumor vasculature. In vivo administration of 
ALK1Fc acted as anti-angiogenic factor by inhibiting BMP9 binding to its receptor ALK1 
on endothelial cells. However, ALK1Fc also indicated a direct effect of BMP9 on tumor cells; 
BMP9 was found to mediate upregulation of the NOTCH ligand JAGGED, the cancer stem 
cell marker Aldehyde dehydrogenase 1 (ALDH1A1) and to enhance the proliferation of 
prostate cancer cells.
In Chapter 7 the findings of this thesis presented in the different chapters are discussed 
under a common denominator; the inhibition of TGFβ/ BMP signaling in human diseases. 
Furthermore, the implications of TGFβ inhibitory strategies in basic and clinical research along 
with future perspectives are discussed. Molecular signatures characteristic of tissue injury 
often reminisce the expression status of human malignancies. Preliminary data indicate a 
role for the TGFβ type III receptor CRIPTO in liver regeneration and human hepatocellular 
carcinoma (Appendix I). Normally, CRIPTO is expressed only during embryonic development. 
We show that reactivation of CRIPTO takes place in the mouse liver after toxin-induced acute 
injury. CRIPTO has the potential to reduce SMAD2/3 signaling by directly binding to TGFβ and 
has been suggested as a mediator of the TGFβ- tumor promoting effect by deactivating the 
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cytostatic role of TGFβ and activating other cell survival signals. Moreover, elevated protein 
levels of CRIPTO in liver tissue specimens of human hepatocellular carcinoma suggest a 
tumor-promoting role of CRIPTO in the liver, which may be of potential diagnostic value 
as biomarker for human hepatocellular carcinoma. 
Collectively, after the discovery of the TGFβ numerous studies have contributed to a holistic 
and comprehensive view of the molecular properties of all the proteins assembling the 
pathway and the biological processes that TGFβ is involved in. Given the disease-promoting 
role of deregulated TGFβ/ BMP signaling the key aspect of current research is therapeutic 
intervention by targeting pathway activation in a clinical relevant way. Based on our 
observations, inhibition of TGFβ is promising in many diseases and has additive beneficial 
effects in combination with other drug compounds, for instance chemotherapeutic, anti-
inflammatory, immune modulatory agents depending on the disease setting.
However, TGFβ inhibition is not panacea mainly because of the TGFβ homeostatic role in 
many organs. Successful modulation of TGFβ requires careful patient stratification and 
disease staging by using prognostic tools such as biomarkers and patient-specific genetic 
variation. Current and future development in drug delivery will hopefully enhance the 
tissue-specific or cell type-specific targeting of drugs against TGFβ pathway members along 




Kanker en chronische fibrose zijn verwoestende ziekten met een hoog sterftecijfer en een 
beperkt aantal therapieën die tot genezing kunnen leiden. Beide ziekten beinvloeden 
het functioneren van en/of beschadigen meerdere organen, waarbij het extracellulaire 
micromilieu een essentiele rol speelt. Gezien de toename van het aantal gevallen per 
jaar is het verkrijgen van een beter inzicht in de biologische drijvers van deze ziekten van 
fundamenteel belang om effectieve therapieën te kunnen ontwikkelen. 
Tijdens de embryonale ontwikkeling en het volwassen leven van een organisme wordt 
homeostase gereguleerd via diverse signaaltransductie routes die op moleculair niveau 
processen als celgroei, differentiatie of apoptose aansturen. Dezelfde signalen en signaal 
routes zijn vaak betrokken bij ziekten en ziekteprogressie, of zelfs de direkte oorzaak 
ervan. Omgevingsfactoren en genetische factoren kunnen namelijk de werking van 
signaleringsmoleculen negatief beinvloeden via mutaties in het DNA of via epigenetische 
mechanismen. 
Een van de signaalroutes die in vele organen een belangrijke regulerende functie heeft, 
is de TGFβ/ BMP route, betrokken bij onder andere homeostase, weefselfibrose en kanker. 
In dit proefschrift is de rol van de TGFβ/ BMP route bij deze processen nader onderzocht, 
en is tevens gekeken naar  het therapeutisch potentieel van het remmen van specifieke 
componenten van de route, daarbij gebruik makend van drugs die momenteel gebruikt 
worden in de kliniek, of nog getest worden in klinische studies. 
Drie verschillende klassen van inhibitoren zijn gebruikt: remmers van de kinase aktiviteit 
van een subklasse TGFβ membraan receptoren (ALK4, 5 en 7); een antisense oligonucleotide 
dat ALK5 mRNA splicing remt; en een zogenaamde ALK1 ligand trap: een peptide waarin 
het extracellulaire domein van ALK1 gefuseerd is met het Fc domein van antilichamen, 
wat daardoor BMP9 en BMP10 kan wegvangen. Deze remmers zijn gebruikt in een ex vivo 
humaan fibrose model en in (in vivo) muismodellen voor acuut leverfalen/ leverregeneratie, 
Dupuytren fibrose, en prostaat en lever kanker.
Hoofdstuk 1 beschrijft de basis aspecten van de TGFβ/ SMAD signaleringsroute, de regulering 
ervan, de interactie met andere signaalroutes en de rol bij homeostase van de lever, prostaat 
en bindweefsel. Bovendien wordt het effect van TGFβ en BMP deregulering geïntroduceerd 
in de context van een aantal daaraan gerelateerde processen en ziekten: lever regeneratie, 
Dupuytren fibrose en prostaatweefsel maligniteiten. Vooruitgang in de ontwikkeling van 
geneesmiddelen heeft onderzoekers voorzien van therapeutische strategieën met potentiële 
klinische toepassing. In dit hoofdstuk worden de eigenschappen van de verschillende klassen 
van medicijnen die de TGFβ route beinvloeden beschreven, en hun status in lopende of 
afgeronde klinische studies. 
In hoofdstuk 2 wordt een overzicht gegeven van de huidige kennis over de TGFβ signalerings-
route in relatie tot de rol van de route bij leverregeneratie. Verschillende aspecten worden 
behandeld, zoals de embryonale ontwikkeling, de moleculaire mechanismen betrokken 
bij de regeneratie van  hepatocyten en ovaal cellen, de plasticiteit van leverceltypen, en 
geïnduceerde herprogrammering van hepatocyten als celtherapie voor menselijke le-
verziekten. Herhaalde weefselbeschadiging leidt tot onherstelbare celregeneratie en een 
verschuiving naar de vorming van littekenweefsel (fibrose). Het eindstadium van overmatige 
fibrose in de lever (cirrose) is tevens een risicofactor voor de ontwikkeling van hepatocellulair 
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carcinoom. Om de progressie van leverziekte te begrijpen is nader onderzoek nodig naar 
de mechanismen die de balans tussen normale cel vervanging en fibrose bepalen. Over-
matig activeren van de TGFβ route leidt tot apoptose van epitheel cellen (acuut leverfalen), 
epitheliale-mesenchymale transitie, levercirrose en uiteindelijk kanker. In vivo remming van 
TGFβ zou daarom gunstige effekten op leverziekten kunnen hebben.
In hoofdstuk 3 onderzochten we in een muizenmodel voor leverregeneratie na acute 
verwonding de in vivo toepasbaarheid van LY364947, een kleine chemische remmer van 
de kinase activiteit van de TGFβ type I receptor ALK5. Toediening van LY364947 aan muizen 
behandeld met het hepatotoxine koolstoftetrachloride (CCl4), versterkte zowel proliferatie 
van levercellen als herstel van het normale lever enzym expressie patroon, wat duidt op 
verbeterde genezing in vergelijking met muizen die de ALK5 remmer niet ontvingen. Het 
mogelijke mechanisme van dit effect is de remming van het cytostatische effect van TGFβ 
door onderdrukking van de celcyclus remmer p21, opregulatie van prolifererend nucleair 
antigen (PCNA) en fosforylering van histon 3.
In hoofdstuk 4 en 5 richtten, we ons op de beperkingen van de bestaande methoden 
in het fibrose onderzoek, om de effecten van TGFβ remming te bestuderen (primaire 
fibroblast kweken). Hiervoor ontwikkelden we nieuwe ex vivo methodiek voor onderzoek 
naar fibrotisch menselijk bindweefsel van de palmaire fascia (Dupuytren fibrose, een 
primair door TGFβ-aangestuurde ziekte). Deze ex vivo methode wordt geïntroduceerd in 
hoofdstuk 4, samen met mogelijke toepassingen, zoals biochemische en beeldvormings-
technieken voor het bestuderen van de patiënt-specifieke pathogenese en de respons 
op potentiele antifibrotische geneesmiddeken. In hoofdstuk 5 hebben we dit nieuwe ex 
vivo kweeksysteem gebruikt om het anti-fibrotische potentieel van TGFβ inhibitoren te 
analyseren. Remming van de ALK5 funktie m.b.v. het antisense oligonucleotide of de kleine 
chemisch kinase-remmer verminderde het aantal collageen producerende myofibroblasten 
en verlaagde de expressie van extracellulaire matrixeiwitten, wat wijst op een verbetering 
van fibrose ex vivo. Zulke preklinische studies benadrukken het belang van TGFβ remming 
voor de behandeling van fibrose, als monotherapie of in combinatie met andere stoffen, 
zoals anti-inflammatoire middelen.
In hoofdstuk 6 is het effect onderzocht van de anti-angiogene verbinding ALK1Fc (ACE-041, 
Acceleron), een stof die zowel aangrijpt op de tumor microomgeving (matrix en vasculatuur) 
als op de tumorcellen zelf. Toediening van ALK1Fc had in vivo anti-angiogene en tumor 
onderdrukkende effecten in een muizenmodel voor primaire prostaatkanker (geinduceerd 
door orthotope transplantatie van menselijke prostaatkankercellen). 
ALK1Fc is, zoals hierboven vermeld, een peptide dat BMP9 en BMP10, de TGFβ familieleden 
die binden aan de TGFβ type I receptor ALK1, kan binden en neutraliseren; de stof wordt 
momenteel getest als tumor angiogenese inhibitor in klinische studies voor de behandeling 
van vaste tumoren. 
ALK1Fc verminderde het volume van primaire prostaattumoren (gevormd door de agressieve 
prostaatkanker cellijn PC3-M-Pro4), mogelijk door verminderde tumorvasculatuur. In vivo 
toediening van ALK1Fc werkte anti-angiogeen door op endotheel cellen de binding van 
BMP9 aan ALK1 te remmen. Echter, gebruik van ALK1Fc duidde ook op een direct effect van 
BMP9 op tumorcellen; BMP9 veroorzaakte opregulatie van de NOTCH ligand JAGGED en de 




In hoofdstuk 7 worden de bevindingen van dit proefschrift die gepresenteerd zijn in de 
eerdere hoofdstukken besproken onder een gemeenschappelijke noemer; de remming van 
TGFβ/ BMP signaaloverdracht in humane ziekten. Bovendien wordt de invloed van TGFβ 
remmende strategieën in fundamenteel en klinisch onderzoek besproken, ook in relatie 
tot de toekomstperspectieven. Moleculaire signaturen kenmerkend voor weefselschade 
lijken vaak op de expressie patronen in menselijke maligniteiten. Onze preliminaire data 
wijzen op een rol van de TGFβ type III receptor CRIPTO in leverregeneratie en humane 
hepatocellulaire carcinomen (Appendix I). Normaliter komt CRIPTO alleen tot expressie 
tijdens de embryonale ontwikkeling. We laten echter zien dat in de muizenlever reactivering 
van CRIPTO plaatsvindt na acute schade door toxine. Door direct aan TGFβ te binden kan 
CRIPTO TGFβ signalering via SMAD2/ 3 verminderen; dit zou het cytostatische functie 
van TGFβ kunnen verminderen en celoverlevings signalen kunnen activeren. Daardoor 
zou CRIPTO  een mediator van het tumor stimulerende effekt van TGFβ kunnen zijn. De 
verhoogde eiwitniveaus van CRIPTO gevonden in biopten  van menselijk hepatocellulair 
carcinoom duiden bovendien op een mogelijke kanker-bevorderende rol van CRIPTO in de 
lever, en geven aan dat CRIPTO gebruikt zou kunnen worden als een potentiële diagnostische 
biomarker voor humaan hepatocellulaire carcinoom.
Samengevat kan gezegd worden dat na de ontdekking van TGFβ zeer veel studies hebben 
bijgedragen aan het tot stand komen van een begrijpelijk overzicht van al de moleculaire 
eigenschappen van de eiwit componenten van de route, en de biologische processen 
waarbij TGFβ betrokken is. Vanwege het ziekte stimulerende effekt van gedereguleerde 
TGFβ/ BMP signaaloverdracht is het belangrijkste aspect van het huidige onderzoek de 
therapeutische interventie in de signalering, op een klinisch relevante wijze. Op basis van 
onze waarnemingen kan remming van TGFβ signalering veelbelovende effekten hebben 
bij vele ziekten en heeft het tevens additieve gunstige effecten in combinatie met andere 
geneesmiddelen, bijvoorbeeld - afhankelijk van de ziekte - in combinatie met chemotherapie, 
of anti-inflammatoire en immune modulerende middelen.
Echter, remming van TGFβ signalering kan niet altijd toegepast worden, voornamelijk 
vanwege de homeostatische functie van TGFβ in vele organen. Succesvolle modulatie van 
TGFβ signalering vereist daarom zorgvuldige patiënt stratificatie en ziektekarakterisering met 
behulp van prognostische middelen zoals biomarkers en analyse van de patiënt-specifieke 
genetische variatie. De huidige en de toekomstige ontwikkelingen in drug toediening zullen 
hopelijk leiden tot verbetering van de weefsel-specifieke of celtype-specifieke targeting van 
de geneesmiddelen die op de TGFβ route aangrijpen, samen met een precieze dosering 
en timing en een gepersonaliseerd behandelingsschema.





ACTA2, αSMA Aorta smooth muscle actin α 2
ACVR2A ACTIVIN A receptor type IIA
ACVR2B ACTIVIN A receptor type IIB
ACVRL (ALK) ACTIVIN A receptor-like kinase
Ad Adenovirus 
AFP α-fetoprotein 
AKT V-akt murine thymoma viral oncogene homolog
ALD Alcoholic liver disease 
ALDH1A1 Aldehyde dehydrogenase 1 family, member A1
ALK1Fc/ ACE-041 Activin receptor-like kinase-1- fragment crystallised region 
ALK5 Activin receptor-like kinase-5 
AMH Anti-Mullerian hormone 
AMSH SH3 domain of signal transducing adaptor molecule
AON Antisense oligonucleotide
AP-1 Activator protein 1
ARKADIA Ring finger protein 11 
BAM (BCL-XL) BCL-2 associated agonist of cell death
BAMBI BMP and ACTIVIN membrane-bound inhibitors
bFGF Basic fibroblast growth factor 
BIM; BCL-2-like 11
BMI-1 B cell-specific Moloney murine leukemia virus integration site 1
BMP Bone morphogenetic protein
BMPR BMP receptor 
BRE BMP-response-element
CAGA Cytosine adenine guanine adenine 
CASP3 Cleaved caspase 3 
CBP (TRX) cAMP response element-binding protein, Trithorax protein 
CCl4 Carbon tetrachloride 
CDC42 Cell division cycle 42
CDK Cyclin-dependent kinases 
CDK4 Cyclin-Dependent Kinase 4
CDKN1A (p21) Cyclin-dependent kinase inhibitor 1A
CDKN1B (p27KIP1) Cyclin-dependent kinase inhibitor 1B
CDKN2B (p15INK2B) Cyclin-dependent kinase inhibitor 2B
cDNA Complementary DNA 
CFc Control Fc 
C-FOS Cellular FBJ (Finkel-Biskis-Jinkins) Murine Osteosarcoma viral oncogene homolog
C-JUN Cellular- ju-nana (Abbreviated from Japanese,the number 17); derived from the ASV 17 provirus.
Ck19 Cytokeratin 19 
CMYC V-myc avian myelocytomatosis viral oncogene homolog
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COL1A1 Collagen type 1 α 1
COL1A2 Collagen type 1 α 2
co-SMAD Common mediator SMAD (SMAD4)
c-SRC Avian sarcoma (Schmidt-Ruppin A2) viral oncogene
CTGF/CCN2 Connective tissue growth factor 
CV Central vein
DAPPER2 Dishevelled-binding antagonist of β-catenin
DCN Decorin 
DD Dupuytren’s disease 
DDCt Delta-delta cycle threhold algorithm 
DNA Deoxyribonucleic acid 
DNDM DNA demethylating complex 
E1A Adenovirus early gene1 
E2F Elongation factor-2 
ECM Extracellular matrix 
EGF Epidermal growth factor 
EGF-CFC EGF-like, cysteine-rich CRIPTO-FRL1-CRYPTIC 
EMT epithelial-to-mesenchymal transition 
ERG v-ets avian erythroblastosis virus E26 oncogene homolog
ERK Mitogen-activated protein kinase 1
ERK Extracellular signal-regulated kinase
FKBP12 Inhibitor FK506-binding protein 
FN Fibronectin 
FOX Forkhead Box 
FOXH1 Forkhead Box H1
GADD34 Growth arrest and DNA damage protein 
GADD45B Growth arrest and DNA-damage-inducible 45 beta
GATA3 GATA binding protein 3 
GC Guanine cytosine




GSK3 Glycogen Synthase Kinase 3
GTPase Guanosinetriphosphatase
HBV/ HCV Viral hepatitis B/ C
HCC Hepatocellular carcinoma 
HDACs Histone Deacetylases
HHT Hereditary telangiectasia 
HMGA2 High motility group AT-hook 2 protein
HSCs Hepatic stellate cells 
ID Inhibitor of differentiation




JAG1 Jagged 1 
JNK C-Jun N-terminal kinase
JUNB Jun B proto-oncogene
LAP Latency-associated peptide 
LEF Lymphoid enhancer-binding factor
LLC Large latency complex 
LRP5 Leucine-rich protein 5
LTBP Latent TGFβ binding protein 
luc Firefly luciferase 
MAPK Mitogen-activated protein kinase
MEK MAPK/ERK
MET Mesenchymal-to-epithelial transition 
MFBs Myofibroblasts
MH1, 2 MAD homology 1, 2 domain 
miRNA Micro ribonucleic acid
MMP Matrix metalloprotease 
mRNA Messenger RNA 
mTOR Mammalian target of rapamycin
MYO-D Myogenic differentiation antigen 
NICD Notch intracellular domain 
NKX2.5 NK 2 homeobox 5
NR4A1 Nuclear Receptor Subfamily 4, Group A, Member 1
NT Non targeting 
OCT4 Octamer-binding transcription factor 4
ODN Oligodeoxynucleotide
OSX Osterix  (Sp7 transcription factor)
p38 Mitogen-activated protein kinase 14
p53 tumor protein p53 
PACE-4 Paired basic amino acid cleaving enzyme-4
PAI-1 Plasminogen activator inhibitor 1
PAR6 Par-6 family cell polarity regulator
PCa Prostate cancer
PCNA Proliferating nuclear antigen 
PDGFβ Platelet derived growth factor β polypeptide
PH3 Phosphorylated histone 3 
PI3K Phosphoinositole-3 kinase 
PP1,2 Protein phosphatase 
PTEN Phosphatase and tensin homolog
PTM Post translational modification 
PV Portal vein 
qRT-PCR Quantititative real time polymerase chain reaction 
RAC Rho Family, small GTP binding protein
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RAF Virus-induced rapidly accelerated fibrosarcoma
RAS Retrovirus-associated DNA sequences
RBP-Jk Recombination signal binding protein for immunoglobulin kappa J region
Ren Renilla luciferase
RGM Repulsive guidance molecule
RHO Rhodopsin
RLU Relative light units (luc/ ren)
R-SMAD Receptor-activated SMAD
RTK Receptor tyrosine kinase 
RUNX Runt-related protein 
Ser Serine 
SHG Second harmonic generation 
shRNA Short hairpin RNA 
SKI Avian sarcoma viral (v-ski) oncogene
SLC Small latency complex
SMAD Small mothers against decapentaplegic 
SMI Small molecule inhibitor 
SMURF SMAD specific E3 ubiquitin protein ligase
SNAIL Snail family zinc finger protein,
SNON SKI-related oncogene 
SOX2 Sry-related HMG box protein 2 
SP1 Specificity protein-1 
SRE SMAD-response element
SWI/SNF SWItch/Sucrose non-fermentable 
TAK1 TGFβ-associated kinase 1 
TDGF1 Teratocarcinoma-derived growth factor 
TGFa Transforming growth factor alpha 
TGFβ Transforming growth factor β
TGIF TGFβ-induced homeobox factor
Thr Threonine
TIMPs Tissue inhibitor of metalloproteinase 1
TMPRSS2-ERG transmembrane protease, serine 2
TOPRO TO-PRO-3 nuclear dye 
TP53 tumor protein p53 
TPF Two photon excited fluorescence 
TRAF6 TNFα-associated factor 6
TSP-1 Thrombospondin-1
TWIST Twist family BHLH transcription factor
Tyr Tyrosine
TβRI Transforming growth factor β receptor type I
TβRII Transforming growth factor β receptor type II




WNT Wingless-Type factor 
X any aminoacid
ZEB zinc finger E-box binding homeobox
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